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General abstract 
 
The use of chemical control measures to reduce the impact of parasite and pest 
species has frequently resulted in the development of resistance. Thus, 
resistance management has become a key concern in human and veterinary 
medicine, and in agricultural production. Although it is known that factors such 
as gene flow between susceptible and resistant populations, drug type, 
application methods, and costs of resistance can affect the rate of resistance 
evolution, less is known about the impacts of density-dependent eco-
evolutionary processes that could be altered by drug-induced mortality. The 
overall aim of this thesis was to take an experimental evolution approach to 
assess how life history traits respond to drug selection, using a free-living 
dioecious worm (Caenorhabditis remanei) as a model.  In Chapter 2, I defined 
the relationship between C. remanei survival and Ivermectin dose over a range 
of concentrations, in order to control the intensity of selection used in the 
selection experiment described in Chapter 4. The dose-response data were also 
used to appraise curve-fitting methods, using Akaike Information Criterion (AIC) 
model selection to compare a series of nonlinear models. The type of model 
fitted to the dose response data had a significant effect on the estimates of LD50 
and LD99, suggesting that failure to fit an appropriate model could give 
misleading estimates of resistance status. In addition, simulated data were used 
to establish that a potential cost of resistance could be predicted by comparing 
survival at the upper asymptote of dose-response curves for resistant and 
susceptible populations, even when differences were as low as 4%. This approach 
to dose-response modeling ensures that the maximum amount of useful 
information relating to resistance is gathered in one study. In Chapter 3, I asked 
how simulations could be used to inform important design choices used in 
selection experiments. Specifically, I focused on the effects of both within- and 
between-line variation on estimated power, when detecting small, medium and 
large effect sizes. Using mixed-effect models on simulated data, I demonstrated 
that commonly used designs with realistic levels of variation could be 
underpowered for substantial effect sizes. Thus, use of simulation-based power 
analysis provides an effective way to avoid under or overpowering a study 
designs incorporating variation due to random effects. In Chapter 4, I 
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investigated how Ivermectin dosage and changes in population density affect the 
rate of resistance evolution. I exposed replicate lines of C. remanei to two doses 
of Ivermectin (high and low) to assess relative survival of lines selected in drug-
treated environments compared to untreated controls over 10 generations. 
Additionally, I maintained lines where mortality was imposed randomly to 
control for differences in density between drug treatments and to distinguish 
between the evolutionary consequences of drug treatment versus ecological 
processes affected by changes in density-dependent feedback. Intriguingly, both 
drug-selected and random-mortality lines showed an increase in survivorship 
when challenged with Ivermectin; the magnitude of this increase varied with the 
intensity of selection and life-history stage. The results suggest that interactions 
between density-dependent processes and life history may mediate evolved 
changes in susceptibility to control measures, which could result in misleading 
conclusions about the evolution of heritable resistance following drug treatment. 
In Chapter 5, I investigated whether the apparent changes in drug susceptibility 
found in Chapter 4 were related to evolved changes in life-history of C. remanei 
populations after selection in drug-treated and random-mortality environments. 
Rapid passage of lines in the drug-free environment had no effect on the 
measured life-history traits. In the drug-free environment, adult size and 
fecundity of drug-selected lines increased compared to the controls but drug 
selection did not affect lifespan. In the treated environment, drug-selected lines 
showed increased lifespan and fecundity relative to controls. Adult size of 
randomly culled lines responded in a similar way to drug-selected lines in the 
drug-free environment, but no change in fecundity or lifespan was observed in 
either environment. The results suggest that life histories of nematodes can 
respond to selection as a result of the application of control measures. Failure to 
take these responses into account when applying control measures could result 
in adverse outcomes, such as larger and more fecund parasites, as well as over-
estimation of the development of genetically controlled resistance. In 
conclusion, my thesis shows that there may be a complex relationship between 
drug selection, density-dependent regulatory processes and life history of 
populations challenged with control measures. This relationship could have 
implications for how resistance is monitored and managed if life histories of 
parasitic species show such eco-evolutionary responses to drug application. 
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Chapter 1: General introduction 
 
 
1.1 Resistance evolution and communication between disciplines 
 
 
Parasitic diseases caused more than one million human deaths in 2013 (GBD 
collaborators 2015), while pests and diseases account for around one third of 
crop losses annually (Oerke 2006), and are a serious concern in the production of 
livestock (Oxford Analytica 2012). The financial cost of controlling parasites and 
pests is considerable: for example, 39.4 billion dollars were spent on pesticides 
globally in 2007 (Grube et al. 2011). Control agents are designed to reduce 
target populations but massive global application has led to extensive 
development of resistance (Kaplan and Vidyashankar 2011; zur Wiesch et al. 
2011). Overcoming the problem of resistance requires finding methods of drug 
use such that parasite and pest populations are kept at low numbers and the 
evolution of resistance is minimised. Several factors are known to affect the rate 
at which parasites can evolve resistance, including the type of drug, dosage, 
timing of application, migration rates between susceptible and resistant 
populations, the standing frequency of resistance alleles in the population and 
the specific mechanisms of resistance (Committee on Strategies for the 
Management of Pesticide Resistant Pest Populations 1986; James, Hudson, and 
Davey 2009; Gilleard and Beech 2007; REX Consortium 2013; Barnes, Dobson, and 
Barger 1995). In addition, life history characteristics of parasites and pests, as 
well as their reproductive strategies could influence the rate at which resistance 
develops (Kliot and Ghanim 2012; Galvani and Gupta 1998). Current research to 
date has considered many of these factors in isolation but there has been little 
attempt to explore interactions between life-history traits and the rate of 
resistance evolution. 
 
Intensive use of pesticides and drugs has generally been followed by the rapid 
evolution of resistance in pathogens, pests and disease vectors (Palumbi 2001). 
Models of resistance evolution take into account the evolutionary forces that 
shape adaptive responses of populations subject to strong directional selection 
(Barnes, Dobson, and Barger 1995; Leathwick 2013). Evolutionary forces such as 
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selection, drift, mutation and migration are common to many pest and pathogen 
groups including viruses (Bull et al. 1997), bacteria (Lenski and Travisano 1994), 
fungi (Anderson et al. 2003) and invertebrates (Leathwick et al. 2012). They are 
therefore likely to play a role in the adaptation of these groups to intense 
perturbations such as drug treatment (Greene et al. 2012). A recent study by the 
REX Consortium (2007) found that research in the field of resistance evolution 
has become divided into two main scientific groups; one group focuses an 
interest in agricultural pests and pathogens while the other focuses on human 
pathogens and their vectors (Rex Consortium 2007). Both groups work in parallel, 
with little exchange of methodology or theory. Within these two groups further 
subdivisions were found; network analysis of citation and authorship revealed 
groups working independently on antibiotic, antiviral, anthelmintic and 
antimalarial drug resistance as well as insecticide, herbicide and fungicide 
resistance. It would seem logical that the scientific community studying the 
evolution of resistance in these organisms should collaborate and quote the 
same references, use similar approaches and strategies to manage resistance 
evolution. However, communication between different disciplines still remains a 
persistent problem. For example, the REX Consortium paper entitled ‗Structure 
of the Scientific community modeling the evolution of resistance‘ (2007), 
highlighting the lack of interdisciplinary work in the field, had only 13 citations 
at the time of writing this thesis. 
 
The flow of information between the scientific community and how that 
information is applied in the field is also an area of concern in resistance 
management. It has been suggested that resistance management practices are in 
need of review and that in some circumstances current practices may even 
promote the evolution of resistance (Leathwick et al. 2009; Greene et al. 2012). 
However, in many cases these warnings have gone unheeded. For instance, the 
use of anthelmintics in managing sheep parasites has largely remained the same 
since the 1980‘s (Leathwick et al. 2009). Over this same period the resistance of 
parasitic worms has gone from rare to being commonplace (James, Hudson, and 
Davey 2009). Management strategies used to control parasites during this period 
have clearly applied significant selection pressure for the development of 
resistance to anthelmintics. This highlights the need for the implementation of 
more effective control measures to prevent the evolution of resistance (Hendry 
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et al. 2011; Greene et al. 2012). In the case of agricultural systems, resistance 
management practices need to be implemented that reduce the level of 
resistance while maintaining an acceptable level of productivity (Committee on 
Strategies for the Management of Pesticide Resistant Pest Populations 1986; 
Leathwick et al. 2009). A thorough knowledge of the factors that affect the rate 
of resistance evolution is therefore required if resistance is to be managed 
effectively (Georghiou and Taylor 1977; Committee on Strategies for the 
Management of Pesticide Resistant Pest Populations 1986; Greene et al. 2012). 
 
 
1.2 Rates of resistance evolution 
 
 
Research has shown that rapid or ‗contemporary‘ evolution, in the sense of a 
novel trait spreading through a population, is possible over a short time period, 
as few as 10-20 generations or less in some circumstances (Stockwell, Hendry, 
and Kinnison 2003). Contemporary evolution was thought to be a relatively rare 
event, restricted to a few cases such as industrial melanism in the peppered 
moth Biston betularia (Cook, Sutton, and Crawford 2005). However, since 
scientists have begun measuring the strength of natural selection in the wild 
they have found that it is stronger than expected, which suggests that 
contemporary evolution may be more commonplace than previously expected 
(Stockwell, Hendry, and Kinnison 2003). For example, studies of wild guppy 
(Poecilia reticulate) populations have shown that their life-histories show rapid 
evolutionary responses when exposed to a predation (Reznick 1997; Reznick et 
al. 2004; Reznick and Ghalambor 2005). Contemporary evolution may be 
promoted by factors such as invasion of new habitats, predation, resource 
availability, competition and environmental perturbations (Hairston et al. 2005; 
Ellner, Geber, and Hairston 2011). Evolutionary responses of populations are 
expected to be high where there is high trait heritability and following an 
increase in the intensity of directional selection (Reznick and Ghalambor 2001). 
Other factors that influence the rate of evolution include population size, gene 
flow and initial allele frequencies within populations (Stockwell, Hendry, and 
Kinnison 2003). Resistance has been shown to spread rapidly through populations 
challenged with xenobiotics (Taylor, Quaglia, and Georghiou 1983; Lopes et al. 
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2008; James, Hudson, and Davey 2009), but how factors such as density 
dependent competition in target populations interact with the evolution of 
resistance is unclear.   
  
Anthropogenic factors such as dramatic environmental changes impose 
particularly strong selection on organisms (Hendry et al. 2011) . The evolution of 
resistance provides many examples of strong selection pressure resulting in 
reduced efficacy of treatments. Bacteria, viruses, insect vectors and 
invertebrate crop pests have all quickly evolved resistance to control measures 
across many different clades (Palumbi and Mu 2001; Whalon, Mota-Sanchez, and 
Hollingworth 2008; Reece et al. 2010; Greene et al. 2012). For instance, in the 
case of pest invertebrates, Whalen et al (2008) summarises 7747 cases of 
resistance to 331 compounds in 553 species. Thus, the rapid evolution of 
resistance as a result of human activities is widespread and understanding how 
species rapidly adapt to efforts to reduce their numbers is of critical importance 
to disease control. In this thesis I will concentrate on resistance of parasitic 
nematodes to anthelmintics as an example of how resistance is managed and 
how rapidly resistance can evolve.  
  
Anthelmintic resistance of parasitic nematodes is now a global problem that 
affects human health as well as threatening the production and welfare of 
agricultural livestock (Sangster and Gill 1999). The treatment of parasitic 
nematodes with anthelmintic drugs has invariably led to the appearance and 
spread of anthelmintic resistance. Application of new anthelmintic drug 
treatments such as benzimidazoles, imodothiazoles and macrocyclic lactones has 
been followed by reports of widespread resistance within three to nine years of 
their introduction (James, Hudson, and Davey 2009). Agricultural practices such 
as treatment, followed by movement of livestock into low contamination pasture 
have been implicated as high-risk strategies that are likely to select for 
resistance, because any worms surviving the treatment become the major source 
of subsequent infection (Leathwick et al. 2009). These measures select for 
highly resistant parasites, which then go on to re-infect hosts as there is no 
dilution of resistance from free-living susceptible parasites within the 
population. Martin et al (1981) have shown that exposing a high proportion of 
parasites that contribute to the next generation will accelerate the rate of 
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resistance evolution. They conducted a study in which populations of 
Haemonchus contortus were passaged through lambs for six generations and 
exposed different proportions of populations to Thiabendazole. Resistance was 
slower to develop in populations with higher proportions of untreated worms. 
However, due to logistical constraints, such studies do not select parasite 
populations beyond a few generations so it is not possible to assess the rate of 
resistance evolution over the long-term.  
 
 
1.3 Dosage and resistance 
 
 
The evolution of resistance is determined by the extent to which survivors of 
drug treatments contribute genes to future generations; timing of treatments 
and drug efficacy moderate this contribution (Barnes, Dobson, and Barger 1995). 
Experimentation and monitoring of complicated host-parasite systems is 
technically difficult, expensive and time-consuming (Leathwick et al. 2009). 
Because many variables interact to determine the size and genetic background 
of parasite populations, mathematical modeling has often been used to predict 
evolutionary responses under different selection regimes (Barnes, Dobson, and 
Barger 1995; REX Consortium 2013). For example, Barnes et al (1995) 
investigated the effects of under-dosing on the evolution of resistance when 
using a single control agent (Barnes, Dobson, and Barger 1995). They found that 
with an initial resistance allele frequency of 0.01% and allowing 10% of 
susceptible worms to survive due to under dosing slowed the rate of resistance 
evolution relative to scenarios where treatment of susceptible worms had 99% 
efficacy. They suggested that under-dosing can slow the rate of resistance 
evolution if homozygous susceptible individuals survive and contribute to the 
next generation. However, they also suggested that if under-dosing occurs at a 
level where heterozygous resistant individuals are more likely to survive then 
this might speed the development of resistance.  
 
A series of empirical studies on rye grass investigating under-dosing have also 
suggested that lower doses may promote the evolution of resistance (Neve and 
Powles 2005; Busi and Powles 2009; Manalil et al. 2011), and that varying the 
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level of under-dosing may affect the rate at which resistance evolves (Busi and 
Powles 2009). For example, Busi and Powles (2009) found that Lolium rigidum 
selected for three generations under both low and high dose treatments of 
glyphosate caused a rapid increase in survival over three generations, and higher 
doses were associated with a greater magnitude of resistance. However, 
assessment of resistance was conducted on first generation offspring at the end 
of selection, meaning that any observed response in survival could have been a 
result of maternal effects. Ideally, to explore the role under-dosing plays in the 
evolution of resistance, selection should occur over more generations than 
maternal effects can influence responses to treatment. In addition, at the end of 
selection treated lines should be passaged through a further three generations 
without treatment to ensure any observed responses to selection are due to 
treatment. Thus, selection over multiple generations at different sublethal doses 
would aid in elucidating the relationship between the strength of selection 
(dose) and the rate of resistance evolution.  
 
Resistance to anthelmintics in nematodes has been shown to evolve in laboratory 
studies (Lopes et al. 2008), though to date much of this work has concentrated 
on mechanisms of resistance (James, Hudson, and Davey 2009), rather than 
focusing on how rates of resistance evolution interact with drug dose. For 
example, James and Davey (2009) exposed a single population of Caenorhabditis 
elegans to gradually increasing doses of Ivermectin for 44 weeks to investigate 
the role of transport proteins in resistance evolution. The study found the 
expression of some transport proteins increased after drug selection and showed 
that they played an important role in resistance. However, using a gradually 
increasing dose does not reflect how treatment is applied in the field. Long-term 
laboratory studies using replicate populations exposed to a consistent level of 
under-dosing would provide a greater insight into what affect dosage has on the 
rate of resistance evolution. 
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1.4 Life history traits and resistance 
 
 
Life history theory addresses the birth and death schedule of an organism in the 
context of its environment and attempts to explain how natural selection is 
expected to shape an organism‘s reproduction, fecundity and survival (Roff 
1992; Stearns 1992). The extent to which individual organisms can adjust 
different combinations of traits is mediated by resource allocation trade-offs. 
This results in organisms splitting finite resources between different processes 
such as growth, survival and reproduction (Roff 1992; Stearns 1992). Fitness 
costs could occur in the production and maintenance of drug resistance in 
parasitic or pest species that divert resources from other fitness-enhancing 
traits. Identifying such costs associated with resistance may be of importance in 
developing strategies that limit the spread of resistant populations (Kliot and 
Ghanim 2012). If fitness costs are high then it is likely to take longer for 
resistance to spread through a population because susceptible individuals may 
have higher reproductive rates or grow faster even though they may have 
reduced survival in a drug-treated environment (Kochin, Bull, and Antia 2010).  
 
Fitness costs associated with insecticide resistance have been extensively 
documented in agricultural systems; see Kliot and Ghanim (2012) for a review. 
For example, Carriere et al (1994) investigated the effects of selection for 
insecticide resistance on the oblique-banded leaf-roller, Choristoneura 
rosaceana (Carriere et al. 1994). Insects were collected from pesticide-free and 
treated orchards; these were then reared in a common garden in the laboratory. 
Resistant insects from treated orchards were found to suffer considerable life 
history costs; they had lower larval and pupal masses, and longer development 
times than susceptible individuals. Also, the degree of resistance was strongly 
correlated with these costs; resistance levels were negatively correlated with 
larval growth rates and pupal mass, and positively correlated with development 
time. Such studies have revealed life history costs to resistant individuals; 
however, they have not documented whether these costs remain constant over a 
period of continued exposure. It is possible that continuous drug exposure may 
promote the selection of modifier genes that reduce the fitness costs associated 
with resistance (Kliot and Ghanim 2012). Lopes et al (2008) found that replicated 
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populations of C. elegans exposed to anthelmintic treatment over 20 generations 
at first incurred a cost to resistance in terms of survival, fecundity and a 
decrease in the proportion of males. However, after 20 generations survival and 
fecundity returned to previous levels, and male frequency had begun to 
increase.  This suggests that populations can indeed adapt to continued exposure 
to drug treatment; however, these studies have only begun to explore the 
relationship between resistance and life history traits. For example, it would be 
interesting to establish whether there are eco-evolutionary feedbacks between 
resistance and life history, and whether other ecological factors such as changes 
in mortality rates and competitive interactions influence resistance evolution. 
  
Differences in mortality rate and population density between treated and 
untreated populations could result in differential selection due to density-
dependent processes such as competition (Gilleard and Beech 2007). Studies of 
resistance evolution can impose strong directional selection on life history traits 
such as development time, size at maturity and investment in and timing of 
reproduction (Chehresa, Beech, and Scott 1997). Because life history traits can 
respond to selection in many types of environments as a result of changes in 
mortality and density (Reznick and Ghalambor 2001), adequate controls are 
needed to assess the effects of changes in traits not directly associated with the 
application of control measures (Gilleard and Beech 2007). Laboratory-based 
selection experiments typically assess resistance evolution by comparing survival 
in treated and untreated control populations (Ranjan et al. 2002; Coles, Rhodes, 
and Wolstenholme 2005; Lopes et al. 2008). However, this methodology does not 
account for differences in mortality and density between treatments. Inclusion 
of treatments that mimic the rate of mortality and density caused by control 
measures would allow the assessment of any responses in life history traits not 
due directly to chemical exposure (Fuller, Baer, and Travis 2005).  
 
 
 
 
 
 
 
   
 
 22 
1.5 Study system 
 
 
1.5.1 Selection experiments 
 
Selection experiments study evolution as it happens, in a controlled and 
replicated manner, in contrast to observational studies made in the wild where 
replication and strict control of environmental variables is difficult (Fuller, Baer, 
and Travis 2005; Garland and Rose 2009; Kawecki et al. 2012). In essence, by 
replicating the number of populations exposed to a novel environment, it can be 
established whether there is a consistent evolutionary response to selection. 
Experimental evolution studies allow the observation of phenotypic and genetic 
change in populations and communities caused by experimentally imposed 
selective pressures. Because other environmental factors not of direct interest 
to a study can be closely controlled, their impact can be reduced to noise, and 
any changes occurring as a result of those intentionally imposed by the 
researcher can be attributed to the selection regime (Fuller, Baer, and Travis 
2005; Buckling et al. 2009; Garland and Rose 2009). Experimental evolution does 
not directly attempt to reproduce or predict evolution in the wild; the main 
purpose is to test evolutionary theory and hypotheses. Selection experiments 
have been classified into two different categories: artificial selection, where 
individuals are selected to propagate the next generation on the basis of a 
specific trait value, and laboratory natural selection (LNS), where the 
investigator decides on the source and intensity of selection but does not control 
which traits respond to selection (Fuller, Baer, and Travis 2005). Other 
categories have been suggested, but these can usually be designated as sub 
categories, such as culling experiments, a subcategory of LNS experiments, 
where populations are exposed to a stressful environment causing some 
mortality, and the offspring of survivors go on to form the next generation. 
Culling experiments have been particularly useful in exploring factors that affect 
the rate of resistance evolution. For example, cage studies of replicate 
populations of flies exposed to insecticide have been used to assess the effect of 
dose and decay rate of a control agent, and immigration rate of susceptibles on 
the rate of resistance evolution (Taylor, Quaglia, and Georghiou 1983). Taylor et 
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al (1983) found that higher insecticide doses with a slow decay rate and little or 
no immigration promoted the rapid evolution of resistance, whereas, with a 
rapidly decaying insecticide and some immigration of susceptible flies, the rate 
of resistance evolution was slower. In addition to exploring what factors affect 
the rate of resistance evolution, culling experiments have been used to assess 
the effectiveness of control strategies used to delay the rate of resistance 
evolution. For instance, the effectiveness of drug combination treatments in 
conjunction with maintenance of refugia for susceptible parasites has been 
investigated in parasitic nematodes (Leathwick et al. 2012). At the end of the 
selection experiment, drug efficacy was highest when using a combined strategy 
of drug combinations and refugia, but maintaining a refuge out performed a 
combination drug treatment when implemented separately, and the use of a 
single drug with no refugia resulted in the highest rate of resistance evolution. 
This experiment illustrates how experimental evolution can be exploited to 
assess the effects of different drug dosage regimes on the rate of resistance 
evolution. 
Culling experiments have also been used to test predictions of life-history 
theory, with much of this work being conducted on fruit flies (Joshi 2000; Prasad 
and Joshi 2003). For example, high rates of extrinsic mortality imposed randomly 
on replicate populations of Drosophila melanogaster resulted in shorter lifespan, 
decreased age and size at maturity, and a shift in peak fecundity to earlier in 
life, relative to populations exposed to a low rate of extrinsic mortality (Stearns, 
Ackermann, and Doebeli 1998; Stearns et al. 2000). The results confirmed 
predictions about how growth, maturation, reproduction, and ageing respond to 
selection in environments varying in the risk of mortality. The application of 
control measures reduces population density and imposes a source of high 
extrinsic morality on target populations, which could both influence life-history 
evolution of pests and parasites. Selection experiments implementing controls 
for differences in density between drug-treated and drug-free environments 
would allow the effects of density and high risk of mortality to be separated 
from those of direct adaptation to a control agent. 
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1.5.2 Caenorhabditis remanei as a model of resistance evolution 
 
Studies of adaptation have mainly been conducted on small organisms, which are 
easy to maintain and have a short generation time. The choice of the study 
system becomes largely a matter of suitability to the question being addressed 
by a study. For instance, phage-bacteria and Daphnia-pathogen systems have 
been used to study questions relating to coevolution (Buckling and Rainey 2003; 
Ebert 2008). For investigating long-term evolution over tractable periods of 
time, using microbes has obvious advantages. However, metazoan systems are 
required to answer evolutionary questions involving complex processes such as 
sexual selection, development and behaviour. Therefore, model systems have 
expanded to include fruit flies, fish, mice and plants, amongst others (Kawecki 
et al. 2012). Recently, the nematode worm Caenorhabditis elegans and closely 
related species have been adopted as powerful models for addressing ecological 
and evolutionary questions using selection experiments (Gray and Cutter 2014). 
The genus contains 26 species, many of which have had their whole genome 
sequenced (Kiontke et al. 2011). In addition, many species within the group have 
differing reproductive modes, making them an ideal model for studying the 
evolution of sex. Caenorhabditis species have numerous other qualities that 
make them an ideal candidate for use in experimental evolution. Under 
laboratory conditions, the Caenorhabditis life cycle is around two days from egg 
to adult at 20°C; therefore, selection experiments can be run over many 
generations within a few weeks. Early larval stages of the genus can survive 
cryopreservation (Hope 2001), meaning that samples of evolving populations can 
be stored and preserved indefinitely, and traits of interest can be compared 
between ancestral and evolved populations. Populations can be reared in liquid 
culture or on a solid agar substrate in petri dishes, and only require a diet of 
bacteria as a food source, which means that large numbers of individuals can be 
cultured quickly and cheaply (Hope 2001). The average lifespan of worms is two 
weeks under standard laboratory conditions and makes them a tractable model 
for studying life-history characters such as lifespan, fecundity, and age and size 
at maturity in replicate populations subjected to different environments (Chen 
and Maklakov 2012). The development of automation, image processing and 
microfluidic techniques complementing the Caenorhabditis system is now 
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making it possible for high-throughput studies of many traits to be conducted 
(Husson 2012). The range of molecular methods open to evolutionary biologists 
using Caenorhabditis species is unrivalled. For instance, reversible gene 
knockout using RNAi is relatively simple to perform in Caenorhabditis by 
inserting or removing a plasmid into the E. coli food source, and can be used to 
assess gene function in different environments (Timmons and Fire 1998). In 
addition, strains with specific gene deletions are available publically, and recent 
work on targeted genome editing using CRISPR/Cas9 has made it possible to 
engineer specific alleles in Caenorhabditis (Frokjaer-Jensen 2013). 
Treatment of nematode infections provides a well-documented area of research 
in which problems relating to the evolution of resistance have been explored 
using C. elegans (Driscoll 1989; Coles et al. 1988; Geary and Thompson 2001; 
Lopes et al. 2008; James and Davey 2009). Because parasitic helminths are 
difficult to culture, research into anthelmintic resistance has used C. elegans in 
screening potentially new candidate drugs and identifying resistance loci 
(Simpkina and Coles 1981; James, Hudson, and Davey 2009; Ghosh et al. 2012). 
However, C. elegans is an androdioecious nematode and reproduces mainly by 
self fertilisation, although low levels of outcrossing do occur due to a small 
proportion of males (Brenner 1974; Barrière and Félix 2007). In contrast, most 
parasitic nematodes are obligately outcrossing; therefore a free-living, dioecious 
nematode species such as C. remanei would provide a more realistic model 
system to explore resistance evolution. Additionally, C. remanei populations, 
like parasitic species, have abundant standing genetic variation and high levels 
of recombination due to their reliance on sexual reproduction (Cutter, Baird, 
and Charlesworth 2006). Both of these attributes should facilitate a rapid 
response to selection in the face of drug treatment. Thus, selection experiments 
using C. remanei as a model organism afford a tractable model system in which 
to explore the factors affecting resistance evolution in commercial drugs. 
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1.6 Thesis aims and objectives 
 
Eco-evolutionary processes such as feedbacks between density-dependence and 
life history could occur as a result of the application of xenobiotics, but this type 
of interaction is difficult to observe in parasitic species. Free-living species from 
clades related to parasitic species can be kept in microcosms allowing 
population density to be manipulated, either by chemical application or 
artificially, over generations as part of a controlled selection experiment. This 
type of experiment allows all other environmental factors to be kept constant 
during selection, and provides an explicit test of what changes in life history 
occur as a result of drug application, due either directly to long-term exposure 
to a control agent or indirectly as a consequence of density-dependent 
processes. C. remanei is a free-living, short-lived nematode worm, and has been 
previously used as a model to study rapid adaptation of life history to changing 
environments. As a model system it offers the opportunity to assess how changes 
in life history, population density and resistance interact. The overall aim of this 
thesis was to take an experimental evolution approach to assessing how life 
history traits respond to drug selection, using a free-living dioecious worm (C. 
remanei) as a model. The principal objectives of each chapter were: 
 
1) Chapter 2: To establish the relationship between C. remanei survival and 
Ivermectin dose over a range of concentrations within a single generation, 
in order to control the magnitude of selection during the selection 
experiments described in Chapter 4. 
2) Chapter 3: To perform simulation-based power analyses aimed at 
optimising the number of replicate lines and the intensity of subsampling 
from those lines after selection, for selection experiments similar to that 
used in Chapter 4. 
3) Chapter 4: To assess whether there is an increase in survival across 
generations of populations selected in drug-treated environments, and 
whether this varied with the intensity of selection (i.e. drug dosage). In 
addition, I asked whether density-dependent selection affects the 
apparent evolution of resistance by measuring survival of randomly culled 
   
 
 27 
lines, which controlled for differences in mortality and density between 
drug-treated and drug free populations.  
4) Chapter 5: To establish whether rapidly passaged control lines, drug 
selected lines or randomly culled lines from the selection experiment 
conducted in Chapter 4 showed any evolved changes in life history. 
 
In Chapter 2, I investigated the relationship between C. remanei survival and 
Ivermectin dose. Two doses were chosen that differed in the intensity of 
selection that would be imposed during the selection experiment in Chapter 4. 
The dose-response data were also used to appraise curve-fitting methods, which 
could be used to improve model fitting of dose-response studies in parasitology. 
In addition, I showed how dose-response modeling that incorporates background 
mortality into the analysis could be used to test for a cost of resistance in terms 
of survival. In Chapter 3, I asked how simulations can be used to inform 
important design choices used in selection experiments; specifically, the number 
of replicate selection lines, the number of samples taken from within each 
replicate line, and variation due to repeated measures used to assess traits at 
the end of selection. In Chapter 4, I investigated how Ivermectin dosage and 
changes in population density affect the rate of resistance evolution. I created 
replicate lines of C. remanei exposed to Ivermectin at high and low doses to 
assess whether survival of lines selected in drug-treated environments increased, 
and if this varied with the intensity of selection. Additionally, I maintained lines 
where mortality mimicked that of treated lines to control for differences in 
density between drug-treatments and to distinguish between the evolutionary 
consequences of drug-treatment vs changes in density-dependent feedback on 
life history traits. Both adult and juvenile survival was measured to explore 
relationships between life-history stage, selection regime and survival. In 
Chapter 5, I investigated whether there were any evolved changes in life-history 
of C. remanei populations after selection in a drug-treated environment. I 
measured larval and adult size, female fecundity and female lifespan in drug-
free and treated environments, asking: 1) Does rapid passage of lines in the 
drug-free (control) environment result in selection for smaller size, lower 
fecundity or shorter lifespan? 2) Does drug selection affect life-history traits? 3) 
Does density-dependent selection affect the life history of randomly culled lines? 
Finally, in Chapter 6, I discuss the broader implications of my work. Specifically: 
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1) how improved methods of analysing dose-response data would benefit 
parasitology studies monitoring resistance; 2) how a priori simulation-based 
power analysis can help to optimise the experimental design of selection 
experiments; 3) how ecological change such as changes in density or extrinsic 
mortality occurring as a result of the application of control measures interacts 
with life history and susceptibility to control measures. 
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Chapter 2: Detecting a cost of resistance using 
dose-response modeling 
 
 
2.1 Abstract 
 
 
Dose response studies are an import diagnostic tool for measuring resistance in 
target populations. Current dose-response models of parasite and vector survival 
often fit simple sigmoidal curves and do not consider alternative models, which 
could affect estimates of the metrics used to assess levels of resistance. 
Standard pre-analysis practices remove valuable data on background mortality, 
which could be used to test for costs associated with resistance. Using survival 
data from a larval development test (LDT) following treatment with Ivermectin 
applied at varying concentrations to Caenorhabditis remanei, this study used 
Akaike Information Criterion (AIC) model selection to compare a range of 
potential dose-response curves, and used maximum likelihood ratios to test for a 
cost of resistance at sublethal drug doses. Specifically, comparisons were made 
between LD50 and LD99 estimates obtained using log-logistic, Weibull and 
hormetic dose-response models. Using the best-fitting model, the upper 
asymptote of the dose-response curve was then used to test whether a cost of 
resistance in survival would be detectable, based on lower survival at these 
sublethal lethal doses (i.e. the background mortality that is often removed prior 
to data analysis) of a simulated resistant population compared to a fully 
susceptible population. The type of model fit to the dose-response data from the 
LDT had a significant effect on the estimates of LD50 and LD99, suggesting that 
failure to fit an appropriate model could give misleading estimates of resistance 
status. A test of difference in asymptotes detected a cost of resistance of 4% 
survival in the simulated resistant population, meaning that even a small cost of 
resistance would be detectable using this approach. The results suggested that 
widening the range of models considered can give more accurate predictions of 
dose-response curve parameters, and that incorporating background mortality 
into the analysis can provide an effective method for assessing potential costs to 
resistance. 
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2.2 Introduction 
 
 
Drug resistance in parasites, parasite vectors and pest species poses serious 
challenges to disease control and agriculture around the world (Oerke 2006; GBD 
collaborators 2015), and the development of new xenobiotics that combat such 
species tends to be slow (Livermore et al. 2011). Diagnostic methods that 
monitor drug efficacy play a key role in preserving the effectiveness of existing 
control measures, and numerous methods are used to detect and measure 
resistance in different disciplines (Coles et al. 2006; Bagi et al. 2015). One 
common approach is to establish the relationship between survival and drug dose 
using dose-response assays (Coles et al. 1988; Michaela Dolinská, Königová, and 
Várady 2012). Samples of resistant populations can then be compared either 
temporally or geographically with known susceptible populations to assess 
differences in their resistance profile. In addition, it is important to establish 
whether there is a cost to resistance; i.e. if resistant individuals have lower 
fitness than susceptible individuals in drug-free environments. If susceptible 
members of the population have higher fitness than resistant individuals this 
could slow the spread of resistance alleles, depending on factors such as the 
frequency of application of control measures (Barnes, Dobson, and Barger 1995; 
REX Consortium 2013). Costs to resistance in terms of survival can be measured 
by exposing susceptible and resistant isolates to untreated environments and 
contrasting survival between the isolates. Current methods of analysis used to 
detect resistance employing a dose-response approach generally do not 
incorporate a measure of the cost of resistance, because survival in treated 
environments is scaled against survival in drug-free environments prior to 
statistical analysis; i.e. mortality occurring in drug-free controls is deducted 
from mortality occurring at each dose used in the dose-response assay. This 
rescaling of survival data means that valuable information about potential costs 
of resistance is lost during the analysis of dose-response data. Measuring costs of 
resistance can be easily incorporated into dose-response analyses by including 
sources of mortality not directly due to a control agent. 
 
Dose-response studies measure the relationship between the quantity of a 
substance or time of exposure and the effect it has on an organism. The 
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response variable may be continuous, as in the case of data measuring growth; 
alternatively, it may be binary (e.g. alive/dead), such as data collected when 
measuring drug efficacy. Dose-response studies are important in numerous 
fields, including: ecotoxicology (Ritz 2010), parasitology (Coles et al. 2006), pest 
control (Bagi et al. 2015) and weed control (Busi and Powles 2009). In addition, 
dose-response studies are used to establish and control the intensity of selection 
during experimental evolution studies, with the aim of applying an 
environmental stressor consistently over the duration of an experiment (Busi and 
Powles 2009). Dose-response models assume a given response variable y is 
explained in terms of a model function f that depends on the dose x (Equation 
1): 
 
   (   )                                                                  ( ) 
 
 
The form of the function f is known as it reflects the assumed relationship 
between x and y, except for the values of the model parameters β, which are 
estimated from the data (Ritz and Streibig 2007). Dose-response curves are 
usually sigmoidal and can be defined by four parameters (Equation 2). The first 
two parameters are d and c are the upper and lower asymptotes and define the 
upper and lower limits of mean survival, respectively. In other words, d is the 
expected survival before increasing dose has any effect (background mortality), 
and c is the expected survival at doses where increasing dose has no further 
effect. The third parameter e, is the inflection point, which is the dose where 
the curve changes from concave to convex and is located at or near the LD50 
(dose causing 50% mortality) for the drug. The fourth parameter b, is the slope 
of the curve at the LD50. Log-logistic models are often used to describe the dose-
response relationship between survival and dose, and generally the 4-parameter 
model is applied, corresponding to the model function:  
 
 (  (       ))      
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                       ( ) 
 
Log-logistic models assume that the dose-response relationship is symmetrical 
around the inflection point e (Fig 2.1 A). However, a range of asymmetric 
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models, such as Weibull and hormetic curves can be applied to dose-response 
data (Fig 2.1). Fitting a range of potentially suitable models that can 
accommodate asymmetry in the dose response relationship, in addition to log-
logistic dose response models, should ensure that the most appropriate model is 
applied to a data set to improve the accuracy of estimates. 
 
Fig 2.1 Symmetric and asymmetric dose-response curves: A) Asymmetric dose- 
response curve (logistic or log-logistic); B) An asymmetric curve where the 
decrease in survival from the upper limit is rapid, but the approach towards the 
lower limit is slow (Weibull-2); C) An asymmetric curve where the decrease in 
survival from the upper limit is slow, but the approach towards the lower limit is 
rapid (Weibull-1); D) An asymmetric curve suitable for modeling an initial 
increase in survival (Hormetic). Figure adapted from Ritz et al (2007). 
 
 
Studies interested in the control of pest and parasite populations often 
summarise estimates from dose response curves of different populations to 
assess any differences in resistance (Amarante et al. 1997; Busi and Powles 
2009). If these estimates are based on inappropriate dose-response models then 
any attempt to evaluate differences between resistant and susceptible 
populations could result in inaccurate conclusions. Two frequently used metrics 
in dose response studies are the LD50 and LD99; the lethal doses representing 50% 
and 99% of a target population. The LD50 is useful when comparing resistant and 
   
 
 33 
susceptible isolates; for example, the degree of resistance (resistance factor) 
can be calculated by dividing the LD50 of an isolate of interest by the LD50 of a 
known susceptible isolate (Amarante et al. 1997). The resistance factors of 
several isolates can then be compared with one another and help in assessment 
of how resistance changes in time or space (Busi and Powles 2009; Michaela 
Dolinská, Königová, and Várady 2012). The discriminating dose is the dose (LD99) 
that represents the maximum dose a given population can tolerate; any 
individuals surviving are considered to be resistant (Coles et al. 2006). Both the 
LD50 and LD99 are estimated from the dose-response model fitted to survival ~ 
concentration data. Thus, fitting an inappropriate model could result in 
inaccurate estimates of LD50 and LD99 and erroneous inferences about the 
comparisons of resistance between populations. Comparing a range of dose-
response models and selecting the most appropriate model could improve the 
accuracy of estimates of the degree of resistance both within and between 
populations. 
 
Investigators using a dose-response approach as a diagnostic method to quantify 
drug resistance usually measure survival over a range of doses but adjustments 
for background mortality prior to analysis could affect model estimates. During a 
dose-response assay survival is measured over a range of doses. Counts of the 
initial number of individuals and the final number of survivors are then used to 
calculate the proportion of mortality due to drug treatment as a function of 
concentration. Data about background mortality can be accounted for by 
subtracting mortality in control (untreated) conditions from that in drug-treated 
environments (Abbott 1925). It is difficult to establish how prevalent this type of 
a priori data manipulation is within the field of dose-response studies associated 
with documenting resistance, but it could be extensive. For example, WHO 
guidelines on conducting dose-response assays on mosquitoes specifically 
incorporate the use of Abbott‘s correction prior to data analyses (World Health 
Organization 2013). In addition, the method of adjusting survival data described 
by Abbott (1925) has over 11,000 citations (Google Scholar), a search within 
citied articles for ‗vector control‘ found 2420 citations, and a search of 
‗parasite‘ found 918 citations. Modifying the data collected from dose response 
assays in this way results in two unwanted outcomes. Firstly, manipulating data 
prior to analysis is not necessary for survival data with a binomial distribution, 
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and can result in incorrect estimates of variance in adjusted data (Rosenheim 
and Hoy 1989). Secondly, fitness costs could occur in relation to drug resistance 
if parasitic species divert resources from other fitness-enhancing traits including 
survival. If resistant populations have lower survival than susceptible populations 
at sublethal doses then a fitness cost can be measured. This information about 
differences in background mortality between resistant and susceptible 
populations is forfeited in the process of adjusting dose response data. 
Identifying fitness costs associated with resistance may be of importance in 
limiting the spread of resistant populations (Kliot and Ghanim 2012). If fitness 
costs are high then it is likely to take longer for resistance to spread through a 
population because susceptible individuals may have higher reproductive rates 
or grow faster even though they may have reduced survival in drug-treated 
environments (Carriere et al. 1994). Testing for a cost of resistance could be 
achieved simply by comparison of susceptible and resistant populations in a 
drug-free environment, but estimating a cost of resistance based on differences 
in survival at sublethal doses across the upper asymptote of the dose-response 
curve will provide a more powerful test given the greater sampling effort. The 
upper asymptote of the dose response curve represents concentrations of drug 
that have no direct effect on survival. Incorporating background mortality into 
the analyses of dose-response data would allow direct comparisons of survival to 
be made between resistant and susceptible isolates across a range of sublethal 
doses, which could be used to quantify costs to resistance in terms of survival. 
Thus, lower survival at the asymptote of a resistant isolate relative to a 
susceptible isolate would provide evidence of a fitness cost. However, to my 
knowledge, there are no studies that have implemented a test of a cost to 
resistance at sublethal doses to infer such costs. In addition, I am unaware of 
any dose response studies assessing drug resistance that have published the 
original survival data along with the study, so a test of upper asymptotes 
between resistant and susceptible cannot be conducted on previously collected 
data. However, simulations can be used to explore the patterns that emerge 
from biological models, and examine whether models based on mathematical 
functions with associated probability distributions provide realistic 
representations of a study system (Bolker 2007). Simulated data with higher 
survival of resistant individuals over the range of doses associated with normal 
drug efficacy and lower survival at sublethal doses, relative to susceptible 
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individuals, would allow the assessment of a test of differences in asymptote. A 
method of modeling survival data, which assesses a range of suitable dose-
response models and incorporates background mortality would provide an 
effective means of increasing the accuracy of estimates of resistance, and 
provide a test of a cost of resistance.  
 
Treatment of parasitic nematodes often involves the application of broad-
spectrum anthelmintics from one of three major classes: benzimidazoles, 
imodothiazoles and macrocyclic lactones. Ivermectin is a macrocyclic lactone 
and has been used commercially since 1981 (James, Hudson, and Davey 2009), 
with the first reports of resistance in 1988 (Kaplan 2004). Ivermectin causes 
paralysis in larvae and adult nematodes and inhibits feeding (Sangster and Gill 
1999) but also has a repellent effect at sub-lethal doses (Ardelli et al. 2009). 
Ardelli et al (2009) found that replicated measures of C. elegans movement 
exposed to 2.5 nM and 5 nM Ivermectin resulted in increased traveling behaviour 
(long-range roaming) relative to zero dose controls, but worms exposed to 10 nM 
showed no increase in movement. Thus, at high doses where worms are 
paralysed, repellency does not occur, but at low doses Ivermectin has a 
repellent effect resulting in hyperactivity and is likely to be an additional source 
of mortality, due to worms attempting to evade the effects of the drug. This 
additional source of mortality should be taken into consideration when assessing 
the relationship between survival and drug dose. Because parasitic helminths are 
difficult to culture, studies of nematode disease have often used the model 
organism Caenorhabditis elegans in both drug screening and identifying 
candidate resistance loci (Simpkin and Coles 1981; James, Hudson, and Davey 
2009; Ghosh et al. 2012). However, C. elegans reproduces mainly by self-
fertilisation, and although low levels of outcrossing do occur, genetic variation 
within the species does not reflect that observed in parasitic species, which are 
usually obligately outcrossing (Geary and Thompson 2001). Other free-living 
dioecious nematodes such as C. remanei may thus provide a more realistic model 
system to explore resistance. C. remanei populations have abundant standing 
genetic variation and high levels of recombination, due to their reliance on 
sexual reproduction (Cutter, Baird, and Charlesworth 2006), which also makes 
them a good candidate for studying resistance.  
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The overall aim of this chapter was to fit the most appropriate non-linear 
regression model to dose-response data, which could then be used to test for 
evidence of a cost of resistance at sublethal doses. Specifically, I asked:  
1) Which dose-response curve model best describes the relationship 
between Ivermectin dose and C. remanei survival? 
2) Can background mortality at sublethal doses be used to detect a cost 
of drug resistance? 
 
 
2.3 Methods  
 
 
2.3.1 Origin and maintenance of worm populations 
 
 
In order to perform a LDT on a population with abundant standing genetic 
variation, I obtained a genetically diverse strain of C. remanei (SP8) from N. 
Timmermeyer in the Department of Biology, University of Tübingen, Germany. 
This strain was originally created by a fully factorial crossing of three wild-type 
strains isolated from geographically distant locations (SP146 from Freiburg, 
Germany; MY31 from Tübingen, Germany; PB206 Ohio, US). Offspring of the 
crosses had been tested to ensure they were fertile then pooled, and maintained 
for eight generations to create recombinant genotypes and allow adaptation to 
standard laboratory conditions (Fritzsche et al. 2014). Upon arrival in Glasgow, 
strain SP8 was cultured for four generations to acclimate to the laboratory 
conditions, which were standard for Caenorhabditis species: 20˚C and 60% 
humidity on Nematode Growth Medium (NGM) petri dishes and fed on a lawn of 
Escherichia coli (OP50) (Hope 2001). 
 
 
2.3.2 Larval development test 
 
 
To quantify the relationship between drug dosage and survival for strain SP8 
replicate samples of the population were exposed to a range of doses of 
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Ivermectin. A stock solution of 2 mg/ml Ivermectin (22,23-Dihydroavermectin 
B1; Sigma-Aldrich) dissolved in DMSO was decanted into 1-ml aliquots and frozen 
to provide a standardised drug dose. I used a modified version of the dose 
response approach taken by Coles et al. (1988), exposing replicate samples of C. 
remanei over a range of 15 doses (0, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9 
and 10 ng/ml); chosen because this range has been previously used in studies of 
C. elegans (James and Davey 2009). Dilutions of Ivermectin were added to 100 
ml liquid NGM (50°C) and mixed with a magnetic stirrer before pouring 7 ml 
aliquots into 5.5 cm plastic petri dishes. These were left to dry, seeded with E. 
coli (OP50) ad libitum to minimise indirect mortality resulting from worms 
leaving the agar surface of the petri dishes in search of food, and incubated at 
20°C overnight. Concurrently to preparing dosed plates, age-synchronised eggs 
were harvested from stock populations of C. remanei by bleaching using 
standard protocols (Hope 2001). This process kills adults and juveniles but leaves 
unhatched developing embryos unharmed. Eggs were moved to fresh drug and 
food-free 9-cm petri dishes and incubated overnight to provide a source of L1-
arrested larvae for drug screening. After 12 hours incubation, larvae were 
suspended in M9 buffer solution (3g KH2PO4, 6g Na2HPO4, 5g NaCl, 1 ml M MgSO4, 
H20 to 1 litre and sterilised by autoclaving) and 5 µl aliquots of this suspension 
were added to Ivermectin-dosed plates, with the aim of applying approximately 
60 larvae per plate. Larvae added to petri dishes were counted as they were set 
up. Survival data were obtained by counting the number of adults present per 
plate at 75 hours, which is long enough to ensure the adult stage was exposed to 
the drug but was not long enough for any offspring of the screened population to 
develop to adulthood and confound accurate survival counts. Twenty replicate 
plates were established for each Ivermectin dose (ten replicates in each of two 
different batches, tested one month apart using separately prepared plates).  
 
 
2.3.3 Statistical analysis 
 
 
Preliminary analysis performed by visual assessment of a range of dose-response 
curves found evidence of an indirect source of mortality at low doses. Models 
using all the survival data resulted in overestimates of mortality at very low 
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doses, and under estimates of survival at the upper asymptote compared to a 
reduced dataset excluding the values at 0.5 and 1 ng/ml Ivermectin. Because 
indirect mortality has been previously observed in C. elegans (Ardelli et al. 
2009), a sister species to C. remanei and because I was interested in modeling 
mortality directly associated with the action of the drug, I used a reduced 
dataset. The reduced dataset excluded survival data at two doses (0.5 and 1 
ng/ml) of Ivermectin where indirect morality was apparent. An assessment and 
justification for removing these data is given in Appendix A. All further analysis 
was conduct on the reduced dataset, which included survival data for 13 doses 
(0, 0.1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9 and 10 ng/ml Ivermectin). 
 
All statistical analyses were performed using the drc package (Ritz and Streibig 
2007) in the statistical environment R v 3.1.2 (R Core Team 2014), and I defined 
a significance threshold of P = 0.05 for all tests. In order to establish the best 
fitting model of survival as a function of the concentration of Ivermectin, dose-
response log-logistic and Weibull and hormetic models were fitted to the 
reduced dataset collected in the LDT, assuming X is a binomially distributed 
random variable, n is the total number of worms, and p is the probability of 
survival at a particular dose determined by the dose response model (Fig 2.1, 
Equation 3). 
 
    (   )                                          (3) 
 
Three parameter Log-logistic, Weibull-1, Weibull-2 and Hormetic models with 
the lower asymptote of the dose-response curve set to zero were used to 
prevent negative predictions of survival in the fitted dose response curves. 
Because 4-parameter Log-logistic models are commonly applied to survival ~ 
concentration data, this model was also used in the analysis. The relationship 
between survival and dose for each of these models is described in Table 2.1.  
Model choice was made using AIC, assuming that the lowest AIC value identified 
the best-fitting model of the dose-response data (Aho, Derryberry, and Peterson 
2014). Estimates of the LD50 and LD99 were calculated for each model to assess 
differences in predictions between models. 
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Table 2.1 List of dose-response models and their functions for describing the 
relationship between survival and dose.  
Model (parameters) Model function 
Log-logistic (4)  
   
   
     ( (   ( )     ( )))
 
Log-logistic (3)  
      ( (   ( )     ( )))
 
Weibull-1 (3)     (     ( (   ( )      ))) 
Weibull-2 (3)  (     (    ( (   ( )     ( ))))) 
Hormetic (4) 
  
    
      ( (   ( )     ( )))
 
NB: The hormetic model has an additional linear parameter (f) to model 
increases in the response variable at low doses (Fig 2.1D).  
 
 
To test for a difference in background mortality (a cost of resistance) between 
susceptible and resistant populations, survival at the upper asymptote of the 
dose-response curve was compared. Survival data for the susceptible population 
was the same data collected in batch one of the LDT. Survival data for a 
simulated resistant population with a cost of resistance in terms of survival was 
generated by adjusting the data from batch two of the LDT. The data set from 
batch two was adjusted to decrease survival by 4% for 0 and 0.1 ng/ml 
Ivermectin to simulate a cost of resistance. In addition, survival across the range 
of doses where survival dropped in batch two was increased by 5% to simulate 
resistance, doses 1.5, 2, 2.5, 3 and 4 ng/ml Ivermectin. Adjustments in survival 
were achieved by changing the number of survivors in each replicate plate of 
batch two. For instance, to simulate a decrease in survival at the asymptote, 
survival data for each replicate plate at 0 and 0.1 ng/ml Ivermectin was 
adjusted by increasing the number of deaths that occurred in each replicate 
plate by 4%. To confirm that the simulated resistant population had significantly 
higher survival than the susceptible population over the range of doses where 
mortality due to drug treatment increases from zero to 100%, a Weibull-1 model 
of the survival-dose relationship was applied to the simulated data with a 
further explanatory variable for population, and contrasted with a null model 
where population was removed. To test for a cost of resistance between the 
simulated susceptible and resistant populations, a Weibull-1 model of the 
survival-dose relationship was applied to the simulated dataset, which assumed 
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different upper asymptotes between populations, compared to a null model 
assuming a common asymptote. In addition, the survival data from a drug-free 
environment (zero dose) was used to test for a cost of resistance in the 
simulated populations using a GLM, assuming a binomial distribution. This test 
was conducted to assess differences in using a comparison of asymptotes as part 
of dose response modeling, with a standard test of a cost of resistance in a drug-
free environment. Differences in survival between susceptible and resistant 
populations were assessed by comparing a full model with population as an 
explanatory variable against a null model assuming no difference in survival due 
to population.  
 
 
2.4 Results 
 
 
2.4.1 The relationship between C. remanei survival and Ivermectin dose over a 
range of concentrations  
 
 
The 3-parameter Weibull-1 model was identified as the best-fitting model to the 
survival ~ concentration data and had a AIC value 30 points lower than the next 
best model (Fig 2.2 and 2.3, Table 2.2). The predicted LD50 of the 4-parameter 
log-logistic model was similar to that of the Weibull-1 model but no estimate of 
the LD99 or confidence intervals could be made due to the negative predictions 
of survival at high doses (Fig 2.2, Table 2.2). There was no difference between 
the 3-parameter Log-logistic and hormetic models, indicating no initial increase 
in survival due to hormesis at low concentrations of Ivermectin (Fig 2.2, Table 
2.2); both models gave the same predicted LD50 as the Weibull-1 model but the 
predicted LD99 was 20% higher than the Weibull-1 model. The Weibull-2 model, 
which predicts a sharp descent in survival at low doses, gave the worst fit to the 
dose response data; the predicted LD50 was 4% lower than the Weibull-1 model, 
whilst the LD99 was 35% higher (Fig 2.2, table 2.2).  
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Fig 2.2 Comparison of 3-parameter log-logistic, 4-parameter log-logistic, 
Weibull-1 and Weibull-2 models for the relationship between C. remanei survival 
and Ivermectin concentration. A hormetic model was indistinguishable from the 
3-parameter log-logistic model. Black circles show raw data for each replicate 
plate of the larval development assay, and red circles show mean survival at 
each concentration of Ivermectin used in the larval development test. 
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Fig 2.3 Observed data (black circles) and fitted Wiebull-1 model of the 
relationship between survival of C. remanei and concentration of Ivermectin 
with survival data at 0.5 and 1 ng/ml (red circles) removed form analysis. Circles 
show observed mean survival at each concentration of Ivermectin used in the 
larval development test. Dark grey bands show 95% confidence intervals for 
mean survival based on the model.  
 
 
 
 
Table 2.2 Estimates of the slope, LD50 and LD99 (ng/ml Ivermectin) for the dose 
response models fitted to the larval development assay reduced data set (CI: 
95% confidence interval for LD50 and LD99). AIC (Akaike Information Criterion) is 
given for each model fit to the full dataset from the larval development test. SE 
is the standard error of the slope.  
Model (no. 
parameters) 
AIC Slope SE LD50 (CI: 95%) LD99 (95% CI) 
Weibull-1 (3) 
Log-logistic (4) 
Log-logistic (3) 
Hormetic (3) 
Weibull-2 (4) 
666.63 
696.86 
732.83 
732.83 
805.71 
3.04 
4.69 
5.70 
5.70 
4.39 
0.116 
- 
0.210 
0.210 
0.13 
1.85 (1.80, 1.90) 
1.84 
1.85 (1.80, 1.89) 
1.85 (1.80, 1.89) 
1.77 (1.74, 1.81) 
3.45 (3.33, 3.56) 
- 
4.13 (3.94, 4.33) 
4.13 (3.94, 4.33) 
4.65 (4.41, 4.89) 
No estimates could be extracted for the standard error or the LD99 of the 4-
parameter log-logistic mode, because of the negative model predictions. 
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2.4.2 Detecting a cost of resistance in simulated survival data 
 
 
The Weibull-1 model applied to the simulated survival data showed a significant 
difference in the relationship between survival and Ivermectin dose between the 
simulated resistant and susceptible populations (χ2 = 84.60, d.f. = 3, P < 0.0001; 
Fig 2.4), and a difference in slopes of the curves (χ2 = 33.68, d.f. = 1, P < 
0.0001; Fig 2.4). The predicted LD50 for susceptibles of 1.80 (95% CI: 1.73, 1.87) 
was 12% lower than the simulated resistant population: 2.07 (95% CI: 1.99, 2.15; 
χ2 = 74.01, d.f. = 1, P < 0.0001). The test of a difference in background 
mortality, as indicated by a difference in asymptotes between curves, showed 
significantly higher mean survival in susceptibles: 78% (95% CI: 75, 80%) than the 
resistant population: 74% (95% CI: 72, 77%; χ2 =4.33, d.f. = 1, P = 0.033; Fig 2.4, 
Table 2.2). A GLM assuming a binomial distribution found no difference in mean 
survival when applied to data from a drug-free environment (χ2 = 3.08, d.f. = 1, 
P = 0.079; Table 2.2); estimated mean survival for the GLM was 77% (95% CI: 73, 
80%) for susceptibles and 73% (95% CI: 70, 76%) for the simulated resistant 
population. Thus, the test of a difference in asymptote suggested a cost of 
resistance, whilst the GLM failed to detect any cost of resistance. 
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Fig 2.4 Comparison of dose response curves for simulated susceptible (circles) 
and resistant (triangles) populations. 
 
 
 
 
 
 
Table 2.2 Predictions of mean survival at the upper asymptote of the dose 
response curve for simulated susceptible and resistant populations. The GLM 
gives predictions of mean survival using only survival data from a drug-free 
environment.  
Model 
 
X2 
 
 
df    P Mean survival 
susceptible      
(CI: 95%) 
Mean survival 
resistant    
(CI: 95%) 
Weibull-1 4.33 1  0.033 78% (75, 80) 74% (72, 77) 
GLM 3.08 1  0.079 77% (73, 80) 73% (70, 76) 
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2.5 Discussion 
 
 
In order to establish the relationship between survival and drug dose it is 
necessary to fit the most appropriate dose response model and recognize other 
biological sources of mortality, which could affect any estimates derived from 
the final model. This study shows that failure to assess a range of potentially 
suitable dose-response models can result in inaccurate predictions of the level of 
resistance. The best model fit was achieved with the 3-parameter Weibull-1 
model (Fig 2.2 and 2.3). In addition, because the survival data were not 
manipulated prior to analysis, this allowed for a test of a cost of resistance in 
terms of comparing survival at the upper asymptote of the dose response curves. 
 
 
2.5.1 The relationship between C. remanei survival and Ivermectin dose over a 
range of concentrations  
 
 
The principal challenge facing diagnostic measures of resistance is their ability 
to provide early detection during the development of resistance when the alleles 
for resistance are rare in the parasite population (Dolinská et al. 2013). Few 
studies concerned with the detection of resistance consider fitting a range of 
dose response curves when estimating parameters such as LD50‘S and LD99‘S, with 
most implementing log-logistic models (Amarante et al. 1997; Tandon and 
Kaplan 2004; Michaela Dolinská, Königová, and Várady 2012; Dolinská et al. 
2013). My analyses suggest that failing to take into consideration other possible 
dose-response models could result in poorly fitting models with erroneous 
estimates of parameters of interest. For instance, in my study, predictions of 
the LD50 and LD99 differed with respect to the type of dose response curve fitted 
to the data. In particular, the log-logistic model gave higher predictions of the 
LD99 than the best-fitting Weibull-1 model, meaning that estimates of the 
maximum dose the population can tolerate were 20% higher than the best-fitting 
model.  
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Reduced efficacy of a drug could lead to other strategies being implemented to 
control parasite populations, and prevent the spread of resistance (Leathwick 
and Besier 2014). If this decision is made based on incorrect estimates of drug 
efficacy then this could mean that a more expensive control measure is applied 
erroneously. Implementing a range of potentially suitable models that can 
accommodate asymmetry in the dose response relationship, in addition to log-
logistic dose response models, should ensure that the most appropriate model is 
applied to a data set to improve the accuracy of estimates of LD50 and LD99 
values. Studies focusing on the detection of resistance may sample a large 
number of parasite populations over a number of years (Martin et al. 1984; 
Michaela Dolinská et al. 2014), assess resistance to a range of drugs (Demeler, 
Küttler, and von Samson-Himmelstjerna 2010), and perform a variety of in-vivo 
or in-vitro diagnostic tests (Taylor, Hunt, and Goodyear 2002), all of which can 
be analysed using a dose-response approach. It seems unlikely that a log-logistic 
dose response model would be the best fitting under all these circumstances but 
this requires further testing. My study shows that a range of dose response 
models, not commonly applied in parasitology, can be easily implemented and 
assessed when quantifying resistance of parasitic populations. Accuracy, 
reliability and sensitivity of early detection methods aimed at assessing the 
resistance status of parasite populations are all likely to be improved by 
choosing the most appropriate model of dose response data. 
 
 
2.5.2 Detecting a cost of resistance in simulated survival data 
 
 
The test of a difference in asymptotes found a 4% difference in background 
survival between the simulated susceptible and resistant population, suggesting 
that this approach provides a sensitive test to detect a cost of resistance in 
survival. This test was more sensitive than a test of differences in survival in a 
drug-free environment because modeling the asymptote assesses differences in a 
range of doses that cause no drug-induced mortality. However, the difference in 
survival between resistant and susceptible populations at 0.1 ng/ml was greater 
than the difference at dose zero so the GLM used only zero dose data and 
assessed a smaller effect size estimate than the drc model. This does not 
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invalidate the approach of testing for a difference in asymptotes because the 
greater sampling effort used in a test of asymptotes will be more powerful than 
the GLM using less data from a drug-free environment. If dose-response analysis 
was routinely conducted on data that was not standardised for background 
mortality, then a test of the cost of resistance in survival of resistant 
populations could be implemented in addition to comparing LD50 and LD99 
derived resistance ratios. Costs of resistance in other traits measured using dose 
response approaches in relation to resistance could also provide useful data on a 
suite of traits for a parasite population. Fitness-defining traits such as 
development time, fertility and size at maturity can all be measured using a 
dose-response approach, meaning that any of these traits could be assessed for a 
cost of resistance (Ritz et al. 2015). Studies focused on costs of resistance often 
measure life-history traits in environments where control measures are not 
applied (Kliot and Ghanim 2012). However, these investigations could be 
performed as part of a dose response study and would provide informative data 
on both the resistance ratio relative to control populations, and a measure of 
any cost to resistance, for a given trait. 
 
 
2.5.3 Conclusions 
 
 
My study suggests that fitting the most appropriate model without removing data 
on background mortality will give more accurate predictions of dose-response 
curve parameters, compared to methods that manipulate data prior to analysis. 
Incorporating background mortality into the analysis also provides an effective 
method for assessing potential costs to resistance. Current software available for 
analysing dose-response data makes it easy to implement a range of models and 
select the most appropriate model (Ritz et al. 2015). This software also allows 
predictions of measures of resistance (LD50 and LD99) to be easily extracted, and 
provides a test for a cost of resistance. To ensure that the amount of useful 
biological information relating to resistance is maximised when conducting dose-
response studies I recommend: 1) not rescaling data to untreated controls; 2) 
fitting a range of models and testing which provides the best fit to the data to 
ensure accurate predictions; and 3) a test for potential costs of resistance by 
   
 
 48 
comparison of asymptotes from dose-response curves from susceptible and 
resistant populations.  
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Chapter 3: Will my selection experiment actually 
be informative? 
 
 
3.1 Abstract 
 
 
Estimating sample size and statistical power for a study is an important part of 
experimental design. Formulae are available to calculate power only for simple 
studies; for more complex designs, simulation provides a potent alternative 
approach. For example, selection experiments to study evolutionary patterns 
often include multiple sources of variation with potentially complex 
interactions. The purpose of this study was to examine how power to detect 
differences in survival among replicate populations exposed to one of two 
different treatments is affected by experimental design.  Specifically, I focused 
on the effects of both within- and between-line variation on estimated power, 
when detecting small, medium and large effect sizes? Using mixed-effect models 
to analyse simulated data, I demonstrated that commonly used designs with 
realistic levels of variation could be underpowered for substantial effect sizes. 
Thus, use of simulation-based power analysis prior to initiation of selection 
experiments provides an effective tool to avoid under- or over-powering study 
designs incorporating variation at multiple levels. 
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3.2 Introduction 
 
 
Selection experiments are an indispensable tool for asking specific questions 
about changes in the evolution of traits. They can provide valuable evidence as 
to whether a given selection pressure is capable of causing a long-term change 
in either single or multiple traits, and the extent to which genetic correlations in 
traits might constrain evolution (Hill and Caballero 1992; Prasad and Joshi 2003; 
Fuller, Baer, and Travis 2005; Hill and Robertson 2007; Garland and Rose 2009). 
The design of an experiment plays a fundamental role in whether a selection 
experiment is likely to provide a robust answer to a given research question. In 
an early selection experiment, Rev Dallinger (1887) cultivated protists in an 
incubator, gradually increasing the temperature from an initial 60°F up to 
158°F, over seven years. Dallinger noted that the ancestral protists were unable 
to tolerate temperatures above 73°F, whilst protists from the derived 158°F 
culture could not withstand a temperature lower than 150°F. He concluded that 
the change in the environment over many generations had resulted in adaptation 
of the protist culture to increased temperature. However, Dallinger omitted 
several features of selection experiments considered desirable when conducting 
experimental evolution studies, including: use of control populations (lines), 
replication of selected lines, and a method of statistical inference used to assess 
evolved changes. Dallinger‘s work is without doubt a brilliant example of 
pioneering research in experimental evolution. To judge his work in the context 
of today‘s research practices would be unfair, but his experiment provides an 
opportunity to ask a fundamental question facing all researchers when designing 
a selection experiment, ‗Will my study design answer my research question?‘ or 
in statistical terms ‗What is the power of my study?‘ (Johnson et al. 2015). 
 
Power is defined as the probability of correctly rejecting a null hypothesis when 
it is false (Cohen 1962). In other words, power is the chance of detecting an 
effect given that it exists. In simple scenarios, power depends on four other 
parameters: sample size, the size and variability of the effect to be detected 
and the significance level, which is typically set at 5%. Although any of these 
five parameters can be the focus of a power analysis, the usual role of power 
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analysis in experimental design is to determine the sample size required to 
achieve sufficient power (typically 80%, but see Di Stefano 2003). Selection 
experiments often seek to address questions within the constraints imposed by 
limited resources.  Failure to adequately consider power prior to conducting an 
experiment, by adopting sampling schemes based solely on constraints or 
educated guess work using previous research, can result in under or over-
powered studies, which are wasteful of resources (Taborsky 2010).  Thus, using 
power analysis in devising a sampling scheme that will optimise the efficiency of 
the experimental design can result in more robust experiments (Kain, Bolker, 
and McCoy 2015). 
 
Power analysis has been used in the design of selection experiments but 
published methods focus on evolve resequence studies (Kim and Stephan 1999; 
Baldwin-Brown, Long, and Thornton 2014; Kessner and Novembre 2015). For 
example, in a study focused on detecting divergence in single nucleotide 
polymorphisms of lines selected during evolve re-sequence experiments, it was 
found that differentiation between populations was affected by selection 
coefficient, population size, number of replicate populations, and initial 
standing genetic variation (Baldwin-Brown, Long, and Thornton 2014). However, 
use of power analysis to detect divergence in phenotypic traits during selection 
experiments has been less common in methods publications. The importance of 
replication, both at the population level, and sampling within replicate lines is 
well appreciated (Fuller, Baer, and Travis 2005; Garland and Rose 2009c), but 
power analyses are not always reported. For example, of the studies involving 
selection experiments published in BMC Evolutionary biology (n = 6) and 
Evolution (n = 12) in the 12 months from April 2015, none explicitly mention 
power analysis being involved in experimental design to justify study design 
choices in terms of numbers of replicate lines or the sampling of those lines. 
Retrospective power analysis using the observed effect size to estimate the 
power to reject the null hypothesis of no evolutionary change in traits of 
interest between selection regimes has been reported (e.g. Sikkink et al. 2015). 
However, this approach has been frowned upon because calculating power 
retrospectively will not change interpretation of the result, high power always 
corresponds with a significant p-value (Hoenig and Heisey 2001). It would be 
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more useful to address the optimal design of an experiment prior to 
implementation. Conducting an a priori power analysis to optimise the sampling 
design of the experiment for a given research question and publishing it along 
with the findings from a study will lend weight to the credibility of the research, 
whereas retrospective power analysis does not aid the design of a study. 
 
A potential obstacle to the use of power analysis is that standard methods are 
too simple to deal with the more complex design of many selection experiments 
(Fuller, Baer, and Travis 2005; Johnson et al. 2015). Selection experiments often 
seek to measure evidence of selection on traits in environments that differ with 
respect to some abiotic, biotic or demographic condition. During the course of 
selection, new genetic variants are produced through recombination, mutation 
or sampling of alleles, meaning that stochastic processes can make the outcome 
of selection unpredictable (Garland and Rose 2009). In addition, initial 
population size, pre-existing genetic variation and the strength of selection are 
all likely to influence change in any trait. Selection experiments usually aim to 
manipulate one or two environmental or genetic conditions and keep all other 
factors fixed, but the magnitude of change in a trait will always be subject to 
sampling error due to stochastic differences in recombination, mutation or any 
other factor which affects the response to selection occurring between selected 
lines. While some of these variables will be of primary interest, others may be 
included as random effects that could affect interpretation of variance 
associated with the focal fixed effects. Experimental units in selection 
experiments are populations, which are replicated within treatments. This type 
of design introduces random variation at two levels, within and between 
populations, and can be dealt with by the use of simulation. The type of trait 
measured during and at the end of a selection experiment will define what type 
of distribution the response variable takes (Gaussian, binomial, Poisson or 
negative binomial). Simulation-based power analysis with non-normal responses 
such as binomial responses need to take account of within- and between-line 
variation because of the potential for large amounts of variation in the response 
due to binomial sampling variation. Binomial sampling could be accounted for by 
assuming approximation to a normal distribution with standard methods, but 
simulations allow sampling variation in the response to be incorporated into 
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power studies. In addition, by performing multiple hypothetical experiments, 
simulations allow the user think about how data will be analysed before it is 
collected, and identify poor models, which would not be possible when only real 
data is analysed. 
  
One common type of selection experiment, sometimes referred to as laboratory 
culling (Juliano 2002), demonstrates the type of complexity that can pose a 
challenge for standard power analyses.  This type of study involves imposing an 
environmental stress that is lethal to some proportion of a population and the 
offspring of survivors are carried through to the next generation under selection. 
Environmental stressors could take the form of temperature, pathogens, 
predators or chemical control agents and often the strength and consistency of 
selection can be controlled by the investigator (Busi and Powles 2009; Morran et 
al. 2011; Chen and Maklakov 2014). Adaptation in the form of increased survival 
or other traits of lines exposed to the environmental stressor can then be 
assessed by comparisons between evolved treated and control lines. One way to 
assess the effect of selection is to test the null hypothesis that there is no 
difference between treated and control populations. Generalised linear mixed 
models (GLMMs) are often used in null hypothesis testing of selection 
experiments, to assess differences in phenotypes between treatments and deal 
with random variation occurring from multiple sources, such as variation in the 
response between replicate lines (Bolker et al. 2009). Calculating power 
analytically for GLMMs is difficult, but an alternative is to use simulations, which 
can incorporate complex experimental designs with multiple sources of variation 
at different levels like those occurring in selection experiments (Bolker 2007; 
Johnson et al. 2015; Kain, Bolker, and McCoy 2015).  
 
The aim of this chapter is to illustrate how simulations could be used to inform 
important design choices used in selection experiments. Specifically, I asked, 
how do multiple sources of variation resulting from within and between-line 
variation affect power estimates of study designs aimed at detecting small, 
medium and large effect sizes? 
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3.3 Methods 
 
3.3.1 Power analysis simulations 
 
Estimating the power of a range of study designs using a test of a null hypothesis 
by simulation requires the following steps (Bolker 2007):  
1. Identify a suitable range of study designs and establish estimates of 
sources of additional variation. 
2. Simulate many data sets over a range of study designs assuming that the 
null hypothesis is false; i.e., that the effect of interest is not zero. 
Typically, 1000 simulations for a given scenario are adequate to ensure 
confidence intervals of power estimates are acceptable (Johnson et al. 
2015). With 1000 simulations and 80% power, 95% of power estimates 
should fall between 77.5–82.4%. 
3. Perform a statistical test of the null hypothesis that the effect size is zero 
for each simulated data set. 
4. The power estimate for a given scenario can then be calculated as the 
proportion of simulated data sets where the null hypothesis was rejected. 
 
3.3.2 Selection experiment scenario 
 
Here I consider the effects that a realistic range of study designs have on the 
power to detect a difference in survival between treatments in a hypothetical 
study assessing adaptation to a control agent. Replicate populations were 
selected in each environment (drug and control) and at the end of selection two 
replicate samples of each line were exposed to the drug treated environment 
during a resistance assay, and survival data collected. Survival data from this 
type of experimental design were analysed using a GLMM assuming a binomial 
error distribution with a logit link (Zuur et al. 2009). In our hypothetical study, 
treatment was fitted as a fixed effect, the evolutionary replicate (line) was 
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fitted as a random effect to account for additional variation in survival due to 
differences in the response to selection between lines. Additionally, variation in 
survival due to repeated sampling from lines after selection (within-line 
variation) was also fitted as a random effect. The GLMM fitted to describe the 
selection experiment models the number of survivors exposed to the control agent 
in the jth repeated sample from the ith line across the number of individuals initially 
exposed, where survivors yij from nij individuals are binomially distributed yij ~ 
Binom (nij, pij). The log odds of survival, sij = logit (pij), is modeled by equation 1. 0 
is the log odds of survival when x = 0, 1 is the difference between the control and 
treatment groups in log odds of survival (or, equivalently, 1 is the log of the 
treatment effect odds ratio [OR]), and xij defines treatment during selection. Where 
the odds ratio (OR) equals one, there is no difference between treatments xij (1 = 
0); as the OR increases, treatments become increasingly different in terms of the 
proportion of individuals surviving. Thus, the odds ratio is a measure of effect size. 
The replicate line random effect, bi and the repeated sampling random effect wij 
are normally distributed with zero means and variances σb
2 and σw
2, respectively, 
i.e. bi ~ N(0, σb
2) and wij ~ N(0, σw
2).  
 
                                                            ( ) 
 
A likelihood ratio test was used to determine whether survival was affected by 
treatment, by comparing the full model (equation 1) and a null model where 
treatment had no effect. The effect size (difference in survival between 
treatments), total sample size (total number of individuals in the resistance 
assay), number of replicate selection lines, and the number of samples taken 
from within each replicate line, will all have an influence on whether the null 
hypothesis was rejected.  
 
3.3.3 Simulation methods 
 
To assess the effect of between-line and within-line variation on power 
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estimates of a range of experimental designs, I simulated survival data. This was 
achieved by estimating power across a realistic range of study designs 
incorporating assumptions about sources of additional variation (Table 1), and 
then identifying those that gave adequate (≥80%) power. For the simulated 
selection experiments the number of replicate lines used for each treatment was 
varied over the range; 2, 4, 6, 8 and 10. To incorporate an estimate of the 
effect of increasing sampling effort in resistance assays used at the end of the 
selection experiment into the simulation, the total number of individuals 
assayed across both treatments was simulated at n = 200, 400, 800, 1600, 3200 
and 6400. To explore the effect of within-line variation on power estimates, 
realistic variance (σw
2 = 0.1) in survival was simulated. This level of variation in 
survival was consistent with that found during analysis of dose-response data in 
Chapter 2. To explore the effect of not accounting for within-line variation, σw
2 
= 0 and σw
2 = 0.1, were simulated only for large effects, with a sampling effort 
of n = 400. Differences in effect size, the absolute difference in survival 
between control and treated lines, were set at 5%, 10% and 20%, and correspond 
to Cohen‘s definition of small, medium and large effect sizes (Cohen 1962). In 
addition, to estimate the chances of making a type I error, the simulations 
included a scenario with no difference between treatments; i.e. survival in the 
control lines equaled survival in treated lines. Survival of drug naive populations 
in a treated environment was fixed at 13%; this information was used to 
establish the predicted log odds of survival in control lines. To explore the effect 
that between-line variation (σb
2) had on power estimates, differences in survival 
due to variation in the response to selection were simulated at three levels (σb
2 
= 0, 0.1, and 0.2) for both treated and control lines: σb
2 = 0, as a means of 
assessing the impact of not incorporating realistic assumptions about variation in 
between-line responses to selection; σb
2 = 0.1, similar to the variation in 
response to selection observed in Chapter 3; and σb
2 = 0.2, a pessimistic 
assumption of strong between-line variance.  
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Table 3.1 Values for the parameters used in the study designs to assess power in 
the simulation-based power analysis.  
Study variable Simulated values 
Number of lines used per treatment 
group 
2, 4, 6, 8, 10 
Between-line variance σb
2 
Total number of individuals assayed 
at the end of selection across both 
treatments 
Number of drug resistance assay 
replicates conducted for each line at 
the end of selection 
Within-line variance σw
2 
0, 0.1, 0.2 
200, 400, 800, 1600, 3200, 6400 
 
2 
 
0a, 0.1 
Initial survival as a result of control 
agent 
13% 
Absolute increase in survival between 
drug-treated and untreated lines 
(Odds ratio) 
0% (1), 5% (1.5), 10% (2), 20% (3.3) 
a: Within-line variance was only simulated at two levels for large effect size 
(20% difference in survival) with a sampling effort of 400 individuals. For 
simulations at medium (10%) and small (5%) effect size, within-line variance was 
fixed at 0.1. 
  
Survival data was then simulated over the range of study designs and sources of 
additional variation. All combinations of the parameter values from table 1 were 
used in the simulations, resulting in 360 scenarios. For each scenario 1000 
datasets were simulated from binomial distributions using the statistical 
environment R (R Core Team 2014). Power was then calculated for each scenario 
by analysing each dataset with a linear mixed effects model (LMM) using Wald t 
tests to assess significance under the null hypothesis that there is no difference 
between treated and control lines, with a significance threshold of P = 0.05. We 
fitted a LMM to the binomial response data rather than a GLMM to test for 
significance because GLMMs have been found to suffer from high type I errors as 
a result of variance in random effects being misspecified (Ives 2015), and high 
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type I errors were observed with GLMMs in preliminary simulations. Where 
samples sizes are large, as was the case in the simulations, the distribution of 
binomial data approaches that of a normal distribution and can be modeled with 
a LMM. The LMMs were implemented using the lme4 package (Bates, Maechler 
2014), and p–values calculated using lmerTest (Kuznetsova, Brockhoff, and 
Christensen 2016). In the final step of the power analysis, the power to detect a 
difference in survival between drug-treated and control populations for each 
scenario was estimated as the proportion of 1000 simulated data sets where the 
null hypothesis was rejected. The simulated survival datasets were then used to 
assess how within- and between-line variation affect power estimates when 
aiming to detect small, medium and large differences in survival between 
treatments.  
 
3.4 Results 
 
The simulation-based power analysis showed that the effect size, the number of 
replicate lines and subsampling effort all affected the power of the experiment 
(Fig 3.1). In terms of trade-offs between the number of lines and total sampling 
effort, power estimates benefitted from greater numbers of lines, but only when 
a certain level of sampling effort was achieved, and higher levels were required 
for smaller effect sizes. In addition, power decreased with increasing variance in 
the between-line response to selection (Fig 3.1; dashed and dotted lines). The 
false positive (Type I error) rate for null hypothesis testing remained at an 
acceptable level (5% ±2%) under all scenarios (Fig 3.1A-F; black lines). Not 
accounting for within-line variation in survival resulting from repeated 
subsampling from lines led to higher power estimates than where this source of 
variation was included, but the magnitude of difference in power estimates due 
to within-line variation decreased with the number of replicate lines (Fig 3.2). 
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3.4.1 Large effect size 
 
In scenarios with a large effect size (20% difference in absolute survival), 
adequate power (≥80%) was not achieved with only two replicate lines per 
treatment group, even when using the highest level of sampling effort, and with 
no variation in the response to selection (Fig 3.1F; blues lines). Where four 
replicate lines per treatment were used in simulations, the 80% power threshold 
was achieved when total sampling effort in the resistance assays was 400 and 
800 individuals, for scenarios where the variance in the response to selection 
was zero and 0.1, respectively (Fig 3.1B; blue solid line, and Fig 1C; blue dashed 
line, respectively). Six replicate lines per treatment and a sampling effort of 400 
individuals ensured ≥80% power when variance in the response to selection was 
at its highest (Fig 3.1B; blue dotted line).  
 
3.4.2 Medium effect size 
 
To detect an absolute difference in survival between treatments of 10%, eight 
replicate lines and a total sampling effort of 800 individuals were required to 
meet the 80% power threshold under scenarios with no variation in the response 
to selection (Fig 3.1C; solid red line). Where σ2 = 0.1 for the between-line 
response to selection, scenarios with eight replicate lines and a sampling effort 
of 3200 individuals were required to meet a target power of 80% (Fig 3.1E; 
broken red line). Under simulations at the highest variance (σ2 = 0.2) scenario 
for between-line variation in the response to selection, 10 replicate lines and a 
sampling effort of 6400 individuals achieved 79% power. 
 
3.4.3 Small effect size 
 
Power estimates from simulations with a small difference in survival (5%) 
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between treatments at the end of selection remained well below the 80% 
threshold under all scenarios, except in the case where sampling effort was at it 
greatest (n = 6400), with 10 replicate lines per treatment, and no variation in 
the between-line response to selection (Fig 3.1F; solid green line).  
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Fig 3.1 The relationship between the power to detect a difference in survival 
between drug-treated and control lines, and the number of replicate lines within 
a treatment after a hypothetical selection experiment. Each power estimate was 
derived from 1000 simulated data sets, generated under scenarios that varied 
effect size (increase in survival relative to control treatment), and variance in 
the response to selection between lines (variance). Panels A through F show the 
effect of increasing sampling effort in resistance assays after selection.  The 
broken grey line shows the target power of 80%, and the solid grey line shows 
the 5% expected type I error rate when there is no survival difference between 
control and treatment. Within-line variance was set at σw
2 = 0.1 for all 
scenarios. 
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Fig 3.2 The effect of increasing variance in survival due to subsampling of 
replicate lines over a range of replicate line numbers, where a large difference 
in absolute survival (20%) between treatments was simulated. Within-line 
variance is variation due to differences in survival between resistance assay 
replicates. Between-line variance represents variation in the response to 
selection between replicated evolutionary lines. 
 
 
3.5 Discussion 
 
 
The results of the simulations presented here show that power increases with 
replication of lines and increasing sampling effort from lines. Study designs 
simulating large differences in absolute survival (≥20%) between treatments 
showed adequate power to reject the null hypothesis even when variation in the 
response to selection was high, so long as line replication was above two. Even 
where there was no variation in the response to selection (i.e. no variation 
between replicate lines), detection of medium effects (10%, difference in 
survival between treatments) required four times the total sampling effort 
needed to detect a large effect. When between-line variation was included in 
simulations, a substantial investment in line numbers and total sampling effort 
was necessary to achieve sufficient power; 10 lines and 1600 individuals in total, 
respectively. All but the most intensive sampling strategy in terms of line 
numbers and total sampling effort was insufficient to achieve target power for 
small effects, and only where there was no variation in the response to 
selection. Collectively, the results of these simulations indicate the importance 
of clearly designating the sources and possible magnitude of variation when 
determining an appropriate experimental design.  
 
Perhaps the most influential constraint facing investigators when planning a 
selection experiment is the number of replicate selection lines to use. Often this 
is constrained by the study organism. Line replication is generally higher in 
systems using viruses and microorganisms (Lenski and Travisano 1994), than in 
the case of invertebrates (Stearns, Ackermann, and Doebeli 1998) and 
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vertebrates (Baer, Travis, and Higgins 2000), but is also influenced by the 
number of treatments used in the experiment. Typical line replication per 
treatment can be in the range of two to ten lines for many of these study 
systems. For example, experimental evolution studies using nematodes all use 
line replication within this range (Lopes et al. 2008; Morran, Parmenter, and 
Phillips 2009; Anderson et al. 2011;Chen and Maklakov 2012; Dutilleul et al. 
2014; Fritzsche et al. 2014; Morran et al. 2014; Savory et al. 2014; Dutilleul et 
al. 2015). My results suggest that replication within this range is prone to low 
power to detect an effect for the specific example of divergence in survival 
during culling selection experiments, under the conditions presented here. The 
low power estimates are of particular concern when detecting smaller effects 
where variation in the response to selection and variation affecting estimates of 
the response to selection is large. It is difficult to assess whether selection 
experiments often have underpowered designs, as such studies are less likely to 
be published, but if the results of my simulations generalise to measures of 
divergence in other traits, as well as survival, then simulation-based power 
studies would do much to ensure the design of new selection experiments is 
optimised. The number of samples taken from within each replicate line at the 
end of selection used to measure divergence in a trait can also be a key 
constraint when designing a selection experiment. Increasing sampling effort 
from within lines will improve the precision of line estimates for the trait of 
interest. Decisions about within-line sampling effort, like replication of lines 
themselves, are not generally justified by investigators other than the suggestion 
that greater replication is better (Fuller, Baer, and Travis 2005; Garland and 
Rose 2009). My study suggests that incorporating both the intensity of repeated 
sampling and variation that occurs as a result of repeated measures into power 
analysis, has significant implications for experimental design. Generally, greater 
sampling effort improves power, but specifically conducting power analysis 
allows the trade-off between replication of lines and the intensity of sampling 
effort from those lines to be explored.  
 
Simulation-based power analysis can be extended beyond the binomial response 
variable modeled in this study, to Gaussian (Arnold et al. 2011), Poisson 
(Johnson et al. 2015), proportional hazards models (Feiveson 2002), and to 
detecting differences in among treatment variation (Kain, Bolker, and McCoy 
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2015). Simulation-based methods of a priori power analysis provide a flexible 
framework in which to test a study design‘s ability to answer a particular 
research question. Given the utility of simulation-based power analysis, it seems 
surprising that it is underused or underreported within the field of experimental 
evolution. Researchers within the field are aware of sources of random variation 
that might affect inferences drawn, and take appropriate measures to deal with 
these effects in statistical analyses (Hurlbert 1984; Bolker et al. 2009). Why then 
is power analysis infrequently used? One reason is that investigators are 
unaware, or aware and lack the know-how involved in testing complicated study 
designs using power simulations.  Alternatively, researchers are aware but 
unconvinced of the value of simulation-based power analysis for their study, and 
instead rely on experience or duplicating designs used by others. My study shows 
that selection experiment designs incorporating multiple sources of variation, 
which would be difficult to deal with using standard analytical techniques, can 
be assessed using simulation-based methods comparable in complexity to the 
methods used to analyse real experimental data. Thus, any barrier in adopting 
simulation-based methods due to lack of know-how can be easily addressed. The 
results of the power simulations also show the danger in adopting a strategy of 
copying other study designs. For example, if the expected effect size differs 
greatly between two studies then a copying strategy to experimental design risks 
over- or under-powering the study, which are both wasteful of resources. 
Instead, power simulations allow a study to be designed, which is aimed at 
detecting the smallest effect judged to be biologically meaningful in the context 
of the question being asked. 
 
My study shows that commonly used designs with realistic levels of variation can 
be underpowered, even for substantial effect sizes. The use of simulation to 
estimate study design power extends conventional power calculations to 
accommodate complex designs that often arise in practice. Researchers can use 
simulations to estimate power for virtually any realistic experimental design; 
meaning that study designs are constructed using a formal statistical approach, 
and thus, more likely to yield informative results. Promoting the use of a 
simulation-based approach would improve the standard of study design in 
evolutionary biology by providing a convenient means to identify and avoid 
under or overpowered designs. 
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Chapter 4: Evolution of drug-tolerant nematode 
populations in response to density reduction 
 
 
4.1 Abstract 
 
 
Resistance to xenobiotics remains a pressing issue in parasite treatment and 
global agriculture. Multiple factors may affect the evolution of resistance, 
including interactions between life-history traits and the strength of selection 
imposed by different drug-doses. We experimentally created replicate selection 
lines of free-living Caenorhabditis remanei exposed to Ivermectin at high and 
low doses to assess whether survivorship of lines selected in drug-treated 
environments increased, and if this varied with dose. Additionally, we 
maintained lines where mortality was imposed randomly to control for 
differences in density between drug-treatments and to distinguish between the 
evolutionary consequences of drug-treatment vs ecological processes due to 
changes in density-dependent feedback. After 10 generations we exposed all of 
the selected lines to high-dose, low-dose and drug-free environments to 
evaluate evolutionary changes in survivorship as well as any costs to adaptation. 
Both adult and juvenile survival was measured to explore relationships between 
life-history stage, selection regime and survival. Intriguingly, both drug-selected 
and random-mortality lines showed an increase in survivorship when challenged 
with Ivermectin; the magnitude of this increase varied with the intensity of 
selection and life-history stage. Our results suggest that interactions between 
density-dependent processes and life-history may mediate evolved changes in 
susceptibility to control measures. 
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4.2 Introduction 
 
 
Pesticide and drug treatments are designed to suppress populations of parasites, 
pests and disease vectors. This makes them strong selective factors; as a result, 
adaptation consistently occurs in natural populations exposed to xenobiotics 
(Jackson 1993; Carriere et al. 1994; Wolstenholme et al. 2004; Sparks et al. 
2012). Resistance can evolve quickly (Lopes et al. 2008; Brausch and Smith 2009; 
Tabashnik et al. 2014), and the development of resistance is becoming an 
important theme in applied evolutionary biology due to the risk of reduced 
efficacy of chemical applications to control parasite and pest species (Palumbi 
and Mu 2001; REX Consortium 2010; REX Consortium 2013; Hendry et al. 2011). 
However, evolutionary strategies which could curtail the rate of resistance 
evolution have yet to be adopted universally (Greene et al. 2012). Several 
factors are known to affect the rate at which parasites can evolve resistance, 
including the type of drug, dosage, timing of application, migration rates 
between susceptible and resistant populations, the standing frequency of 
resistance alleles in the population and the specific mechanisms of resistance 
(Committee on Strategies for the Management of Pesticide Resistant Pest 
Populations 1986; James, Hudson, and Davey 2009; Gilleard and Beech 2007; REX 
Consortium 2013; Barnes, Dobson, and Barger 1995). Low population densities in 
drug-treated environments may also have some influence on susceptibility if 
there are interactions between susceptibility and competition for resources or 
any other density-dependent processes. However, it is difficult to tease apart 
the effects of mortality caused by the drug from those caused by density-
dependence (Gilleard and Beech 2007). In addition, life history characteristics 
and reproductive strategies of parasites and pests could influence the rate at 
which resistance develops (Galvani and Gupta 1998; Lynch, Grimm, and Read 
2008; Kliot and Ghanim 2012). The influence of such factors, and their 
interactions, on resistance evolution has been considered theoretically but there 
has been little attempt to show that these factors are of practical significance in 
the laboratory or field.  
 
Experimentation and monitoring of complicated host-parasite systems is 
technically difficult, expensive and time-consuming (Leathwick et al. 2009) and 
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thus resistance evolution is often predicted by simulations. For example, Barnes 
et al (1995) used mathematical modeling to investigate the effects of under-
dosing on the evolution of resistance. They suggested that the outcome of 
under-dosing in terms of the rate of resistance evolution would depend on the 
genetic mechanism underlying resistance. An alternative to allow specific testing 
of factors associated with resistance while maintaining more biological 
complexity, is to use laboratory models to simulate the evolutionary process 
(Taylor, Quaglia, and Georghiou 1983; Lopes et al. 2008; Busi and Powles 2009).  
Previous experimental evolution studies have reported rapid evolution of drug 
resistance in a variety of organisms; including insects, nematodes and other 
invertebrates (Barros et al. 2001; Lopes et al. 2008; Jansen et al. 2011). These 
studies often employ one of two strategies in generating resistance: 1) impose a 
continuous drug or pesticide dose on a population and monitor adaptation over a 
number of generations; or 2) increase drug dose at regular intervals, often every 
generation, to track the dose of drug required to cause a target mortality level 
(e.g. 50% mortality; LD50) in the population under selection. Few studies have 
specifically looked at the effect of dosage on the rate of resistance evolution, 
although Busi and Powles (2009) found that selection under exposure to both low 
and high doses of glyphosate caused a rapid increase in survival of rye grass over 
three generations and that higher doses promoted a greater magnitude of 
resistance. However, resistance screens were performed on the first generation 
offspring of selected plants therefore any response could have been due to 
maternal effects. Experimental selection over multiple generations at different 
sublethal doses would help to further elucidate the relationship between dose 
and the rate of resistance evolution. 
 
In addition to dosage, differences in population density between treated lines of 
parasites and pests could result in differential selection due to density-
dependent processes such as competition (Gilleard and Beech 2007). Laboratory-
based selection experiments often impose strong selection on generation time or 
timing of reproduction when reproductive strategies are influenced by density-
dependent effects (Chehresa, Beech, and Scott 1997). Since the application of a 
drug or pesticide treatment reduces population size, this will create differences 
in population density between treatments, which could alter apparent evolution 
of resistance due to changes in traits that are not directly associated with 
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responding to the chemical exposure (Gilleard and Beech 2007). Selection 
experiments investigating the rate of resistance evolution typically involve 
comparisons of survival and/or life history in a drug treatment compared to a 
control treatment with no drug applied (Ranjan et al. 2002; Coles, Rhodes, and 
Wolstenholme 2005; Lopes et al. 2008). However, this methodology does not 
account for differences in population density resulting from differences in 
mortality between the treatments. If studies are to be biologically realistic and 
drug treatments involve the bottlenecking of populations then the experimental 
design must separate the indirect effects of reduced density from the direct 
effects of the drug (Fuller, Baer, and Travis 2005). 
 
The treatment of helminth diseases provides a well-documented field of 
research in which to explore problems related to resistance evolution using an 
experimental approach (Driscoll 1989; Kaplan et al. 2011; Sangster and Gill 
1999). Ivermectin is a broad-spectrum antiparasitic drug and has been used 
commercially since 1981 (James, Hudson, and Davey 2009), with the first reports 
of resistance in 1988 (Kaplan 2004). Ivermectin causes paralysis in larvae and 
adult nematodes and inhibits feeding (Sangster and Gill 1999) but also has a 
repellent effect at sub-lethal doses (Ardelli et al. 2009). Because parasitic 
helminths are difficult to culture, research into anthelmintic resistance has a 
long history of using the model organism Caenorhabditis elegans in both drug 
screening and identifying candidate resistance loci (Simpkin and Coles 1981; 
James, Hudson, and Davey 2009; Ghosh et al. 2012). However, C. elegans is an 
androdioecious nematode species that reproduces mainly by sef-fertilisation, 
although low levels of outcrossing do occur as a result of the small proportion of 
males present in a population (Brenner 1974; Barrière and Félix 2007). Since 
most parasitic nematodes are dioecious and obligately outcrossing, other free-
living dioecious nematodes such as C. remanei may provide a more realistic 
model system to explore resistance evolution. C. remanei populations have 
abundant standing genetic variation and high levels of recombination due to 
their reliance on sexual reproduction (Cutter, Baird, and Charlesworth 2006). 
Both of these attributes should facilitate a rapid response to selection. 
Additionally, Caenorhabditis species provide an effective microcosm system, 
which has been used to answer a broad range of evolutionary questions related 
to rapid evolutionary change (Lopes et al. 2008; Morran et al. 2011; Gray and 
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Cutter 2014). Manipulating drug dosage, as well as controlling for differences in 
population density between treated lines in simple microcosm systems, may 
provide us with a better understanding of how natural populations of parasites 
and pests adapt to control measures. 
 
The terms resistance and tolerance are often used inter-changeably when 
defining reduced susceptibility to xenobiotics and has led to much confusion on 
their relative importance in the evolution of reduced susceptibility. Tabashnik et 
al. (2014) define resistance as a genetically based decrease in susceptibility as a 
result of exposure to a control agent; this definition emphasizes a heritable 
change in susceptibility of a target population due to previous exposure to a 
control measure. In other words, the spread of resistance through a population is 
the result of an increase in frequency of pre-existing alleles conferring reduced 
susceptibility, novel or spontaneous mutations or migration of resistance alleles 
between populations during a period of time where the population is exposed to 
a drug (Gilleard and Beech 2007). By this definition a population cannot be 
resistant prior to exposure to a control agent and resistance results as an 
evolved response, specifically due to drug application. Tolerance, on the other 
hand, is due to natural variation in susceptibility already pre-existing within or 
between populations rather than a result of selection pressure imposed by 
control measures (Scott 1995). Tolerance may also be used to describe pre-
existing differences in susceptibility between different species or between life-
history stages of organisms (Coles and Dryden 2014). For example, sensitivity to 
Ivermectin has been shown to vary substantially among species of sepsid dung 
flies (Puniamoorthy et al. 2014). Puniamoorthy et al (2014) found that tolerance 
was explained by phylogenetic relationships; more closely related species had 
similar levels of susceptibility to Ivermectin on naïve exposure. However, they 
could not rule out the possibility of rapid adaptation of species to Ivermectin but 
suggested that this was unlikely as they found more variation in Ivermectin 
sensitivity between species within sample sites than variation within species 
between sample sites. Additionally, some of the least susceptible species were 
known to be drug naïve as they were sampled from locations where 
anthelmintics have not been used. This suggests that tolerance may occur due to 
pleiotropic effects and selection on some other unknown trait may result in pre-
adaptation in the form of reduced susceptibility. If the frequency and magnitude 
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of tolerance within a population is affected by selection on unknown traits, the 
factors which effect selection on those traits will play an important role in 
governing susceptibility to control agents prior to exposure. In addition, drug-
treated populations could evolve tolerance in parallel to resistance if evolved 
decreases in susceptibility are associated with density-dependent selection, and 
affect the apparent rate of resistance evolution (Gilleard and Beech 2007). It is 
difficult to separate tolerance from resistance unless this is explicitly 
incorporated into the experimental design but this also requires knowledge 
about which traits confer differences in tolerance to a particular xenobiotic.  
 
The overall aim of this study was to assess how Ivermectin dosage, and changes 
in population density affect the rate of resistance evolution in replicate lines of 
C. remanei. Specifically, we asked: 1) What is the relationship between C. 
remanei survival and Ivermectin dose over a range of concentrations within a 
single generation? 2) Is there an increase in survivorship across generations of 
populations selected in drug-treated environments, and does this vary with 
dosage? 3) Does density-dependent selection affect the apparent evolution of 
resistance in selected lines? 4) Is there a cost of adaptation to drug-treated 
environments in terms of survival in drug-free environments? We also explored 
the relationship between life-history and drug selection, asking: 5) Does survival 
of different life-history stages (juvenile and adult) respond to drug-selection in 
the same way? 
 
 
4.3 Methods 
 
 
4.3.1 Origin and maintenance of experimental lines 
 
 
In order to maximise the degree of standing genetic variation available to select 
for resistance we obtained a genetically diverse strain of C. remanei (SP8) from 
N. Timmermeyer in the Department of Biology, University of Tübingen, 
Germany. This strain was originally created by a fully factorial crossing of three 
wild-type strains isolated from geographically distant locations (SP146 from 
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Freiburg, Germany; MY31 from Tübingen, Germany; PB206 Ohio, US). Crosses 
had been tested for fertility, offspring pooled, and maintained for eight 
generations to create recombinant genotypes and allow adaptation to standard 
laboratory conditions (Fritzsche et al. 2014). Upon arrival in Glasgow, strain SP8 
spent a further four generations adapting to any differences in conditions 
between laboratories and was maintained under standard laboratory conditions 
for Caenorhabditis species: 20˚C and 60% humidity on NGM (Nematode growth 
medium) petri dishes and fed on a lawn of Escherichia coli (OP50) (Hope 2001). 
 
 
4.3.2 Dose response assay 
 
 
In order to choose two distinct doses that differ in the intensity of selection 
imposed during the selection experiment, it was first necessary to quantify the 
relationship between drug dosage and survivorship for strain SP8. A stock 
solution of 2 mg/ml Ivermectin (22,23-Dihydroavermectin B1; Sigma-Aldrich) 
dissolved in DMSO was decanted into 1 ml aliquots and frozen to provide a 
standardised drug dose. We used a modified version of the dose response 
approach taken by Rufener et al. (2010) to quantify survivorship of C. remanei 
over a range of doses (0, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9 and 10 
ng/ml). Appropriate dilutions of Ivermectin were administered to 100 ml liquid 
NGM (50°C) and mixed with a magnetic stirrer before pouring 7 ml aliquots into 
5.5 cm plastic petri dishes. These were left to dry, seeded with E. coli (OP50) ad 
libitum to minimise indirect mortality resulting from repellence at low doses and 
incubated at 20°C overnight. Concurrently to preparing dosed plates, age-
synchronised eggs were harvested from stock populations of C. remanei by 
bleaching using standard protocols. This process kills adults and juveniles but 
leaves developing embryos unharmed (Hope 2001). Eggs were moved to fresh 9 
cm drug and food-free petri dishes and incubated overnight to provide a source 
of L1-arrested larvae for drug screening. After 12 hours incubation, larvae were 
suspended in M9 buffer solution (3g KH2PO4, 6g Na2HPO4, 5g NaCl, 1 ml M MgSO4, 
H20 to 1 litre and sterilised by autoclaving) and 5 µl aliquots of this suspension 
were added to Ivermectin-dosed plates with the aim of applying approximately 
60 larvae per plate. Larvae added to petri dishes were counted as they were set 
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up; survival data were obtained by counting the number of adults present per 
plate at 75 hours. C. remanei become reproductively active two days after 
hatching (Diaz, Lindström, and Haydon 2008) so survivorship was measured at 75 
hours after L1 larvae were exposed to the relevant dose of Ivermectin. Twenty 
replicate plates were established for each Ivermectin dose (ten replicates in 
each of two different batches conducted at different times).  
 
 
4.3.3 Selection experiment 
 
 
Two Ivermectin doses were chosen as drug treatments for experimental 
evolution (Fig B1: Appendix B) a high dose that corresponded to 80% mortality at 
75 hours in naïve populations; and 2) a low dose that corresponded to 40% 
mortality. These two doses were combined with a control of no drug application 
(zero = Z, low drug = LD, and high drug = HD, Fig 1A). In addition, a random 
mortality treatment was included for the low and high dosages to account for 
differences in density between drug treatments (low random = LR, and high 
random = HR) by randomly removing the same number of individuals from these 
plates as had died in response to the corresponding drug treatment. For 
instance, if two females and six males had died in a drug-treated line, a sister 
random mortality line had the same number of each sex removed. All lines were 
exposed to high (HD and HR) and low mortality environments (LD and LR), with 
three replicates per experimental line per treatment, with the exception of the 
controls, which were replicated six times. 
 
Experimental lines were cultured for 10 generations. The ancestral stock strain 
(generation 0) as well as samples of larval worms from each line at generations 5 
and 10 were cryogenically frozen at -80˚C Fig. B1: Appendix B), at a density of 
approximately 2000 L1 larvae in liquid freezing solution as described in Hope 
(2001). Generation 1 (18 lines overall) was initiated using standard bleaching 
methods from the ancestral stock strain of SP8 cultured in the lab for four 
generations after thawing and represents the ancestral condition (generation 0; 
Fig 4.1B). L1-arrested larvae were suspended in M9 buffer and worm density of 
the suspension obtained by counting worms from five replicates of 5-µl aliquots. 
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A volume of the suspension corresponding to 400 L1-larvae was then added to E. 
coli seeded NGM plates (9 cm) with the appropriate dose of Ivermectin. 
Establishing populations with 400 larvae prevented density-dependent 
competition but still contains sufficient numbers of individuals to ensue a 
substantial proportion of standing genetic variation (Allendorf 1986). After 48 
hours of development worms reach the 4th larval stage (L4) at which point the 
sex can be determined. At this time, 25 pairs of male and female L4 larvae were 
transferred to fresh agar plates of the appropriate dose for each replicate. 
These 50 adults constituted generation one, day one. After 24 hours adults were 
counted and census data were used to impose an equivalent mortality on the 
random mortality lines for the respective treatments. After 48 hours of drug 
exposure the same process of adult census and compensatory-induced mortality 
was repeated. By 72 hours larvae from the next generation had developed to L4 
larvae: 25 pairs were selected to continue the next generation and transferred 
to fresh petri dishes. This was continued for 10 generations. Census data were 
gathered each generation to assess whether there was an increase in 
survivorship of lines selected in drug-treated environments and whether this 
increase varied with dosage. In addition to adult census, a juvenile census was 
performed after 48 hours to provide an estimate of juvenile population 
densities.  L2 and L3 larval stages were counted along a 1cm transect covering 
the center of the petri dish; L1 juveniles were too small and numerous to gather 
reliable counts. 
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Fig 4.1 A) Schematic representation of dose-response assay, selection 
experiment and resistance bioassay. The starting population of SP8 was adapted 
to lab conditions. The lab-adapted strain was then assayed for variation in 
susceptibility to Ivermectin over a range of 15 doses, to select an appropriate 
high and low dose for the selection experiment. The lab-adapted strain was then 
randomly divided into five treatments with three replicates each for HD, LD, HR, 
and LR lines, and six replicates for Z lines. After 10 generations of selection, 
lines were frozen and later thawed, before being challenged with the three 
doses of Ivermectin used during the original selection experiments. B) Schematic 
representation of selection experiment showing initial population set up and one 
generation. Initially, lines were established with 400 larvae exposed to the 
relevant dose of Ivermectin; 50 adults were then selected to begin generation 
one on day one. After 24 hours lines were counted and compensatory mortality 
imposed on random lines; this was repeated at 48 hours. After 72 hours sub-
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adults from the next generation were transferred to new plates. Generations 2 
to 10 proceeded as for generation 1. HD: High dose treatment; HR: High random 
treatment; LD: Low dose treatment; LR: Low random treatment; Z: Zero dose 
treatment. 
 
 
4.3.4 Drug resistance bioassays 
 
 
In order to formally assess whether heritable increases in survivorship were 
imposed by selection with Ivermectin, ancestral stocks (generation 0) as well as 
each of the selected lines from generation 5 and 10 were exposed to the same 
high and low doses of Ivermectin used during selection and raised in a drug-free 
environment. Firstly, to test the effects of drug dosage on survival, revived 
samples of HD, and LD lines were exposed to a dose of Ivermectin corresponding 
to that used during selection. Survival of these lines was then contrasted with 
survival of Z lines to assess whether there was a change in evolved lines. 
Secondly, to test for effects of differences in population density on survival of 
selected lines we exposed HR and LR lines to a high and low dose of Ivermectin, 
respectively. Survival of HR and LR lines were contrasted with Z lines, with any 
significant differences in survival between random mortality and Z lines 
indicating an effect of population density on relative survival. Thirdly, we tested 
for any cost to adaptation to selection regime in terms of survival by raising 
evolved lines in a drug-free environment, with the hypothesis that if there is a 
cost to adaptation then experimentally treated lines should show significantly 
lower survival than control (Z) lines.  
 
Preserved samples of lines from the selection experiment at generations 0, 5 and 
10 were thawed and raised for three generations in a drug-free environment to 
ensure that any observed responses in survival were due to genetic differences 
among populations and not maternal or environmental effects due to freezing. 
Larvae were thawed at room temperature and maintained at a density of 
approximately 1000 individuals per 9cm agar plate over the three generations 
from thawing to age synchronization with ad libitum lawns of E. coli OP50. 
Transfers between generations were achieved by cutting out sufficient agar from 
plates already containing samples and transferring these to fresh E. coli seeded 
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plates ensuring the density remained as constant as possible. Agar plates, 
synchronisation of experimental lines and set-up of larvae were conducted with 
the same protocol used in the dose response assay. Mortality due to drug 
application may differ between life history stages; in order to gain some 
measure of this difference we measured survival both at 52 hours, encompassing 
juvenile development and 75 hours, during the first day of reproduction. 
Generations 5 and 10 of each experimental line were replicated four times, as 
was the ancestral line (generation 0). 
 
 
4.3.5 Statistical analyses 
 
 
All statistical analyses were performed using R v 3.1.2 (R Core Team 2014) and 
we defined a significance threshold of P = 0.05 for all tests. A more detailed 
description of the rationale for the statistical approaches used is provided in the 
Supplementary information.  The doses required to cause 40% and 80% mortality 
of the ancestral SP8 strain were estimated, with 95% CI‘s, using the drc package 
(Ritz and Streibig 2007). In order to calculate estimates of these two doses we 
constructed a dose-response curve of the relationship between worm survival 
and concentration of Ivermectin. We fitted a range of dose-response models 
(log-logistic, Weibull-1 and Weibull-2) with the lower asymptote of the curve 
fixed at 0% survival and used maximum likelihood to select the most appropriate 
model of survival data. Ivermectin concentration and batch were fitted as fixed 
effects in our full model. To assess whether the relationship between 
survivorship and Ivermectin concentration remained the same between batches 
performed at different times (i.e. repeatability), batch was removed from the 
model and compared against the full model using a likelihood ratio test. 
Estimates of the required doses, with 95% CIs, were then derived from model 
predictions. 
 
Our experimental design incorporated a power analysis, which specifically 
adjusted for the effects of the number of lines, interline variation, the potential 
observable difference in survival between treatments (effect size), and bioassay 
replicate (Johnson et al. 2015). We estimated that our experimental design gave 
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93% power to detect an absolute difference in survivorship of 10% in the high 
dose environment between the control Z lines and both HD and HR lines. To 
assess whether survivorship changed over the course of the selection 
experiment, data from the resistance bioassay were analysed using generalised 
linear mixed models using the glmer function in the lme4 package assuming a 
binomial error distribution with a logit link function (Bates et al 2014; see 
Appendix B). Treatment and generation and the interaction between them were 
fitted as fixed effects. The evolutionary replicate (line) was fitted as a random 
effect. An observation-level random effect was fitted to account for any 
overdispersion between replicate lines in the selection experiment and repeated 
sampling of populations in the drug resistance bioassay (Browne et al. 2005). 
Treatment effects in the selection experiment were tested using likelihood ratio 
tests. The null hypothesis of no difference in survival between the three 
treatments (H0: Drug = Random = Zero) was tested independently for high and 
low mortality selection regimes by comparing the full model with a null model 
with no fixed effect of treatment or interaction terms. Generation was kept in 
the null model to account for any drift in survivorship. Three post-hoc tests 
comparing treatment pairs were then conducted to assess the effects of 
individual treatments. This general approach was used to answer each of our 
research questions.  
 
 
4.4 Results 
 
 
4.4.1 What is the relationship between C. remanei survival and Ivermectin dose 
over a range of concentrations within a single generation? 
 
 
Two Ivermectin doses were chosen as drug treatments for experimental 
evolution (Fig B1: Appendix B): 1) a high dose that corresponded to 80% 
mortality in the stock strain at a concentration of 2.46 ng/ml Ivermectin (95% CI: 
2.41, 2.50); and 2) a low dose that corresponded to 40% mortality at 75 hours at 
a concentration of 1.61 ng/ml Ivermectin, (95% CI: 1.55, 1.68). Analysis using 
comparisons of log likelihood found that a three-parameter Weibull-1 model with 
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the lower asymptote fixed at zero gave the best fitting model of survival as a 
function of the concentration of Ivermectin (Fig B1: Appendix B) and there was 
no difference between the two survival curves for data collected in the two 
batches (χ2 = 6.821, d.f. = 3, P = 0.0778; Fig B1: Appendix B). 
 
 
4.4.2 Is there an increase in survivorship of populations across generations 
selected in a drug-treated environment, and does this vary with dosage? 
 
 
In the selection experiments (Fig 4.2), survival in zero-dose populations 
remained constant over generations; the mean adult survival in generation 1 was 
94% (CI: 90%, 99%), at generation 5 survival was 94% (CI: 90%, 98%) and at 
generation 10 survival was 94% (CI: 91%, 97%). Larval offspring densities of zero 
dose lines also remained relatively constant over the course of 10 generations; 
mean larval density at generations 0, 5 and 10 was 2079, 2051 and 1878 
respectively (Fig B2: Appendix B). In lines treated with the lower dose of 
Ivermectin, survival increased gradually over 10 generations, from 47% in 
generation 1 (CI: 36%, 57%) to 73% (CI: 45%, 100%) at generation 5 and 75% (CI: 
62%, 87%) in generation 10. Larval offspring numbers remained low in LD lines 
throughout the course of the selection experiment; the mean number of 
offspring at generation 1 was 1088 at generations 5 and 10 it was 1132 and 1248 
respectively (Fig B2: Appendix B). Survival in high-dose treated populations 
increased more dramatically, from 30% (CI: 20%, 39%) at generation 1, to 65% 
(CI: 54%, 76%) at generation 5 and 77% (CI: 49%, 100%) at generation 10. 
Offspring numbers of HD lines increased during the selection experiment; the 
mean number of offspring was 394, 1166 and 1435 at generations 0, 5 and 10 
respectively (Fig B2: Appendix B). 
 
In our formal test of changes in susceptibility of evolved lines, challenge with 
the dose used during selection, HD lines exposed to a high dose of Ivermectin for 
75 hours exhibited an increase in mean survival of 19% and 10%, at generations 5 
and 10 respectively, relative to Z lines (H0: HD = Z: P < 0.0001; Fig 4.3A, Table 
4.1). Survival was relatively consistent between lines within a treatment (Fig B3: 
Appendix B). Mean survivorship of the three HD lines remained between 59% and 
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66% at both generations 5 and 10, except in the case of one line in generation 10 
where survivorship dropped to 48%. Variation in the mean survivorship of the six 
Z lines ranged between 37% and 51% at both generations 5 and 10. At 52 hours of 
exposure to Ivermectin the HD lines showed a similar increase in mean survival 
to data collected at 75 hours (Fig B4A, Table B1: Appendix B). Thus, both 
juveniles and adults exhibited a comparable response to selection in terms of 
increased survival in the high dose environment. LD lines exposed to a low dose 
of Ivermectin for 75 hours showed no increase in survival relative to control lines 
(H0: LD = Z: P = 0.11; Figure 4.3D, Table 1), but at the earlier observation time 
of 52 hours LD lines exhibited increased survival relative to Z lines at both 
generations 5 and 10 (H0: LD = Z: P = 0.022; Fig B4D, Table B1: Appendix B). 
Therefore, selection at the low dose of Ivermectin resulted in higher survivorship 
of juveniles but not adults when re-exposed to a low drug dose. 
 
Exposing drug-selected lines to a dose other than that imposed during selection 
tested the effects of how evolved responses in survivorship might vary with drug-
dosage. After 75 hours of drug exposure HD had significantly higher survivorship 
than Z lines; the mean difference in survival between treatments was 9% at 
generation 5 and 15% at generation 10 (H0: HD = Z: P < 0.0001; Fig 4.3C, Table 
1). In addition, there was an interaction between generation and treatment (χ2 
= 7.07, df = 2; P = 0.029), accounted for by the increase in survival of HD lines 
between generation 5 and 10 (Fig 4.3C, Table 1). At 52 hours of exposure to a 
low Ivermectin dose, experimental lines from the HD treatment exhibited an 
increase in mean survival across generations relative to Z lines (H0: HD = Z: P = 
0.0005; Figure B4C, Table 1). Mean survival of HD populations was 10% higher 
than Z lines at both generation 5 and 10. There was no interaction between 
generation and treatment (χ2 = 3.20, df = 2, P = 0.20). Thus, the observed 
evolutionary response in juvenile survivorship of HD lines remained of a similar 
magnitude from generation 5 to 10. When exposed to a high Ivermectin dose LD 
lines showed no significant change in survivorship relative to control (Z) lines 
across generations when challenged with a high drug dose environment at both 
52 and 75 hours (H0: LD = LR = Z: P = 0.43, P = 0.38, respectively for 52 and 75 
hours; Figures 4.3B and B4B, Table 1). Therefore, selection in a low drug-dose 
environment conferred no advantage on survivorship in a high-dose environment. 
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Fig 4.2 Survivorship during original selection experiments. Lines represent mean 
survival for each treatment; points are the proportion of adults surviving on day 
two of each generation for each replicate line within a treatment. Circles, solid 
line = zero dose; squares, dotted line = low dose; triangles, dashed line = high 
dose.  Error bars; standard error for mean survival. 
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Fig 4.3 Seventy-five hour survival when exposed to the three drug doses used 
during selection (A and B = high; C and D = low: E and F = zero) of samples taken 
from generations 0, 5 and 10 during selection. Panels A, C and E show 
survivorship of high mortality lines: HD and HR. Panels B, D and F show 
survivorship of low mortality lines: LD and LR. Points are raw survival data from 
resistance bioassays, lines represent predictions of maximal models (generation 
+ treatment + generation*treatment) for each treatment: circles, solid line = 
zero dose; triangles, dashed line = drug treatment; diamonds, dotted line  = 
random mortality.  Error bars; 95% confidence intervals for mean survival. 
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4.4.3 Does density-dependent selection affect the apparent evolution of 
resistance in selected lines? 
 
 
In the selection experiment, survival in both random mortality treated lines 
remained of a similar magnitude to zero dose lines prior to random removal of 
worms; the mean adult survival of LR lines at generation 1 was 95% (CI: 92%, 
98%), at generation 5 survival was 97% (CI: 86%, 100%) and at generation 10 
survival was 93% (CI: 90%, 96%). Larval densities of LR lines remained similar to 
those of LD lines during the selection experiment; the mean number of larvae 
was 1088, 1132 and 1248 at generations 0, 5 and 10 respectively (Fig B2: 
Appendix B). Mean adult survival of HR lines at generation 1 was 96% (CI: 91%, 
100%), at generation 5 survival was 96% (CI: 87%, 100%) and at generation 10 
survival was 95% (CI: 87%, 100%). Offspring numbers of HR lines during the 
selection experiment remained lower than zero dose controls; the mean number 
of offspring was 1083, 1203 and 1172 at generations 0, 5 and 10 respectively (Fig 
B2: Appendix B). 
 
Surprisingly, in the resistance bioassays, high random mortality (HR lines) 
showed an increase in mean survival when populations were challenged with a 
high dose of Ivermectin. Mean survival of HR lines was 9% for both generations 5 
and 10 after 75 hours (H0: HR = Z: P = 0.014; Fig 4.3A, Table 2). Therefore, 
reducing density by removing individuals randomly had a similar effect to drug 
treatment in HD lines. However, there was a difference between HD and HR 
treatments; HD lines showed higher survival at generation 5 but not 10 (H0: HD = 
HR: P = 0.038; Fig 4.3A, Table 1). Variation in mean survivorship of the three HR 
lines remained consistently between 50% and 56% at both generations 5 and 10; 
smaller than the between-line variation observed in both HR and Z lines (Fig B3: 
Appendix B). At 52 hours of drug exposure, the increase in survival of HR lines 
relative to Z lines was comparable to that of data collected at 75 hours (Fig B4A, 
Table B1: Appendix B). Thus, when exposed to the high dose of Ivermectin, 
survival of both juveniles and adults from HR lines responded to selection in a 
similar manner. Survivorship of lines selected in the LR environment showed no 
response to selection when exposed to a low dose of Ivermectin for 75 hours; 
survivorship remained comparable to that of Z lines at both generations 5 and 10 
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(H0: LD = LR = Z: P = 0.11; Fig 4.3D, Table 1). However, when survival of LD lines 
was observed at 52 hours of exposure to a low drug dose, survival was similar to 
LD lines, relative to Z lines (H0: LR = Z: P = 0.035; Fig B4D, Table B1: Appendix 
B). As was the case with LD lines, increased survivorship of LR lines in the low 
dose environment was only observed for juveniles at 52 hours, and not adults at 
75 hours.  
 
When exposed to the low dose of Ivermectin, there no was evidence of a 
difference between survival and treatment in HR lines relative to Z lines at both 
generation 5 and 10 (H0: HR = Z: P = 0.098; P = 0.16, respectively for 52 and 75 
hours; Fig 4.3C and B4C, Table 1). In addition, mean survival of HR lines was 
lower than HD lines in the low-dose environment at both generations 5 and 10 
(H0: HD = HR: P = 0.005, P < 0.0001, respectively for 52 and 75 hours; Fig 4.3C 
and B4C, Table 1). When exposed to a high Ivermectin dose LR lines showed no 
change in survivorship relative to control (Z) lines across generations at both 52 
and 75 hours (H0: LD = LR = Z: P = 0.43, P = 0.38; Figures 4.3B and B4B, Table 1). 
 
 
4.4.4 Is there a cost of adaptation to drug-treated environments in terms of 
survival in drug-free environments? 
 
 
In an environment where no drug was administered, HD and HR lines performed 
equally as well as Z lines in terms of survival over 75 hours (H0: χ2 = 3.95, df = 2, 
P = 0.47; Figure 4.3E, Table 1). In contrast, LD lines had significantly lower 
survivorship than Z lines in the drug-free environment. However, this was only 
apparent at generation 10 and the magnitude of the effect was relatively small 
(H0: LD = Z: P = 0.0035; Figure 4.3F, Table 1). LR lines also maintained a similar 
response in survivorship as Z lines at both generation 5 and 10 (H0: LR = Z: P = 
0.40; Figure 4.3F, Table 1), and there was no significant difference between LR 
and LD lines with respect to survival (H0: LD = LR: P = 0.20; Figure 4.3F, Table 
1). The relationship in survival measurements taken at 52 hours for the evolved 
lines remained similar to survival measured at 75 hours for all treatments (Table 
A1, Fig B4E and B4F: Appendix B). 
 
   
 
 85 
 
4.4.5 Does survival of different life-history stages (juvenile and adult) respond 
to drug-selection in the same way?  
 
Mortality due to drug challenge continued between 52 hours and 75 hours in HD 
and LD selected lines when challenged with Ivermectin and was of a greater 
magnitude than observed in a drug-free environment (Fig 4.3 and B4: Appendix 
B). When exposed to the dose used during selection, HD lines showed no 
interaction between generation and selection regime at 52 hours (χ2 = 1.33, df = 
2, P = 0.51) but at 75 hours an interaction was apparent (χ2 = 5.96, df = 2; P = 
0.05). The change in significance of treatment and generation interactions 
indicates a change in the way juvenile and adult survival responded to drug 
selection in HD lines; juvenile survival remained similar between generations 5 
and 10, whilst adult survival declined (Fig 4.3A and B4A: Appendix B). When 
worms were exposed to a low dose of Ivermectin, we observed differential 
survival between LD and control (Z) lines at 52 hours but not at 75 hours (Fig 
4.3D and B4D: Appendix B, Table 1); suggesting that juvenile survival responded 
to drug selection but adult survival remained unaffected by drug treatment. 
 
In our pooled data sets, we found no evidence of a three-way interaction 
between selection experiment treatment, bioassay dose and life-history stage at 
generations 5 or 10 (χ2 = 2.77, df = 4, P = 0.60, χ2 = 0.47, df = 4, P = 0.98, 
respectively). However, there was a significant two-way interaction between 
selection experiment treatment and bioassay dose at both generations 5 and 10 
(χ2 = 28.98, df = 4, P < 0.0001, χ2 = 38.96, df = 4, P < 0.0001, respectively); 
suggesting that survival in drug-treated environments was dependent on 
selection regime. In addition, there was an interaction between bioassay dose 
and life-history stage at generation 5 but not generation 10 (χ2 = 6.07, df = 2, P 
= 0.048, χ2 = 3.82, df = 2, P = 0.15, respectively). There was no evidence of an 
interaction between selection experiment treatment and life-history stage for 
generations 5 or 10 (χ2 = 0.77, df = 2, P = 0.68, χ2 = 4.40, df = 2, P = 0.11, 
respectively). 
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4.5 Discussion 
 
 
4.5.1 What is the relationship between C. remanei survival and Ivermectin dose 
over a range of concentrations within a single generation? 
 
 
The dose-response curve of the survival of the drug-naive ancestral strain of C. 
remanei (SP8) was similar to those previously reported for drug-naive C. elegans 
when challenged with a range of Ivermectin concentrations (James and Davey 
2009). The confidence intervals of the two Ivermectin doses used in the 
selection experiment differed; the high dose had narrower intervals than the low 
dose. This suggests that the intensity of selection applied to the first generation 
of the selection experiment was more variable in lines exposed to low doses of 
Ivermectin, though even at low doses this would translate into no more than ± 
3.25% variation in survival.  
 
 
4.5.2 Do drug-treated lines show an increase in survivorship across generations 
in drug-treated environments, and does this vary with dose? 
 
 
Census data from the selection experiment indicated that populations of C. 
remanei exposed to low and high doses of Ivermectin showed a response to 
selection in terms of increased survival over 10 generations (Fig 4.2, Table 1). 
Furthermore, the increase in survivorship in HD lines was of a greater magnitude 
than LD lines, suggesting that evolution was more rapid in populations exposed 
to a higher drug dose. The data from resistance bioassays support the responses 
observed in the selection experiment in terms of the greater magnitude of 
response in survivorship of HD lines relative to LD lines. In both dosage regimes, 
the increase in survivorship during the selection experiment slowed over the 
course of the experiment, suggesting a rapid response of populations to drug 
treatment that reached a peak for a given drug dose. Rapid responses to drug 
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selection and peaking of the response have been previously observed in 
Levamisole-selected strains of C. elegans (Lopes et al. 2008). 
 
Previous research focused on under-dosing has suggested that lower doses (doses 
below recommended use) may promote the evolution of resistance, especially 
where the basis of resistance is polygenic (Manalil et al. 2011; Shi et al. 2013), 
and that varying the level of under-dosing may affect the rate at which 
resistance evolves (Busi and Powles 2009). Our data suggest that selection at a 
low dose of Ivermectin conferred no advantage on LD lines when re-exposed to 
the low-dose environment for 75 hours. However, HD-selected lines showed 
higher survivorship relative to Z lines on exposure to the high drug dose. Thus, 
the intensity of selection played a role in how selected populations responded to 
Ivermectin treatment. The lack of a response in survival of LD lines exposed to 
the low dose for 75 hours conforms to models of resistance evolution in 
nematodes where under-dosing retards the development of resistance (Barnes, 
Dobson, and Barger 1995). Under such models under-dosing may reduce the 
evolution of resistance by allowing more susceptible worms to survive.  
 
 
4.5.3 Does density-dependent selection affect the apparent evolution of 
resistance in selected lines?  
 
 
Intriguingly, survival of lines selected in random mortality environments showed 
a similar trend, but of a lower magnitude, to drug-selected lines, and in contrast 
to zero-dose lines, suggesting that density-dependent effects on life history 
traits might be affecting the apparent rate of resistance evolution. Random 
culling of adults reduced larval densities in random-mortality treated lines; 
meaning that larval densities remained comparable to drug-treated lines and 
lower than control (Z) lines. Density-dependent natural selection has been 
shown to affect the competitive abilities of selected lines; Mueller (Mueller 
1988) showed that the feeding efficiency of K-selected (high density) lines was 
58% greater than r-selected (low density) lines of Drosophila melanogaster after 
128 generations of density-dependent selection. Though our selection 
experiment design aimed to provide an abundant bacterial food source, at the 
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time lines were transferred to new plates, bacterial lawns were patchy and no 
doubt some competition for resources is likely to have occurred. Life-history 
traits such as development time, size at maturity and reproduction may all be 
influenced by density-dependent selection ( Joshi, Prasad, and Shakarad 2001; 
Prasad and Joshi 2003; Dey, Bose, and Joshi 2012). If traits associated with 
selection in a low-density environment confer an advantage in a novel drug-
treated environment then this may explain the observed increase in survivorship 
of random mortality lines relative to control (Z) lines. Thus, much of the 
observed response in survivorship in drug-treated and random-mortality lines 
when challenged with Ivermectin could be due to increased tolerance as a result 
of density-dependent processes, rather than resistance evolution per se. Put 
another way, if the response in survival of HR lines is attributable to the 
evolution of tolerance then perhaps a large part of the response in survival of HD 
lines, which would have faced similar density-dependent processes to HR lines, 
is also due to selection for tolerance rather than resistance.  
 
Alternatively, the increase in survivorship of drug-treated and random-mortality 
lines when exposed to drug treatment could be a result of loss of genetic 
variation due to drift. This hypothesis would require all lines to drift in the same 
direction, which could have occurred during bottlenecking of drug treated and 
random mortality lines, particularly in the early generations of selection. 
However, the loss of diversity may not have been severe relative to the control 
zero dose lines (see Appendix: drift and loss of diversity). Our theoretical 
predictions of the loss of genetic diversity in HR and Z lines suggest that both 
treatments went through similar losses of genetic diversity. Predicted 
heterozygosity and the total number of alleles decreased more rapidly in HR 
lines relative to Z lines but the difference between the two treatments was 
small. In the case of rare alleles, it is likely that any rare allele would have been 
lost from populations in both HR and Z lines. Thus, it seems likely that any 
evolved increase in survivorship of HR and potentially drug-treated lines, was 
due to ecological processes occurring as a consequence of density-dependent 
selection and not loss of genetic variation due to drift. 
 
Differentiating between the effects of drug selection and traits not directly 
associated with resistance has been a long-standing problem in studies of 
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resistance evolution (Chehresa, Beech, and Scott 1997; Gilleard and Beech 
2007). The increase in survival of HR lines over generations when challenged 
with both low and high drug doses was of a lower magnitude than HD lines; this 
difference in absolute survival could represent the effects of selection solely due 
to drug treatment. If this is the case, then our experimental design provides a 
means of partitioning the evolved response in survival due to drug application 
and responses due to the effects of population size, density and the risk of 
mortality. Increased parasite densities generally have a negative effect on traits 
such as survival and fecundity (Churcher, Filipe, and Basáñez 2006); however, 
how density-dependence interacts with drug treatment remains unclear and may 
depend upon which life history stage is most severely affected by the drug 
(Churcher and Basáñez 2008). It is also possible that the difference in 
survivorship between HR and HD lines was due to the experimental protocol 
during selection. Random mortality populations were culled once every 24 hours 
to simulate the same level of mortality as ‗sister‘ drug-treated populations, but 
drug-treated populations are likely to have suffered additional mortality over 
the course of this 24 hour period. This would have resulted in a lag between 
drug-induced mortality and culling between ‗sister‘ populations. If HR lines had 
tracked the rate of mortality in HD lines more closely, maintaining similar 
densities between HD and HR treatments, potentially the same magnitude of 
response could have been observed in both high mortality treatments, regardless 
of mortality source. A more synchronised method of tracking drug-dependent 
mortality and imposing compensatory mortality on random mortality lines would 
reveal whether the lag in random culling is responsible for the difference in 
survivorship between HR and HD lines. 
 
 
4.5.4 Is there a cost of adaptation in drug-treated environments in terms of 
survival in drug-free environments? 
 
 
When random mortality and drug-treated lines were exposed to a drug-free 
environment, no differences were observed in survivorship relative to Z lines. 
Therefore, bottlenecking and small population size of random mortality lines 
resulted in no beneficial or detrimental effects on survival in an environment 
   
 
 90 
where no extrinsic mortality was imposed. It has been suggested that the 
evolution of reduced susceptibility may lead to fitness costs in life-history traits 
if resistance is costly (Roush and McKenzie 1987). In order to asses the fitness 
costs that might result from reduced susceptibility one could either measure 
gene frequencies of susceptible alleles over a number of generations in the 
absence of the drug (Roush and McKenzie 1987) or estimate fitness based on 
measures of life-history traits such as fecundity, development time, fertility and 
mating competitiveness (Carriere et al. 1994; Gassmann, Carrière, and 
Tabashnik 2009) in the presence and absence of the drug. In this study we 
looked solely at differences in survival in drug-free and drug-treated 
environments; it would be interesting to assess a suite of traits associated with 
fitness and explore their relationship with apparent susceptibility to Ivermectin.  
 
 
4.5.5 Do different life-history stages respond to drug selection in the same way? 
 
 
Mathematical models have suggested that the life history of parasites may 
evolve in response to drug-treatment as a result of altering parasite survival and 
reproduction (Lynch, Grimm, and Read 2008). The differing responses of life 
history stage (juveniles and adults) in HD and LD lines at low and high dosages 
suggest that age-related effects and interactions with selection intensity may be 
important to consider in predicting resistance or tolerance evolution. We 
observed a significant interaction between resistance bioassay dose and life 
history. In addition, resistance bioassay data from 75 hours showed a response in 
survivorship of HD lines but not LD lines; i.e. adults of HD lines were less 
susceptible than Z lines whereas LD lines remained of a similar susceptibility to Z 
lines, across selected generations. However, 52-hour bioassay data showed that 
both HD and LD lines responded to drug selection in terms of increased 
survivorship. Therefore, at the high dose of Ivermectin, both juveniles and 
adults responded to drug selection, whereas at low doses only juveniles 
responded to selection.  
 
Body size is often used as a predictor of fecundity across a range of nematode 
species (Morand 1996). Under standard life history theory, interventions that 
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reduce adult life expectancy should select for parasites that mature earlier at a 
reduced size and produce fewer offspring (Roff 1992; Stearns 1992; Skorping and 
Read 1998). However, Lynch et al. (2008) used mathematical models to 
demonstrate that interventions that affect mortality rates of mature parasitic 
nematodes could have complicated effects on optimal age to maturity, 
regardless of whether mortality is size dependent or independent. They argued 
that where an intervention measure is continuously applied, the optimum age at 
maturity may be longer relative to a situation with no intervention and that 
parasites should benefit from a greater reproductive life span. Field experiments 
studying the evolutionary effects of anthelmintics on Teladorsagia circumcincta 
showed that worm size was consistently larger in resistant isolates when 
compared to susceptible isolates (Leignel and Cabaret 2001). Worryingly, if drug 
selection favours increased size at maturity then resistant worms may be more 
fecund than susceptibles. It would be interesting to measure size at maturity as 
well as other life history traits of our evolved lines and investigate whether any 
responses in such traits correlate with apparently reduced susceptibility to 
Ivermectin.  
 
 
4.5.6 Conclusions  
  
 
Our inclusion of a novel treatment that controls for both the increased risk of 
mortality and changes in population size of drug-treated populations raises the 
question of whether previous studies that have not incorporated such controls 
should be re-evaluated. For example, Lopes et al (2008) report the rapid 
evolution of resistance to Levamisole within 10 generations of exposure under 
very similar experimental conditions to this study. Levamisole was administered 
at a concentration lethal for 75% of the ancestral population. A resistance 
bioassay was then performed on samples from generations 10 and 20, which 
showed a 25% increase in survival of populations under drug selection at 
generations 10 and 20. However, as there was no control for mortality between 
drug-treated and control populations, it is difficult to assess whether there were 
effects of differences in density and mortality between treatments. We 
recommend that future work on resistance should incorporate adequate controls 
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for parasite/pest density when assessing drug resistance evolution.  In addition, 
controlling for differences in population size and rate of mortality could be 
implemented in any experimental evolution study where the selective agent 
induces greater mortality than control treatments. 
 
Standing genetic variation in the form of susceptibility to chemical applications 
is important in the study of resistance evolution (Gilleard and Beech 2007). This 
study suggests there may be a complex relationship between the intensity of 
selection and, density-dependent regulatory processes and life history of 
populations challenged with control measures. How these factors interact and 
affect characteristics such as tolerance and resistance could result in significant 
impacts on the evolution of susceptibility. For instance, studies of drug 
susceptibility in nematodes have shown that environments where conditions are 
inhospitable to free-living larvae, which reduces larval densities, promote the 
evolution of resistance (Besier and Love 2003; Lawrence et al. 2007; Leathwick 
and Besier 2014). What proportion of this reported resistance is due to drug 
application or tolerance, and how it interacts with life history, is difficult to 
establish in the field. In order to understand how drug tolerance and resistance 
evolution may interact, future research should aim to identify precisely which 
traits are associated with tolerance and what influence they may have on 
resistance. The Caenorhabditis system allows a range of traits to be assessed 
over the course of selection experiments (Gray and Cutter 2014), and therefore 
should provide an invaluable model to explore factors which may affect the 
evolution of resistance and tolerance. 
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Chapter 5: The evolution of life-history traits of 
nematodes in response to drug selection  
 
5.1 Abstract 
 
 
Resistance management is a key concern in human and veterinary medicine and 
in agricultural production systems. Studies of resistance evolution consider the 
influence of factors such as gene flow, drug type, application method and costs 
of resistance, on the rate of resistance evolution. However, how life history 
traits of susceptible parasites interact with control measures remains unclear. 
This study used a free-living soil nematode to investigate the evolutionary 
effects of drug treatment on life-history traits. I experimentally evolved 
replicate populations (derived from the same ancestral line) of Caenorhabditis 
remanei in three environments: drug-treated (Ivermectin), drug-free, and drug-
free with random-mortality to match the mortality in the drug-treated 
population. This last group was included to distinguish effects of drug treatment 
and population density on life history evolution. The effect of these treatments 
on larval and adult size, female lifespan and fecundity was assayed in both drug-
treated and drug-free environments after 10 generations. Adult size was larger 
for both drug-selected and random-mortality lines compared to control lines, but 
only when assayed in drug-free environments. In contrast, lifespan was longer 
for drug-selected lines in drug-treated environments and was not affected by the 
random-mortality treatment. Higher fecundity was found in drug-selected lines 
relative to control lines in both treated and drug-free environments while that of 
random mortality lines was intermediate to drug-selected and control lines in 
drug-free environments but similar to controls in the treated environments. Our 
results suggest that life histories of nematodes may respond to selection, acting 
via ecological processes due to mortality and density-dependence. Failing to 
take these responses into account when applying control measures could result 
in adverse outcomes, such as larger and more fecund parasites.  
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5.2 Introduction 
 
 
Parasitic diseases caused more than one million human deaths in 2013 (GBD 
collaborators 2015), while pests and diseases account for around one third of 
crop losses annually (Oerke 2006). The financial cost of controlling parasites and 
pests is considerable: for example, 39.4 billion dollars were spent on pesticides 
globally in 2007 (Grube et al. 2011). Control agents are designed to reduce 
target populations but massive global application has led to extensive 
development of resistance (Kaplan and Vidyashankar 2011; zur Wiesch et al. 
2011). Standard models of resistance evolution consider the influence of factors 
such as gene flow, drug type, application method and costs of resistance 
(Barnes, Dobson, and Barger 1995; James, Hudson, and Davey 2009; Consortium 
2013). Evolved responses in life-history in the form of fitness costs associated 
with insecticide resistance have been extensively documented in agricultural 
systems (reviewed by, Kliot and Ghanim 2012). Tolerance, natural variation in 
susceptibility already existing within a population, which is not a result of 
selection pressures imposed by control measures (Scott 1995; Coles and Dryden 
2014), could also influence life history responses to drug-selection via feedbacks 
between ecological and evolutionary processes. For instance, changes in density 
as a result of application of control measures may lead to evolutionary responses 
in life history traits, which in turn affect susceptibility to the control agent. The 
potential influence of eco-evolutionary interactions between pathogen or pest 
life history traits and control measures on the evolution of susceptibility 
(tolerance and resistance) has been paid little attention beyond theoretical 
consideration (Skorping and Read 1998; Lynch, Grimm, and Read 2008; Ferguson 
et al. 2012), and it remains unclear how such traits will respond to drug 
selection. The consequences of responses in life history traits to drug selection 
may be alarming given that epidemiological properties such as pathogenicity and 
virulence are often linked to the life cycle of parasites (Anderson and May 1982; 
Frank 1996; Gandon et al. 2001). 
 
Life history theory predicts how the birth and death schedules of an organism 
are shaped by its environment. The theory relies on optimality models, which 
assume trade-offs between fitness-related traits such as growth, survival and 
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reproduction when making predictions about how populations will respond to 
selection (Medawar 1952; Roff 1992; Stearns 1992). Human interventions have 
imposed intense selection on life history traits of commercially exploited species 
and have resulted in strong responses in such traits. For instance, meta-analysis 
of commercial fisheries showed that age and size at maturity have been 
significantly reduced by intense size-dependent harvesting (Sharpe and Hendry 
2009). The application of control measures to pest and pathogen populations 
dramatically changes their environment and will affect both birth and death 
schedules as a result of high extrinsic mortality caused by the treatments. Thus, 
drug treatment is likely to induce a change in the optimal allocation of resources 
between growth, lifespan and reproduction (Skorping and Read 1998). 
 
Some theoretical studies have predicted that the evolution of life history traits 
of parasitic nematodes in response to drug treatment could be beneficial from 
the perspective of disease control (Gemmill, Skorping, and Read 1999; Lynch, 
Grimm, and Read 2008), if increased extrinsic mortality of adult parasites due to 
drug treatment selects for early maturation and lower investment in growth, 
resulting in smaller less fecund worms; a situation often found in fisheries-
induced evolution (Sharpe and Hendry 2009). A reduction in fecundity could be 
beneficial in terms of disease control because it may reduce transmission of the 
parasite (Walker et al. 2009; Reece et al. 2010). Selection experiments imposing 
high extrinsic mortality on adults have been shown to cause this type of 
predicted response in life history. For instance, a long-term laboratory study 
using Drosophila melanogaster exposed replicate populations of flies to different 
extrinsic mortality regimes in early adult life (high and low) over a period of five 
years (Stearns, Ackermann, and Doebeli 1998; Stearns et al. 2000); they found 
that higher extrinsic mortality rates led to the evolution of shorter lifespans, 
earlier maturity at a smaller size, and a shift in peak fecundity to earlier in 
adulthood. However, divergence in all life history traits between the two 
treatments did not occur until after the first year of the experiment, when 
larval food quality was lowered and larval density was increased; suggesting 
density-dependent competition modulating selection on life history. If parasites 
respond to drug selection in the same way as invertebrate models like 
Drosophila then the application of control measures could be beneficial from a 
disease control perspective. That is, if parasites respond to drug selection by 
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evolving earlier maturation and lower investment in growth, resulting in smaller 
less fecund worms, then the number of offspring available to transmit infections 
will be reduced. In addition, life history traits of parasites could respond 
differently in drug-free and treated environments as a result of adaptive changes 
in phenotypic plasticity, which occur during drug selection (Reece et al. 2010; 
Kochin, Bull, and Antia 2010). Therefore, to quantify any evolved changes in life 
history due to drug-selection, measures of traits should be performed in both 
drug-free and treated environments (Carriere et al. 1994; Lopes et al. 2008). 
 
Mathematical models have predicted that drug-induced mortality could select 
for larger more fecund pathogens (Skorping and Read 1998), for example, if the 
risk of mortality differs between life history stages (Lynch, Grimm, and Read 
2008). Where the risk of mortality is higher throughout adult life relative to 
juvenile mortality (e.g. because adults are more susceptible to the drug 
treatment), selection may favour delayed maturity, larger size and greater 
fecundity. In a 20-generation study of the effects of harvesting on the life 
history in replicate populations of soil mites, populations exposed to adult 
harvesting showed delayed maturation and had a larger adult size than un-
harvested controls (Cameron et al. 2013). This contradicts studies of fisheries 
induced evolution of life history, where harvesting results in earlier maturation 
at a smaller size (Sharpe and Hendry 2009). The difference in outcome on life 
history between the two studies is due to the timing of extrinsic mortality 
(Stearns et al. 2000). High extrinsic mortality imposed early in adulthood favours 
selection for early maturation, but if mortality is imposed at the time of 
maturation and for the whole of the adult lifespan, then selection favours 
remaining in a juvenile stage for longer. Distinguishing between these two 
possible evolutionary outcomes in terms of the effects of drug application on life 
history traits could be achieved by measuring fitness-defining traits 
(development time, size, lifespan and fecundity) of populations challenged with 
drug treatment. Previous studies have focused on evolved changes in size 
(Leignel and Cabaret 2001) or fecundity (Kelly et al. 1978; Maingi, Scott, and 
Prichard 1990) of treated populations of parasites: a study focusing on a range of 
life history traits would provide a clearer picture of how life history responds to 
drug selection. 
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Differences in population density between drug-treated and untreated 
populations of parasites and pests could result in differential selection due to 
density-dependent processes such as competition (Gilleard and Beech 2007), and 
these processes can also result in evolutionary changes in growth, survival and 
reproduction (Reznick et al. 2012). For example, a 20-generation experiment 
selecting replicated populations of D. melanogaster in high or low-density 
environments found that low-density lines evolved longer development times in 
both growth environments (Roper, Pignatelli, and Partridge 1996). Longer 
development time was also associated with larger adult size and higher 
fecundity, but only in low-density growth environments, suggesting environment-
mediated evolved differences in size and fecundity. In addition, the same study 
measured lifespan of high and low-density selected lines and found no 
differences in lifespan in either growth environment. Thus, long-term 
differences in population density can be influential on the evolution of life 
history traits. In order to understand the effects of drug treatment on 
evolutionary responses in life history it is necessary to separate indirect effects, 
such as reduced density, from the direct effects of drug application. Adequate 
controls that compensate for differences in density between treatments are 
often overlooked in selection experiments but can be achieved with an 
additional treatment, which mimics mortality and density patterns imposed on 
drug-selected lines (Fuller, Baer, and Travis 2005).  
 
Measuring life-history traits of parasites within a host is technically difficult and 
time consuming (Leathwick and Hosking 2009). Studying how model organisms 
respond to selection pressures causing high extrinsic rates of mortality, and 
differences in population density, may provide insights into how parasite life 
history responds to drug selection. C. elegans has been used as a model organism 
to study both evolutionary processes (Manoel et al. 2007; Morran, Parmenter, 
and Phillips 2009; Fritzsche et al. 2014) and mechanisms of drug resistance 
(Simpkina and Coles 1981; James, Hudson, and Davey 2009; Ghosh et al. 2012). 
However, C. elegans is a hermaphroditic species and most reproduction is due to 
self-fertilisation (Brenner 1974), whereas most parasitic nematodes are 
dioecious and obligately outcrossing. Therefore, dioecious nematodes such as C. 
remanei can provide a more realistic model system to study potential 
evolutionary changes in life history-traits in response to drug selection. The 
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basic demography of C. remanei has been previously studied under laboratory 
conditions; the species shows high variation in development time, lifespan and 
fecundity (Diaz, Lindström, and Haydon 2008; Reynolds and Phillips 2013). 
Lifespan and fecundity have also been previously studied in C. remanei in 
relation to selection for condition-dependent mortality when subjected to high 
temperature (Chen and Maklakov 2012). Furthermore, Lopes et al (2008) 
explored the relationship between survival and fecundity in Levamisole-selected 
populations of C. elegans but did not measure traits such as lifespan and size at 
maturity. However, to date there are no studies of how life-history traits 
respond to drug-selection in a free-living dioecious species of nematode. 
Laboratory-based selection experiments can often impose strong selection on 
the timing of reproduction and development time due to the desire of 
researchers to achieve rapid progress through numerous generations (Chehresa, 
Beech, and Scott 1997; Gilleard and Beech 2007). Caenorhabditis nematodes can 
be cryogenically frozen and revived, making them an ideal model to test 
whether control treatments are effected by the design of a selection 
experiment. By reviving ancestral and selected control lines and measuring a 
trait of interest, any differences in control lines relative to ancestral lines can 
be detected (Gray and Cutter 2014; Sikkink et al. 2015). Thus, if there is a no 
response to selection in control lines relative to ancestral lines, and a response 
to selection in treated lines relative to controls, then any change associated 
with phenotypes between treated and control lines must be due to treatment 
during selection and not rapid passage during experimental evolution.  
 
In a previous study (Chapter 4; Reynolds et al. 2016), I explored the relationship 
between drug selection, population density and the evolution of resistance to 
Ivermectin. Replicate lines of C. remanei exposed to the anthelmintic 
Ivermectin, and drug-free control lines, which had mortality imposed randomly 
at the same rate as drug-treated lines, evolved an increase in survival relative to 
standard drug-free control lines over 10 generations. The results suggested that 
similarities in the population density and mortality between drug-treated and 
random mortality lines could be responsible for the increased apparent drug 
tolerance observed in both treatments. In this study I asked if the evolutionary 
changes in survival of these selected lines were associated with changes in other 
life history traits (larval and adult size, female fecundity and female lifespan), 
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whether there is a trade-off between adaptation to the drug-treated 
environment and fitness, and does any trade-off differ in drug-free and treated 
environments. I specifically asked: 1) Does rapid passage of control lines through 
numerous generations have an effect on life-history traits; 2) Does drug 
application have an effect on life-history traits; 3) Do conditions with high 
extrinsic mortality and density-dependent selection have an effect on life 
history traits? 
 
 
5.3 Methods 
 
 
5.3.1 Origin of experimental lines and selection experiment 
 
 
The construction of the ancestral strain and the details of the selection 
experiment have been described previously (Chapter 4). Briefly, a genetically 
diverse starting population of C. remanei (SP8) created by crossing three strains 
(SB146, PB206 and MY31) was provided by N. Timmermeyer in the Department of 
Biology, University of Tübingen, Germany. After the crosses were performed, 
strain SP8 was maintained for eight generations to create recombinant 
genotypes and allow adaptation to standard laboratory conditions (Fritzsche et 
al. 2014). Upon arrival in Glasgow, strain SP8 spent a further four generations 
adapting to any differences in conditions between laboratories and was 
maintained under standard laboratory conditions for Caenorhabditis species: 
20˚C and 60% humidity on NGM (Nematode Growth Medium) petri dishes and fed 
on a lawn of Escherichia coli (OP50) (Hope 2001). Experimental lines derived 
from the ancestral SP8 stock strain underwent three selection treatments (Fig 
5.1): exposure to Ivermectin at a dose calibrated to cause 80% mortality in a 
non-resistant population (drug-treated, D); a drug-free control (zero-dose, Z); 
and a second zero-dose control where the population size was reduced by 
randomly removing adult worms to match the level of mortality in the drug-
treated lines (zero-dose + random mortality, R). The random mortality control 
was included to control for effects of differences in density between treated and 
untreated lines. Experimental lines were cultured for 10 generations with three 
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replicate lines for the D treatment and R control lines and six for the Z controls, 
making a total of 12 lines. The ancestral (A-line) stock strain as well as samples 
of larval worms from generation 10 of each selected line were cryogenically 
frozen at -80˚C), at a density of approximately 2000 L1 larvae in liquid freezing 
solution as described in Hope (2001).   
 
Prior to each life history assay, preserved samples of the ancestral line and lines 
from the selection experiment at generation 10 were thawed and raised for 
three generations in a drug-free environment to ensure that any observed 
responses in survival were due to genetic differences among populations and not 
maternal or environmental effects due to freezing. Larvae were thawed at room 
temperature and maintained at a density of approximately 1000 individuals per 
9cm agar plate over the three generations from thawing to age synchronization 
with ad libitum lawns of E. coli OP50. Transfers between generations were 
achieved by cutting out sufficient agar from plates already containing samples 
and transferring these to fresh E. coli seeded plates ensuring the density 
remained as constant as possible. L1 synchronised larvae from revived lines were 
generated using a standard bleaching protocol for the beginning of each life 
history assay (Hope 2001).  
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Fig 5.1 Schematic representation of selection experiment and life-history assays. 
The starting population of SP8 was adapted to lab conditions. The lab-adapted 
strain was then randomly divided into three treatments with three replicates 
each for drug-selected (D), and random mortality (R) treatments, and six 
replicates of zero dose (Z) lines. After 10 generations of selection, lines were 
frozen and later thawed, before being exposed to drug-free and treated 
environments and data gathered on life-history traits.  
 
 
5.3.2 Larval and adult size 
 
 
Size estimates for larvae, females and males were calculated by collecting 
digital images of worms and then estimating their volume from these images. 
Images of 50-100 developmentally arrested larvae from the ancestral line and 
each selected line were collected three hours after hatching on 9 cm NGM plates 
in the drug-free environment. Larval sizes were not taken in the drug treated 
environment because they could not be exposed to Ivermectin over the same 
period of time, as size measures taken for adults. To collect images of adults in 
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the drug-treated environment 9 cm plates were prepared by adding 2.46 ng/ml 
Ivermectin dissolved in the solvent DMSO (0.02%) to NGM media: the media was 
kept at 50˚C and mixed thoroughly using a magnetic stirrer prior to pouring. The 
dry plates were seeded with E. Coli and approximately 1000 L1 synchronised 
larvae per line were added to the drug-treated plates and incubated for 75 
hours. After 75 hours adults were washed onto clean (i.e. no E. coli) plates and 
images were collected with a Zeiss Stemi 200-C stereomicroscope using a 
Celestron digital microscope camera (Model: 44421) at x 30 magnification. 
Depending on how many adults had survived to 75 hrs, 50 to 100 images of 
females and males were collected for each of the 12 selected lines + 1 ancestral 
line. To collect images of adults in the drug-free environment the same 
procedure was conducted as for the drug-treated environment but without the 
addition of Ivermectin to the solvent. The volume of worms in picolitres was 
estimated from digitised images using wormSizer software (Moore, Jordan, and 
Baugh 2013); volume calculations assume worms are made up of a series of 
frustums (cones with the tip removed) and the sum of the volume of all frustums 
equals total volume for an individual worm. 
 
 
5.3.3 Female lifespan and fecundity 
 
 
Lifespan was assessed only for females so that it could be compared with 
differences in reproductive output based on fecundity.  I assessed only three out 
of the six control lines for comparison with the three replicates of the drug-
treated and random-mortality lines, to maximise the number of replicates per 
experimental line. I chose control lines on the basis of the results from the size 
assay, choosing three lines that had the largest, smallest and intermediate 
volumes of the six control lines to prevent any bias due to size. Lifespan was 
measured by counting the number of females alive every two days during the 
course of the experiment. To measure lifespan in a drug-treated environment L1 
synchronised larvae from each line were cultured in drug-free conditions at a 
density of approximately a 1000 until developing till the L4 stage. At the L4 
stage sex can be distinguished but mating does not occur. L4 females were taken 
from these cultures and transferred to drug-treated 2.5 cm E. coli seeded agar 
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plates, maintained with male worms from their source population, of which the 
number of individuals was adjusted throughout the experiment to maintain a 1:1 
sex ratio on all plates at all times. Females were transferred to fresh drug-
treated plates every 48 hours to prevent larval offspring development 
confounding counts of females. Census data were collected whilst transferring 
replicates to new plates; census continued until the last female died. Measuring 
lifespan in the drug-free environment followed the method used for the treated 
environment except Ivermectin was not added to agar plates. I measured the 
lifespan of 20 females per line (four replicates of five females) in both the drug-
free and treated environments. Lifespan measurements were taken for 400 
females in total: 10 lines (3 treatments x 3 replicates + 1 ancestral) x 4 plates 
per line x 5 females per plate x 2 environments). 
 
Fecundity of selected and ancestral lines was evaluated by census of the number 
of eggs produced by females from each line during the lifespan assay. The 
number of eggs laid by females on each replicate plate was counted for a 3-hour 
period every 48 hours: this was done at the beginning of the experiment and 
three hours after each transfer, and repeated until females either died or 
stopped producing offspring. I recorded two measures of fecundity: the total 
number of eggs counted, which provided an index of total lifetime reproductive 
output; and the number of eggs counted on day two when fecundity reached a 
maximum in all lines, which was used as an index of peak fecundity. 
 
 
5.3.4 Statistical analysis 
 
 
My three main questions were concerned with assessing the effects of treatment 
during selection on life history traits (larval and adult size, female fecundity and 
female lifespan). The analysis separately compared each life history trait of lines 
from the original selection experiment (drug-treated, random mortality and zero 
dose), as well as the ancestral line, in both drug-free and treated environments, 
using generalised linear mixed models. I used the same approach to test for 
differences between treatments for each trait, but models varied for traits 
depending on the distribution of the response variable and the random effects 
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included in the model. The first step of the analysis tested for the significance 
of an interaction between treatment during selection and environment, and 
provided a test of whether responses of life history traits were the same in drug-
free and treated environments; a full model with fixed effects for treatment, 
environment and their interaction was compared with a null model with no 
interaction term. Because of differences in sample sizes and variance in the 
response variable between environments, further tests of differences between 
treatments were performed on datasets for each environment (drug-free and 
drug) separately. The second step of the analysis involved testing for a 
difference in the specified trait between the four treatments, by comparing the 
full model with a null model with no fixed effect of treatment (H0: Ancestral = 
Zero = Drug = Random). A further four post-hoc measures were then used to 
address my main questions, with the tests performed on discrete datasets for 
specific treatment pairs addressing each question. The effect of passage of 
control lines through 10 generations of the selection experiment was assessed 
for each trait individually by comparing a full model with treatment as a fixed 
effect to a null model without treatment (H0: Ancestral = Zero). A difference in 
a trait due to drug selection was assessed by using the same model but for the 
zero-dose and drug selected lines (H0: Drug = Zero). To answer the question: Do 
conditions with high extrinsic mortality and density-dependent selection have an 
effect on life history traits? Differences in the response of traits to the random 
mortality treatment (H0: Random = Zero) and density-dependence in response to 
selection (H0: Drug treatment = Random treatment) were tested in the same 
way, comparing a full model with a fixed effect of treatment against a null 
model without treatment. The second step was repeated for each trait in each 
environment providing an assessment of how traits responded to selection in 
terms of their phenotype when challenged with each environment. 
 
All statistical analyses were performed using R v 3.1.2 (R Core Team 2014) and I 
defined a significance threshold of P = 0.05 for all tests. I tested for differences 
in life-history traits between experimental treatments using generalized linear 
mixed effects models (GLMMs) fitted using the lme4 package (Bates, Maechler 
2014). I fitted a GLMM with a normal error distribution to assess differences in 
larval and adult size between lines. Treatment during selection and assay 
environment was fitted as a fixed effects and evolutionary replicate (line) as a 
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random effect. The interaction between treatment and environment was 
performed for females and males only, because data on larval size was only 
collected in the drug-free environment. Furthermore, no interactions between 
sex and selection regime were explored, because female size was twice that of 
males in both drug-free and treated environments. Differences in lifespan were 
assessed with the same model structure as size but included a further random 
effect for replicate plate in the lifespan assay. In addition, a parametric survival 
model with a Weibull distribution and a fixed effect of treatment during 
selection was fitted to the lifespan data to provide a plot of survival over time. 
Differences in egg count data were evaluated using a GLMM with a Poisson error 
distribution. Treatment during selection and assay environment were fitted as 
fixed effects and random effects were fitted for evolutionary line and repeated 
sampling of lines during the fecundity assay. An additional random effect was 
added for each observation to account for the overdispersion in the response 
variable (Browne et al. 2005). 
 
 
5.4 Results 
 
 
5.4.1 Size 
 
 
In the drug-free environment, there were no differences in larval size due to 
treatment during selection (P = 0.54; Fig 5.2E, Tables 5.1 and 5.2). There was a 
significant interaction between assay environment (drug-free or drug-treated) 
and treatment during selection in terms of adult size for both females and males 
(females: χ2 = 169.57, df = 3, P < 0.0001; males: χ2 = 47.51, df = 3, P < 0.0001). 
In the drug-free environment there were significant differences in mean size 
accounted for by treatment during selection for both females and males 
(females: P = 0.0023; males: P = 0.0072; Fig 5.2A and C, Tables 5.1 and 5.2). 
There was no significant difference in mean size between ancestral and zero-
dose lines for either females or males (females: P = 0.08; males: P = 0.66; Fig 
5.2A and C, Tables 5.1 and 5.2). Thus, rapid passage of control lines had no 
effect on adult size when comparing the ancestral and zero-dose lines. Females 
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and males from drug-selected lines were significantly larger (14% and 15%, 
respectively) than those from zero-dose lines (females: P < 0.0001; males: P = 
0.00022; Fig 5.2A and C, Tables 5.1 and 5.2). Females and males from random 
mortality lines were also significantly larger (9% and 8%, respectively) than those 
from zero-dose lines (females: P = 0.016; males: P = 0.035; Fig 5.2A and C, 
Tables 5.1 and 5.2). Therefore, density-dependent selection had an effect on 
size in the drug-free environment. There was no significant difference in size 
between drug-treated and random mortality lines for either females or males 
(females: P = 0.30 males: P = 0.35; Fig 5.2A and C, Tables 5.1 and 5.2). In the 
drug-treated environment there were no differences in mean adult size of either 
females or males with respect to selection regime (Females: P = 0.13; Males: P = 
0.20; Fig 5.2 B and D, Table 1 and 2). 
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Fig 5.2 Violin plots showing the kernel density estimation of the distribution of 
size at maturity for selected (Drug, Random and Zero) and Ancestral lines. The 
grey areas show how size data were distributed within a given treatment. 
Diamonds represent estimated mean volume for each treatment (estimated from 
the maximal model – see methods). Females (panel A and B) and males (panel C 
and D) when exposed to drug-free (panel A and C) and drug-treated (panel B and 
D) environments. Panel E shows larval size in a drug-free environment. Error bars 
indicate 95% confidence intervals for mean volume. 
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5.4.2 Female lifespan 
 
 
There was a significant interaction between assay environment and treatment 
during selection in terms of female lifespan (χ2 = 9.52, df = 3, P = < 0.023). No 
differences were observed in lifespan between females from different selection 
regimes in the drug-free environment (P = 0.76; Figs 5.3 and 4, Tables 5.1 and 
5.2); mean (95% CI) lifespan was 8.7 (6.6, 10.8), 7.8 (6.6, 9.0), 7.9 (6.7, 9.1), 
7.6 (6.4, 8.8) days for ancestral, drug-selected, random mortality and zero-dose 
lines, respectively (Fig 5.3A and 5.4A, Tables 5.1 and 5.2). Treatment during 
selection had an effect on female lifespan in the drug-treated environment (P = 
0.017, Figs 5.3B and 5.4B, Tables 5.1 and 5.2). There was no difference between 
ancestral and zero-dose lines in terms of lifespan (P = 0.23; Figs 5.3B and 5.4B, 
Tables 5.1 and 5.2), suggesting the selection experiment had no effect on 
lifespan in the control treatment. In the drug-treated environment, females 
from drug-selected lines had a 42% longer lifespan than the zero-dose lines (P = 
0.015; Figs 5.3B and 5.4B, Tables 5.1 and 5.2). There was no difference in 
female lifespan between random mortality and zero-dose lines in the treated 
environment (P = 0.86; Figs 5.3B and 5.4B, Tables 5.1 and 5.2); and female 
lifespan of random mortality lines was significantly shorter than that of drug-
selected lines. Therefore, differences in density between random mortality and 
zero-dose lines during selection had no effect on lifespan when the selected 
lines were exposed to Ivermectin. 
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Fig 5.3 Violin plots of mean lifespan for selected (Drug, Random and Zero) and 
Ancestral lines, grey areas show how lifespan data were distributed within 
treatments. Diamonds represent estimated mean lifespan in drug-free (panel A) 
and treated (panel B) environments for each selection regime (estimated from 
the maximal model – see methods). 95% confidence intervals for mean volume. 
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Fig 5.4 Survival curves of females from selected and ancestral lines when 
exposed to drug-free (A) and drug-treated (B) environments. Solid line = zero 
dose; dashed line = drug treatment; dotted line = random mortality: dot-dashed 
line = ancestral population. On plot A, the random mortality curve (dotted) is 
difficult to see because it is very similar to the drug treatment curve (dashed). 
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Table 5.1 Effect of treatment during selection on size, female life span and 
fecundity in treated and drug-free environments, assessed by null models, using 
likelihood ratio tests. Maximal models assumed a difference between the 
selection regimes. For each trait and environment, null model 1 assumed no 
difference between treatments and was tested against a maximal model 
assuming treatment had an effect. Null models 2-5 are post hoc tests and 
assumed no difference between the specified pair of selection regimes; they 
were tested against a model assuming a difference between paired treatments. 
D: Drug-treated; R: Random mortality; Z: Zero dose; A: Ancestral line. 
Trait Environment Null models χ2 (d.f.) P-value 
Female 
size 
Drug free 1) A = Z = D = R 
2) A = Z 
3) D = Z 
4) R = Z 
5) D = R 
14.47 (3) 
2.96 (1) 
18.9 (1) 
5.78 (1) 
1.06 (1) 
0.0023 
0.08 
< 0.0001 
0.016 
0.30 
Drug 1) D = R = Z = A 5.59 (3) 0.13 
Male size Drug free 1) A = Z = D = R 
2) A = Z 
3) D = Z 
4) R = Z 
5) D = R 
12.07 (3) 
0.19 (3) 
13.65 (1) 
4.44 (1) 
0.088 (1) 
0.007 
0.66 
0.00022 
0.035 
0.35 
Drug 1) A = Z = D = R 4.59 (3) 0.20 
Larval 
size 
Drug-free 1) A = Z = D = R 2.14 (3) 0.54 
Female  
lifespan 
 
Drug-free 1) D = R = Z = A 1.38 (3) 0.71 
Drug 1) A = Z = D = R 
2) A = Z 
3) D = Z 
4) R = Z 
5) D = R 
10.25 (3) 
1.46 (1) 
5.95 (1) 
0.03 (1) 
4.97 (1) 
0.017 
0.23 
0.015 
0.86 
0.026 
Lifetime 
fecundity 
Drug-free 1) A = Z = D = R 
2) A = Z 
3) D = Z 
4) R = Z 
5) D = R 
9.68 (3) 
1.62 (1) 
6.55 (1) 
1.44 (1) 
1.50 (1) 
0.022 
0.20 
0.011 
0.23 
0.22 
Drug 1) D = R = Z = A 
2) A = Z 
3) D = Z 
4) R = Z 
5) D = R 
22.03 (3) 
6.87 (1) 
13.47 (1) 
1.21 (1) 
10.81 (1) 
< 0.0001 
0.0088 
0.00024 
0.27 
0.0010 
Peak 
fecundity 
Drug-free 1) A = Z = D = R 
2) A = Z 
3) D = Z 
4) R = Z 
5) D = R 
11.06 (3) 
2.21 (1) 
6.96 (1)  
0.20 (1) 
4.83 (1) 
0.011 
0.14 
0.0083 
0.66 
0.028 
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Trait Environment Null models χ2 (d.f.) P-value 
Peak 
fecundity 
Drug 1) A = Z = D = R 
2) A = Z 
3) D = Z 
4) R = Z 
5) D = R 
11.50 (3) 
4.09 (1) 
5.69 (1) 
0.56 (1) 
4.68 (1) 
0.0093 
0.043 
0.017 
0.81 
0.031 
Table 5.1 Continued.  
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Table 5.2 Effect of treatment during selection on adult and larval size (volume; 
nanolitres), female lifespan (days) and fecundity (predicted egg numbers) in 
drug-free and drug-treated environments, as assessed by predicted trait means 
of the maximal model with selection treatment as a fixed effect (CI: 95% 
confidence interval for estimated trait means). Estimates significantly different 
from Zero dose lines are highlighted in bold. 
Trait Environment Selection 
treatment 
Trait mean  (95% CI) 
Female size Drug-free Ancestral 
Drug 
Random 
Zero 
6.4 (5.8, 7.0) 
7.1 (6.7, 74) 
6.8 (6.4, 71) 
6.2 (5.9, 6.4) 
Drug Ancestral 
Drug 
Random 
Zero 
5.3 (2.6, 8.0) 
8.3 (6.8, 9.9) 
6.4 (4.8, 8.0) 
7.0 (5.9, 8.1) 
Male size 
 
  
Drug-free Ancestral 
Drug 
Random 
Zero 
2.9 (2.5, 3.2) 
3.2 (3.0, 3.4) 
3.0 (2.9, 3.3) 
2.8 (2.7, 3.0) 
Drug Ancestral 
Drug 
Random 
Zero 
2.2 (0.9, 3.6) 
3.5 (2.7, 4.3) 
2.7 (1.9, 3.4) 
3.4 (2.2, 3.9) 
Larval size Drug-free Ancestral 
Drug 
Random 
Zero 
155 (123, 186) 
158 (139, 176) 
143 (124, 161) 
145 (132, 158) 
Female 
lifespan 
Drug-free Ancestral 
Drug 
Random 
Zero 
8.7 (6.6, 10.8) 
7.8 (6.6, 9.0) 
7.9 (6.7, 9.1) 
7.6 (6.4, 8.8) 
Drug Ancestral 
Drug 
Random 
Zero 
2.0 (0.9, 3.1) 
3.8 (3.1, 4.4) 
2.6 (2.0, 3.3) 
2.6 (1.9, 3.2) 
Lifetime 
fecundity 
Drug-free Ancestral 
Drug 
Random 
Zero 
38.1 (36.0, 40.3) 
52.8 (50.7, 54.7) 
48.0 (45.9, 50.0) 
43.2 (41.1, 45.3) 
Drug Ancestral 
Drug 
Random 
Zero 
1.9 (0, 4.5) 
13.6 (11.3, 15.9) 
3.6 (1.3, 5.9) 
4.7 (2.4, 7.0) 
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Trait Environment Selection 
treatment 
Trait mean  (95% CI) 
Peak 
fecundity 
Drug-free Ancestral 
Drug 
Random 
Zero 
23.9 (21.7, 26.1) 
37.5 (35.4, 39.6) 
31.5 (29.4, 33.6) 
30.0 (27.9, 32.1) 
Drug 
 
Ancestral 
Drug 
Random 
Zero 
4.0 (1.3, 6.7) 
15.9 (13.6, 18.3) 
8.0 (5.6, 10.3) 
8.3 (6.0, 10.7) 
Table 2.2 Continued. 
 
 
 
5.4.3 Fecundity 
 
 
5.4.3.1 Lifetime fecundity 
 
 
There was a significant interaction between assay environment and treatment 
during selection in terms of lifetime fecundity (χ2 = 57.34, df = 3, P = 0.0001). In 
the drug-free environment there was a significant effect of selection regime on 
lifetime fecundity (P = 0.022; Figs5.5A, Tables 5.1 and 5.2). Independent 
contrasts of ancestral and zero-dose lines showed no difference in lifetime 
fecundity in the drug-free environment (P = 0.20; Figs 5.5A, Tables 5.1 and 5.2), 
suggesting the zero-dose selection regime had no effect on lifetime fecundity 
relative to the ancestral population. Drug-selected lines had higher lifetime 
fecundity than zero-dose lines in the drug-free environment (P = 0.011; Figs 
5.5A, Tables 5.1 and 5.2); the mean number of eggs produced by females from 
drug-selected lines was 22% higher than from zero-dose lines. Thus, selection in 
a drug-treated environment led to higher reproductive output in the drug-free 
environment relative to the zero-dose lines. Mean lifetime fecundity of random 
mortality lines was intermediate to drug-treated and zero-dose lines and was not 
significantly different from either (P = 0.23; P = 0.22, respectively for drug-
treated and zero-dose lines, Figs 5A, Tables 5.1 and 5.2). Estimates of lifetime 
fecundity of females from random mortality lines were 9% lower than drug-
   
 
 115 
treated lines but 11% higher than zero-dose lines. Selection regime also had a 
significant effect on lifetime fecundity in the drug-treated environment (P = 
0.0001; Figs 5B, Tables 5.1 and 5.2). Lifetime fecundity in zero-dose lines was 
significantly higher than in the ancestral lines (P = 0.0093; Figs 5B, Tables 5.1 
and 5.2). Drug-selected lines had significantly higher lifetime fecundity than 
zero-dose lines (P = 0.00024; Figs 5B, Tables 5.1 and 5.2); mean lifetime 
fecundity of drug-selected lines was three times that of zero-dose lines. Lifetime 
fecundity of random mortality lines was not significantly different from zero-
dose lines but was lower than that of drug-treated lines (P = 0.27; P = 0.0010, 
respectively; Figs 5B, Tables 5.1 and 5.2); mean fecundity of random mortality 
lines was 23% less than zero-dose lines but 74% less than drug-treated lines in 
the treated environment. Thus, differences in density between random mortality 
and zero-dose lines during selection had no effect on lifetime fecundity when 
the selected lines were exposed to Ivermectin. 
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Fig 5.5 Violin plots showing the kernel density estimation of the distribution of 
fecundity (number of eggs). The grey areas indicate how fecundity data were 
distributed within a given treatment. Diamonds represent estimated mean 
number of eggs for each treatment (estimated from the maximal model – see 
methods). Lifetime fecundity (panels A and B) and peak fecundity (panels C and 
D) when exposed to drug-free (panels A and C) and drug-treated (panels B and D) 
environments. Error bars denote 95% confidence intervals for mean fecundity. 
 
 
5.4.3.2 Peak fecundity  
 
 
There was no interaction between assay environment and treatment during 
selection in terms of fecundity at the peak time of two days (χ2 = 1.30, df = 3, P 
= 0.73). In the drug-free environment, peak fecundity was significantly different 
between selection regimes (P = 0.011; Fig 5.5C, Table 5.1 and 5.2). Independent 
contrasts of peak fecundity for ancestral and zero-dose lines indicated no 
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difference in fecundity in the drug-free environment (P = 0.14; Figs 5.5C, Tables 
5.1 and 5.2) suggesting that selection in the control environment had no effect 
on peak fecundity when comparing the ancestral line to zero-dose lines. 
Predictions of peak fecundity from drug-selected lines were 25% higher than 
zero-dose lines (P = 0.0083; Figs 5C, Tables 5.1 and 5.2) indicating selection in a 
drug-treated environment resulted in increased reproductive output under drug-
free conditions. Peak fecundity of random mortality lines was not different from 
zero-dose lines (P = 0.66), but was 16% lower than in drug-treated lines (P = 
0.028; Figs 5.5C, Tables 5.1 and 5.2). In contrast to lifetime fecundity, peak 
fecundity in random mortality lines remained similar to that of the zero-dose 
lines suggesting differences in density between these lines had no effect on peak 
fecundity in the drug-free environment. 
 
In the drug-treated environment, selection regime also significantly affected the 
mean number of eggs produced per female (P = 0.0093; Figs 5D, Tables 5.1 and 
5.2). Peak fecundity of zero-dose lines was two-fold greater than that of 
ancestral lines when exposed to the drug-treated environment (P = 0.043; Figs 
5D, Tables 5.1 and 5.2) indicating that experimental evolution increased peak 
fecundity in zero-dose lines relative to the ancestral line. In the drug-treated 
environment, peak fecundity of drug-selected lines was 92% higher than zero 
dose lines (P = 0.017; Figs 5D, Tables 5.1 and 5.2). Peak fecundity of random 
mortality lines was similar to that of zero-dose lines (P = 0.81), but 50% lower 
than drug-selected lines (P = 0.031; Figs 5D, Tables 5.1 and 5.2). Thus, there was 
no evidence that density had an effect on peak fecundity in the drug-treated 
environment. 
 
 
5.5 Discussion 
 
 
My study sought to test what effects drug treatment has on life history traits, 
and at the same time assess the effects of high extrinsic mortality and 
differences in density-dependent effects, which occur when control measures 
are applied. In addition, I aimed to test whether life history traits of control 
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lines were affected by rapid passage through the 10 generations of the selection 
experiment.  
  
 
5.5.1 Does rapid passage of control lines through numerous generations have an 
effect on life-history traits? 
 
 
Control zero-dose lines showed no response to selection relative to the ancestral 
line in either size or lifespan. However, zero-dose lines did show increased 
fecundity relative to ancestral lines but only in the drug-treated environment, 
and though significant, the absolute difference in numbers of eggs was small. 
Chehresa et al (1997) performed an experiment focused on measuring changes in 
life history traits of replicate lines of the parasitic nematode Heligmosomoides 
polygyrus bakeri selected for rapid passage using a mouse host over eight 
generations. By generation eight, development of the parasite was faster and 
fecundity was higher early in life, suggesting rapid passage of the parasite was 
associated with evolved changes in life history. In my study, I did not measure 
development time but changes in worm size can be used to infer changes in 
development time, as selection for early maturity is associated with small size at 
maturity (Roff 1992; Stearns 1992). Also, higher peak fecundity in my study 
would be suggestive of earlier investment in reproduction. I found no evidence 
of smaller size in either sex for zero-dose lines and a reduction in fecundity was 
only observed in the drug-treated environment, indicating that my experiment 
did not select for rapid development and early reproduction in drug-free 
environments. The lack of response to selection of zero-dose lines relative to the 
ancestral line means that any differences in life history between the zero-dose 
lines and drug-selected or random mortality lines must be associated with 
treatment during selection, and not with rapid passage during experimental 
evolution.  
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5.5.2 Effects of drug-selection on life history 
 
 
In drug-free environments, there were no differences in lifespan between drug-
selected and zero dose lines but adults of drug-selected lines were larger than 
zero-dose lines, suggesting a greater investment in growth of the former. In 
addition, females from drug-selected lines showed greater reproductive output 
than zero dose lines. In drug-treated environments, longer lifespan and higher 
fecundity were apparent in drug-selected lines relative to zero dose lines, but 
there was no difference in size at maturity. Body size has been associated with 
drug tolerance; i.e. larger individuals require a higher dose of drug to achieve 
the same effect (Anderson and Weber 1975; Lavadinho 1975; Maggi et al. 2012), 
and evolved differences in size have been observed in susceptible populations of 
parasitic nematodes exposed to drug treatment (Leignel and Cabaret 2001). For 
example, Liegnel and Cabaret (2001) found that both susceptible and resistant 
genotypes of an isolate of Teladorsagia circumcincta exposed to Benzimidazole, 
increased in size over the course of a two-year experimental infection study. If 
larger size is advantageous in treated environments then drug-treatment could 
favour selection on investment in growth (Lynch, Grimm, and Read 2008). Lynch 
et al (2008) used mathematical models to show that later development and 
larger size at maturity could be favoured in drug-treated environments but was 
dependent on the difference in the rate of mortality experienced by juveniles 
and adults in treated and drug-free environments, on whether survival was size 
dependent in treated environments, and on how the drug was applied 
(continuously or in pulses). Their results showed that size-dependent mortality 
to the drug, in particular, favoured delayed maturation and a larger adult size. I 
found no differences in juvenile size in our study and therefore attribute the 
larger size of adults from drug-treated lines in the drug-free environment as 
evidence of greater investment in growth. I suggest that exposure of populations 
to a high rate of mortality in adults may favour late maturation or greater 
investment in growth during the juvenile stage to achieve a larger size, as has 
been observed in some studies of the effects of harvesting (Conover et al. 2005; 
Cameron et al. 2013). Similar observations have also been noted in experimental 
life-history evolution of wild guppies in streams driven by predation by large or 
small predators specialising on adult or juvenile guppies (Reznick, Bryga, and 
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Endler 1990; Reznick et al. 1996). Spending a longer period as a juvenile in these 
circumstances could be beneficial as it lowers the risk of mortality over the 
same time period, and could result in higher fecundity due to more time to 
invest in juvenile growth. Such a scenario might explain the observed increase in 
size at maturity of drug-selected lines in drug-free environments, if drug-
induced mortality of adults was high relative to juveniles then selection would 
favour spending a greater period as a juvenile and investing in growth. 
 
The lack of any difference in female lifespan between drug selected and zero-
dose lines in the drug-free environment suggests that any adaptation to the 
treated environment incurred no cost in the untreated environment.  A previous 
study using the same species found that where mortality was related to survival 
in heat stress, lifespan increased for populations selected in a high mortality 
heat-stressed environment (Chen and Maklakov 2012b). Replicate lines of C. 
remanei were selected for 12 generations in heat-shocked environments (high 
and low mortality), while other lines were selected in random culling 
environments (high and low mortality) before measuring lifespan of evolved 
populations in a benign environment. Mean lifespan increased in high mortality 
heat-shocked lines relative to both low mortality treatments and where 
mortality was imposed at random (Chen and Maklakov 2012b). In addition, the 
authors found that high-mortality random-culling of lines led to a shorter 
lifespan relative to low-mortality controls. Their results confirmed predictions 
that selection of populations in high mortality environments can result in 
reduced lifespan (Medawar 1952; Gadgil and Bossert 1970); however, if mortality 
was condition-dependent longer lifespan was favoured. In my study, selection in 
a drug-treated environment could also be view as selection based on condition in 
a similar way to heat stress, but drug-selected lines showed no increase in 
female lifespan. However, In Chen and Maklakov‘s study (2012) selection for 
heat tolerance (condition-dependent) was achieved by exposure to acute heat-
shock as opposed to the drug-selection conducted in this experiment, which 
involved chronic, constant exposure of lines to drug treatment. Thus, the length 
of exposure to an environmental stress may be of importance in determining the 
evolutionary outcome of condition-dependent mortality. 
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The observed longer lifespan of females from drug-selected lines in the drug-
treated compared to the drug-free environment suggests that females from 
drug-treated lines had adapted to the drug-treated environment. Increases in 
female lifespan in treated environments could have important implications for 
transmission dynamics of offspring in parasitic nematodes, if females are able to 
continue reproduction throughout their lifetimes (Skorping, Read, and Keymer 
1991; Walker et al. 2009). Furthermore, if my drug-selected lines represent a 
larger drug-tolerant but still susceptible phenotype due to size-dependent 
selection, rather than a resistant phenotype, this could have significant 
consequences for managing the rate of resistance evolution. Maintaining 
susceptible individuals in a population is thought to play a critical role in slowing 
the rate of resistance evolution (Leathwick and Hosking 2009): if drug-tolerant 
and resistant phenotypes compete in terms of the number and duration of 
offspring they produce, this could potentially affect the rate of resistance 
evolution. Potentially, larger more fecund drug-tolerant susceptible phenotypes 
could have higher fitness than resistant phenotypes, especially if there is a cost 
to resistance, and act to slow the rate of resistance evolution. However, it may 
be difficult to differentiate between tolerant and resistant phenotypes. 
 
My observation that fecundity (lifetime and peak) of females from drug-selected 
lines was greater in both drug-free and treated environments relative to control 
lines has significant implications for the treatment of nematode infections. 
Several previous studies on parasitic nematodes have compared reproductive 
fitness of resistant and susceptible strains, but the results have been 
contradictory. For instance, a study of Benzimidazole-resistant strains of 
Haemonchus contortus found that their fecundity was higher than that of 
susceptible strains (Kelly et al. 1978) but a similar study using different strains 
of the same species obtained the opposite result (Maingi, Scott, and Prichard 
1990). However, both of these studies used resistant and susceptible isolates 
from different locations and therefore the contrasting results could be due to 
the different environmental background of isolates. When resistant and 
susceptible isolates from the same strain have been compared, no difference 
was observed in fecundity (Elard, Sauve, and Humbert 1998). Humbert et al 
(1998) compared female nematodes collected from slaughtered sheep infected 
with a strain containing resistant and susceptible worms. The number of 
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offspring produced by these females and the development time of the offspring 
did not differ with respect to genotype. Collectively, these studies show that 
differences in life history traits have been observed following field and artificial 
selection for anthelmintic resistance but in other cases no response in life 
history occurred. This could be due to life histories of worms responding to 
differently to different classes of drug. Alternatively, life histories of different 
species of nematode could respond differently to individual drugs. However, 
responses of life histories to drug selection have shown to be inconsistent even 
in situations where a single species has been selected for resistance to one drug 
(Bartley et al. 2015). Bartley et al (2015) selected three different isolates of T. 
circumcincta in vivo for resistance to Monepantel over 9 to 13 generations and 
measured responses in life history relative to ancestral isolates. Shorter 
development time, larger adult size and higher fecundity was observed in only 
one of the selected isolates. Interestingly, this isolate was also resistant to four 
other classes of anthelmintic prior to selection. Thus, the previous history of 
populations, as well as species and drug type could play a role in how life 
histories of parasites respond to drug selection. The larger size of drug-selected 
lines in my study is most likely responsible for the observed increase in 
fecundity. Body size has been found to be a good predictor of fecundity across a 
range of nematode species (Morand 1996); therefore, evolved increases in size 
are likely to be associated with greater fecundity. Worryingly, if drug selection 
favours increased size then resistant or tolerant parasites may be more fecund 
than drug naive susceptible parasites.  
 
 
5.5.3 Effects of high mortality and density-dependant selection on life history 
traits 
 
 
The random-mortality lines showed a similar increase in size as drug-selected 
lines in the drug-free environment relative to zero-dose lines but not in the 
drug-treated environment. In the drug-free environment, lifespan of random-
mortality lines remained similar to drug-treated and zero-dose lines. Lifetime 
fecundity of random-mortality lines was intermediate to drug-treated and zero-
dose lines, but peak fecundity of random-mortality lines was similar to zero-dose 
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lines. In contrast, in the drug-treated environments all measured life history 
traits of random-mortality lines were similar to zero-dose lines. In my previous 
study (Chapter 4; Reynolds et al. 2016), random mortality lines showed higher 
survival relative to the zero dose lines when challenged with Ivermectin. The 
drug resistance assay used to assess susceptibility in that study measured 
juvenile survival and one day of adult survival, whereas, the drug-treated 
environment in the lifespan assay exposed females to the drug throughout their 
lives. A response in survival of juveniles and not adults, suggests that the 
response is stage specific, as only juveniles from random mortality lines show a 
decrease in susceptibility. A stage specific reduction in drug sensitivity has been 
previously observed in juveniles of Haemoncus contortus (Sarai et al. 2015). In 
Sarai et al 2015, juvenile stages of the parasite were treated with Levamisole for 
nine generations, but adults remained unexposed during selection; drug 
resistance assays on both juveniles an adults showed only juveniles had evolved 
resistance. However, in my study, the drug-selected lines showed an increase in 
lifespan when exposed to a treated environment, suggesting adaptation of drug-
treated lines beyond that observed in random–mortality lines. During the 
selection experiment worms from the drug-treated regime were exposed to 
Ivermectin throughout their life, and both juvenile survival and adult lifespan in 
the treated environment showed an increase after drug selection. Thus, drug-
selected lines showed adaptation beyond that observed in random–mortality 
lines in treated environments, and selection of random mortality lines in a low-
density drug-free environment, only conferred an advantage in survival for the 
juvenile stage when challenged with a novel drug treated environment. 
 
The similarities between drug-treated and random mortality lines in terms of 
size and fecundity in a drug-free environment could be due to similarities in 
mortality and density between the two treatments during selection. Roper et al 
(1996) found that populations of D. melanogaster selected at low densities 
evolved larger size when maintained in a low-density environment, and larger 
size was associated with greater fecundity. Low-density environments can select 
for larger size if selection favours delayed maturation because of benefits in 
fecundity to larger adults (Bassar et al. 2010). However, where low density 
occurs as a result of high extrinsic mortality, a different response of life history 
might be expected. For example, early maturation and reduced fecundity will be 
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selected for where the timing of extrinsic mortality on adults is imposed 
relatively early in adult life (Roff 1992; Stearns 1992; Stearns, Ackermann, and 
Doebeli 1998). In contrast, if adult mortality is high immediately after 
maturation then selection will favour remaining in the juvenile stage longer and 
achieving a larger adult size and greater fecundity (Stearns et al. 2000; Cameron 
et al. 2013). During the selection experiment, adult worms were culled early in 
their lives to simulate the high mortality occurring in drug-treated regimes. 
Thus, high mortality in both drug-treated and random mortality lines resulted in 
a greater investment in growth and higher fecundity. 
 
 
 
5.5.4 Conclusions 
 
 
This study is the first to my knowledge that explores how a range of life history 
traits of nematodes changes in response to drug-treatment. I have shown that 
size at maturity, fecundity and lifespan are all affected in lines previously 
selected in a drug-treated environment, but this depends on which environment 
populations are exposed to. If these results generalise to parasitic nematodes, 
this may have important consequences for their pathogenicity and transmission, 
especially if individuals from drug-treated populations become larger, and thus 
could cause more host damage as well as producing greater numbers of 
offspring, increasing the chances of transmission (Skorping 2007; Skorping and 
Read 1998). In addition, the immune response of hosts is another complicating 
factor that makes the study of life-history responses to drug selection 
complicated, as immune responses of the host may vary with differences in life-
history of parasites (Leignel and Cabaret 2001). Experimental studies using free-
living nematodes provide an opportunity to explore how life-history traits 
respond to drug-treatment in isolation of host immune responses and allow 
control of density-dependent effects. Developing such studies to encompass 
effects including host immune responses would be a logical next step and bring 
us closer to making accurate predictions of how parasite life histories will 
respond to drugs and vaccines. 
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Chapter 6: General discussion 
 
 
6.1 Summary 
 
 
The overall aim of this thesis was to assess how life-history traits change in 
response to drug selection, and whether changes in population density and the 
risk of mortality resulting from drug application are involved in the observed 
evolved responses in these traits. In Chapter 2, I established the relationship 
between C. remanei survival and Ivermectin dose so that the strength of 
selection imposed in the experimental evolution study in Chapter 4 could be 
chosen and applied at a consistent dose. Additionally, the survival data from the 
dose response assay were used to show that current methods of fitting dose 
response data in parasitology studies can be improved upon and provide a test of 
a cost of resistance by not removing background mortality from survival data 
prior to analysis. Using the best-fitting dose response curve was shown to 
improve the accuracy of estimates of summary statistics used to measure 
resistance, such as LD50 and LD99, and incorporating a cost of resistance into the 
analysis ensured that the maximum amount of useful information on resistance 
could be extracted from dose response data.  
 
In Chapter 3, I used simulation-based power analyses to explore how design 
choices used in selection experiments, such as the number of replicate selection 
lines, the number of samples assayed within each replicate line, and variation 
due to repeated measures when assessing traits at the end of selection, can 
affect the power of a study. My study demonstrated that selection experiment 
designs incorporating multiple sources of variation can be assessed using 
simulation-based methods comparable in complexity to those used to analyse 
experimental data. This forces researchers to think about the analytical tools 
they will use prior to conducting a study. My results showed that the number of 
replicated experimental lines, and within-line sampling effort that have typically 
been used in published studies to measure responses in survival in culling 
selection experiments, were prone to low power to detect a difference between 
treatments, when all potential sources of variation were considered.   
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Chapter 4 explored the relationship between dose and the rate of resistance 
evolution in replicated lines of Caenorhabditis remanei, asking whether survival 
of lines selected in drug-treated environments increased, and if this varied with 
dose. In addition, I maintained lines where mortality was imposed randomly to 
control for differences in density between drug-treatments to distinguish 
between the evolutionary consequences of drug-treatment vs ecological 
processes due to differences in density and mortality between drug-treated and 
control lines. After 10 generations, both drug-selected and random-mortality 
lines showed an increase in survival when challenged with Ivermectin, and the 
magnitude of this increase varied with the intensity of selection and life-history 
stage. My results suggest that interactions between density-dependent 
processes, and life-history traits may mediate evolved changes in susceptibility 
to control measures.  
 
Finally, in Chapter 5, I investigated the effects of selection in the high mortality 
environments (drug-treated and random mortality; Chapter 4) on life history 
traits, by measuring larval and adult size, female lifespan and fecundity in both 
drug-free and treated environments, compared to control populations. In 
addition, life history traits of controls were compared to the ancestral 
population to distinguish effects on life history due to rapid passage through 10 
generations of selection. Adult size was larger for both drug-selected and 
random-mortality lines compared to control lines, but only when assayed in 
drug-free environments. In contrast, lifespan was longer for drug-selected lines 
in drug-treated environments and was not affected by the random-mortality 
treatment, when compared to controls. Drug-selected lines had higher fecundity 
in both drug-free and treated environments, whereas fecundity of random 
mortality lines was intermediate to drug-selected and control lines in the drug-
free environment but similar to controls in the treated environment. These 
results suggest that life histories of nematodes respond to selection in drug-
treated environments, which acts via ecological processes due to the timing of 
mortality and density-dependence. Failure to take responses of life history traits 
into consideration when applying control measures could lead to unfavourable 
outcomes, such as larger, more fecund parasites and over-estimation of 
evolution of genetically controlled resistance. 
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6.2 Dose response modelling and costs of resistance 
 
 
Drug efficacy can be preserved with the help of effective monitoring practices, 
which measure changes in resistance of populations treated with control 
measures (Coles et al. 2006; Bagi et al. 2015). An approach common to 
assessment of resistance in many parasite and pest species is to use a dose-
response assay to characterise the relationship between survival and dose of the 
control agent. My results suggest that a risk for such studies is that they will fail 
to fit the most appropriate dose curve simply because only a single model is 
assessed; fitting the wrong curve could result in incorrect estimates of summary 
statistics used to quantify resistance. My study focused on the relationship 
between dose and survival in only one species and using a single drug treatment. 
Comparing a range of dose-response curves fit to data collected in dose-response 
field studies of parasites or disease vectors would give a clearer picture of what 
effect model selection has on the accuracy of resistance estimates.   
 
The common practice of removing background mortality from datasets prior to 
analysis means that an opportunity to measure a cost of resistance is lost. I have 
shown that by incorporating background survival into the analysis of dose 
response data, a test of a difference in the upper asymptote of the survival 
curve could be used to detect a relatively small cost of resistance. Fitting a 
range of dose response curves, which allow the most appropriate model to be 
selected and including a test of the cost of resistance maximises the amount of 
useful data extracted from a study. This information could play an important 
role in decisions about management strategies employed to control target 
species, such as whether or not to replace an existing treatment with another 
where the costs of resistance are greater and could slow the rate of resistance 
evolution. In this case, using a treatment with a higher cost of resistance would 
slow the rate of resistance evolution, because susceptible individuals with higher 
survival are likely to produce more offspring, resulting in a smaller proportion of 
resistant individuals in the next generation. My study used simulated data to test 
for a cost of resistance in terms of a difference in the upper asymptote of the 
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dose-response curve. Conducting the same analysis on field data across a number 
of different species and control agents would provide a more effective test of 
how model estimates are affected by choice of dose-response curve, and 
whether incorporating a test of a cost of resistance into analysis would be 
useful.  
   
 
6.3 Powering future selection experiments 
 
 
Research areas such as animal behaviour (Taborsky 2010; Smith, Hardy, and 
Gammell 2011) and biomedical science (Ioannidis 2005; Button et al. 2013) have 
expressed concern that the statistical power of reported studies is often below 
the recommended minimum of 80%. This could be attributed to a lack of 
awareness and/or understanding of the concept of power analysis. Alternatively, 
researchers may lack the technical know-how needed to conduct power analysis 
for studies that have complex designs incorporating multiple sources of 
variation. Within the field of experimental evolution, specific guidance on using 
simulation-based power studies to optimise the design of selection experiments 
has recently become available, and has been used to optimise designs of evolve 
re-sequence studies (Baldwin-Brown, Long, and Thornton 2014; Schlötterer et al. 
2015). However, little attention has been paid to optimising the design of 
selection experiments measuring changes in phenotypes, in terms of publications 
about power analysis, but it is difficult to demonstrate evidence of a problem 
with underpowered studies without conducting a meta-analysis. Funnel plots can 
be used to detect bias in meta-analyses, and could give an indication whether 
there is any evidence of a publication bias against non-significant results (Egger 
et al. 1997; Sterne and Egger 2001). 
 
My results, concerning the number of replicate selection lines and the number of 
samples taken from within each replicate line, conform to those of power 
simulations of evolve re-sequence studies: increasing the number of selection 
lines and sampling effort from those lines resulted in higher power (Baldwin-
Brown, Long, and Thornton 2014). Furthermore, my results suggest that besides 
tradeoffs between these types of logistical constraints, additional sources of 
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variation such as those that occur during measurement of phenotypes have a 
negative effect on study power. I have demonstrated with a practical example 
how to use simulation-based power analysis methods to optimise the study 
design of selection experiments, based on simulating data for the actual 
response and explanatory variables that would be used in the analysis of the real 
data. These simulations can be extended to accommodate most complex 
designs, and to incorporate a range of response variable distributions (Bolker 
2007). My study focused on a response variable with a binomial error 
distribution, conducing similar power studies for other types of response variable 
would given an indication of what kind of experimental design is appropriate for 
traits with different error distributions. In addition, my study did not incorporate 
many other factors, which are important in experimental evolution studies e.g. 
initial population size, standing genetic variation, strength of selection and the 
number of generations under selection. Simulation allows all these factors to be 
included in power studies in addition to accounting for multiple sources of 
variation. Collectively, my results indicate the importance of clearly defining a 
biological question and designating sources of variation before performing 
simulations aimed at detecting evidence of a biologically meaningful effect for a 
given study design scenario.   
 
 
6.4 Drug dosage and the rate of resistance evolution 
 
 
Previous research on under-dosing has suggested that low doses may promote 
the evolution of resistance, especially where the basis of resistance is polygenic 
(Manalil et al. 2011; Shi et al. 2013), and that varying the level of under dosing 
could affect the rate at which resistance evolves (Busi and Powles 2009). The 
mathematical modeling study of Barnes et al (1995) used to explore the effects 
of under dosing suggested that the outcome in terms of the rate of resistance 
evolution would depend on the genetic mechanism underlying resistance. My 
study supports the view that lower doses slow the rate of resistance evolution 
because lines selected at the lower drug dose showed less response to selection 
than high dose lines.  This conforms to the view that under-dosing may reduce 
the evolution of resistance by allowing more susceptible individuals to survive 
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(Barnes, Dobson, and Barger 1995). My results also add to the current body of 
work on dosage and resistance evolution (Barnes, Dobson, and Barger 1995; Busi 
and Powles 2009; Manalil et al. 2011), with the finding that life history stage 
interacts with drug dose. Both juveniles and adults from high-dose lines evolved 
resistance to Ivermectin, but only juveniles from low-dose lines showed 
increased survival in the treated environment. My experiment used only two 
doses of Ivermectin, but it would be interesting to select populations over a 
range of doses and explore the interaction between life history stage, dose and 
susceptibility. 
 
 
6.5 The evolution of tolerance 
 
 
Resistance to a control agent is defined as a genetically based decrease in 
susceptibility occurring as a direct result of exposure to a control agent 
(Tabashnik et al. 2014). This definition of resistance emphasizes heritable 
change in susceptibility due to long-term exposure. Thus, the spread of 
resistance through a population occurs because of an increase in the frequency 
of pre-existing alleles conferring reduced susceptibility, novel mutations or 
migration of resistance alleles between populations, when populations are 
exposed to a control agent for an extended period of time (Gilleard and Beech 
2007). By this definition, resistance evolves because of an increase in the 
frequency of resistance alleles due to drug application. In Chapter 3, I showed 
that reduced susceptibility to drug treatment in random mortality lines evolved 
in populations exposed to an environment that mimicked the mortality and 
population density observed in the drug-treated environment. I defined this 
reduced susceptibility as tolerance rather than resistance, because reduced 
susceptibility evolved in drug-naive populations as a result of selection on traits 
conferring a benefit in a random mortality environment, which also conferred an 
advantage in terms of survival in the drug-treated environment. Although 
tolerance has many definitions, one version is natural variation in susceptibility 
already pre-existing within or between populations rather than a result of 
selection pressure imposed by control measures (Scott 1995). The evolution of 
tolerance is therefore distinct from that of resistance in that tolerance evolves 
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due to pleiotropic effects and selection on some other unknown trait that results 
in pre-adaptation in the form of reduced susceptibility or reduced efficacy of 
the drug (Puniamoorthy et al. 2014).  
 
How the factors that affect resistance and tolerance interact could have 
significant impacts on the evolution of susceptibility. For example, environments 
which are inhospitable to free-living larval stages of parasitic nematodes reduce 
density, and promote the evolution of resistance (Besier and Love 2003; 
Lawrence et al. 2007; Leathwick and Besier 2014); although, what proportion of 
resistance is due to drug application or tolerance in this case is difficult to 
establish. A further example of the potential of tolerance evolution to influence 
susceptibility can be seen in increasing cuticle thickness of bed bugs (Lilly et al. 
2016). Resistance to pyrethroid insecticides was found to be associated with 
thicker cuticles of bed bugs collected in Sydney, Australia. However, resistance 
to pyrethroids could have occurred as a result of tolerance, as thicker cuticles 
could be selected for in drier environments (Benoit et al. 2007), and increased 
resistance to pyrethroid insecticides by bed bugs coincides with increasing use of 
air-conditioning since the turn of the century. In addition, tolerance evolution 
may not be confined to metazoans; drug naive soil bacteria have been shown to 
exhibit reduced susceptibility to commercial antibiotics, due to selection on 
efflux pumps, which overcome the effects of natural toxins, but are also 
effective against synthetic drugs (Walsh and Duffy 2013). 
 
It is difficult to separate resistance from tolerance unless this is explicitly 
incorporated into experimental design but this also requires knowledge about 
which traits confer differences in tolerance to a particular control agent. To 
understand how resistance and tolerance interact, future research should focus 
on identifying which traits are associated with tolerance and the degree of 
influence they may have on susceptibility. The Caenorhabditis model system 
allows a range of traits to be assessed over the course of selection experiments 
(Gray and Cutter 2014), and would provide an invaluable model to explore 
factors which may affect the evolution of resistance and tolerance. For example, 
establishing continuous populations with over lapping generations in flasks would 
allow large populations to be kept, which approximate those of parasitic 
nematodes in the field. Manipulating population size by drug-treatment and 
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artificially by random culling in addition to maintaining control lines would allow 
the population dynamics and age structure of drug-treated lines to be explored 
in detail. Furthermore, measuring life-history traits of continuous populations at 
the same intervals as population counts would allow any changes in population 
density that affect life-history to be identified. This type of selection 
experiment could potentially provide a clearer picture of the eco-evolutionary 
responses to drug-selection. 
 
 
6.6 Susceptibility and life history evolution 
 
 
Differences in population density between drug-treated and drug-free 
populations of parasites and pests could result in differential selection due to 
density-dependent processes such as competition (Chehresa, Beech, and Scott 
1997; Gilleard and Beech 2007), and these processes can also result in 
evolutionary changes in growth, survival and reproduction (Reznick et al. 2012). 
In addition, high extrinsic mortality imposed by application of a control agent 
could select for either early maturation, small size and low fecundity or delayed 
maturity, larger size and greater fecundity, depending on the timing of mortality 
(Stearns et al. 2000). High extrinsic mortality imposed early in adulthood favours 
selection for early maturation, but if mortality is imposed at the time of 
maturation and for the whole of the adult lifespan, then selection favours 
remaining in a juvenile stage for longer. In Chapter 4, I found that lifespan and 
fecundity of drug-selected lines increased, relative to controls, when evolved 
lines were challenged with drug treatment, suggesting that the life history of 
drug-treated lines adapted to the treated environment. In addition, worms from 
drug-treated lines were larger and more fecund than control lines when exposed 
to the drug-free environment, suggesting that drug treatment of parasites could 
result in larger, more fecund parasites, as suggested by Skorping and Read 
(1998) and  Lynch, Grimm, and Read (2008). If parasite life histories adapt to 
treated environments and drug-selected populations have greater fitness in 
drug-free environments then this could have serious implications for parasite 
control and transmission; drug-adapted phenotypes would produce more 
offspring than susceptible phenotypes, resulting in increased transmission of 
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drug-adapted populations. However, imposing the same density, and rate and 
severity of mortality on random mortality lines described in Chapter 4 had no 
effect on the life history of random mortality lines when exposed to the drug-
treated environment, which contradicted the findings of Chapter 3, where 
selection in the random mortality environment caused higher survival in the 
treated environment. A response in life history only in juveniles could explain 
this discrepancy (Sarai et al. 2015); juvenile survival of random mortality lines in 
the resistance assays responded to selection in low density environments, whilst 
adult lifespan in the life history assays showed no response to this novel 
environment. However, in the drug-free environment, similarities between the 
life history of both drug-treated and random mortality lines in terms of larger 
size and greater fecundity could be due to similarities in mortality and density 
between the two treatments during selection. These findings are in agreement 
with the view that high extrinsic mortality early after maturity or density 
dependant processes could favour remaining in the juvenile stage longer and 
achieving a larger adult size and greater fecundity (Stearns et al. 2000; Reznick 
et al. 2012; Cameron et al. 2013). Measuring development time in addition to 
lifespan of selected lines in treated environments would give a clearer picture 
whether juvenile or adult worms suffer greater extrinsic mortality. My thesis 
suggests that there may be a complex relationship between extrinsic mortality, 
density-dependent regulatory processes and life history of populations 
challenged with control measures. I recommend that future work on resistance 
should incorporate adequate controls for differences in parasite/pest density 
between treatments when assessing drug resistance evolution.   
 
 
6.7 Conclusions 
 
 
Understanding life histories and the selection pressures that shape them is a 
fundamental goal of evolutionary ecology. Ecological change such as changes in 
density or extrinsic mortality can lead to evolutionary changes in life history 
traits (Reznick 1982; Roff 1992; Stearns 1992), which in turn can affect density, 
resulting in a feedback loop (Kokko and López-Sepulcre 2007). These types of 
eco-evolutionary interactions can result in rapid evolutionary responses in a 
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variety of traits induced by changes in the environment, mortality rates, and 
competitive interactions (Reznick and Ghalambor 2001). Rapid adaptive change 
is often associated with populations subject to human activities such as 
predation (Darimont et al. 2009), so it is logical to assume that our efforts to 
control parasitic and pest species will result in similarly rapid adaptive 
responses. Previous research on the effects that control measures have on life 
history traits has tended to focus on evidence of costs of resistance (reviewd by, 
Kliot and Ghanim 2012), but it has been proposed that control measures could 
have a positive effect on life history (Lynch, Grimm, and Read 2008). My thesis 
shows that ecological changes occurring as a result of selection in treated 
environments could result in increased fitness of parasites and pests via 
interactions with life history. This will have significant implications for control 
methods if selection in treated environments drives the evolution of larger more 
fecund parasites and pests. My results suggest that life histories of parasites and 
pests should be monitored as part of mitigation strategies to control populations 
in order to prevent unintentional selection of undesirable traits in the target 
populations. Future work should explore the limits of how much evolutionary 
change is possible in the life history of populations treated with control 
measures. For example, parasitic nematode species vary massively in size, 
development time, longevity and fecundity (Skorping, Read, and Keymer 1991); 
thus, intense selection in treated environments could drive significant change in 
life history traits. To explore the limits of evolved responses of life-history to 
drug selection using experimental evolution, the strength of selection could be 
gradually increased every generation, to track the dose of drug required to 
cause a target mortality level. The rate of change in life history traits could then 
be measured from frozen samples taken at regular intervals during selection.   
 
My use of a novel treatment during the selection experiment, which controls for 
both the greater mortality and differences in density of drug-treated 
populations, suggests that a population‘s tolerance to control measures can 
evolve independently (i.e. without previous exposure), as a result of pleiotropic 
effects of selection on traits that confer reduced susceptibility. My results 
provide experimental evidence of the evolution of tolerance in action. This 
raises the question of whether previous studies of resistance not incorporating 
such controls should be re-evaluated, and how influential tolerance evolution is 
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in efforts to control parasite and pest species. My thesis suggests that eco-
evolutionary processes involved in life history adaptation to control measures 
could be responsible for the evolution of tolerance. Therefore, eco-evolutionary 
responses of target populations to changes in the environment, mortality rates 
and competitive interactions should be taken into consideration when 
implementing control strategies. Research into invertebrate susceptibility to 
insecticides might provide a good opportunity to establish how important 
tolerance evolution is in the field, because crop pests have been intensively 
studied and life history traits, as well as evolutionary processes are much easier 
to monitor than in parasitic species.  
 
Finally, my thesis shows that both resistance and tolerance can affect 
susceptibility to xenobiotics, and that the evolution of both should be viewed as 
distinct processes. Resistance is driven directly by drug selection, tolerance on 
the other hand is driven by selection on some other unknown trait that results in 
pre-adaptation, and both result in reduced susceptibility. Thus, possible 
environmental drivers of tolerance should be considered in resistance 
management strategies. In addition, both these processes have the potential to 
interact with life history, which could affect the reproductive schedule of the 
target populations and their chance transmission.   
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Appendix A 
 
 
Assement of indirect mortality at low doses of Iveremctin 
 
 
To explore whether low doses affects model fitting of the survival-dose 
relationship, Weibull-1 curves were fitted to the whole LDT dataset including 15 
doses (0, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9 and 10 ng/ml Ivermectin), 
and a reduced dataset in cases where higher mortality due to indirect mortality 
was suspected at 0.5 and 1 ng/ml Ivermectin. Weibull-1 models were fitted to 
the survival data because these are the most accommodating in cases where 
asymmetry in the dose-response curve occurs, causing survival to decrease more 
gradually over the initial upper slope of the dose response curve, compared to 
log-logistic models. Because the datasets for each curve were of different sizes, 
models could not be compared formally using likelihood ratio tests. Instead, 
estimates of model parameters (LD50, LD99, and survival at the upper asymptote) 
were used to assess the goodness-of-fit of the two dose response models. 
 
 
Does indirect mortality at low doses affect fitting a dose response curve? 
 
 
The three-parameter Weibull-1 model using all the data collected in the dose 
response assay estimated the LD50 and LD99 of Ivermectin at 1.83 (95% CI: 1.78, 
1.89), and 3.57 (95% CI: 3.44, 3.71), respectively (Fig A1); predicted mean 
survival at the upper asymptote of the dose response curve was 72% (95% CI: 71, 
74%). The three-parameter Weibull-2 model with data excluded at 0.5 and 1 
ng/ml Ivermectin estimated the LD50 and LD99 of Ivermectin at 1.85 (CI: 95%: 
1.80, 1.90; Fig 2.3, Chapter 2), and 3.45 (3.34, 3.56), respectively; predicted 
mean survival at the upper asymptote was 76% (95% CI: 74, 78%). Thus, the LD50 
and LD99 estimates of the two curves were similar, but at higher survival (>50%) 
the Weibull-1 model using all the data resulted in an overestimate of mortality 
at very low doses, and underestimate of survival at the upper asymptote, 
compared to the reduced dataset excluding the values at 0.5 and 1 ng/ml 
Ivermectin (Fig A1 and Fig 2.3, Chapter 2).  
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Fig A1 Observed data and fitted Wiebull-1 model of the relationship between 
survival of C. remanei and concentration of Ivermectin using all the data 
collected in the dose response assay. Black circles show observed mean survival 
at each concentration of Ivermectin used in the larval development test. Dark 
grey bands show 95% confidence intervals for mean survival based on the model.  
 
 
 
My data suggest that indirect mortality not due to the drug occurred at low 
doses of Ivermectin and had a significant effect on predictions of survival, both 
at low doses, where the drug causes little mortality, and in the estimation of 
background mortality. It is difficult to assess whether indirect mortality at low 
doses of Ivermectin is common in other studies using LDTs because often only 
estimates of the LD50 and LD99 are published and the original data are not 
included. This additional source of mortality could be due to repellency at sub-
lethal doses as a result of worms leaving the surface of agar plates in an attempt 
to evade the effects of the drug. Hyperactivity of worms exposed to low doses of 
Ivermectin has been shown to occur in C. elegans (Ardelli et al. 2009), and the 
mode of action of the drug is thought to be similar in parasitic species, 
suggesting that repellency could occur in parasitic species (Cook et al. 2006). 
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Assays which measure motility over a range of doses could clarify the effect that 
low doses have on worm movement, with the expectation that the dose-response 
relationship between motility and concentration would show a hormetic trend if 
repellency had an effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
Appendix B 
 
 
Statistical methods 
 
 
All statistical analyses were performed using R v 3.1.2 (R Core Team 2014) and 
we defined a significance threshold of P = 0.05 for all tests. Our first question 
was concerned with drug dose efficacy and asked ‗What is the relationship 
between C. remanei survival and Ivermectin dose over a range of 
concentrations?‘ The doses required to cause 40% and 80% mortality were 
estimated, with 95% CI‘s, using the drc package (Ritz and Streibig 2007). In order 
to calculate estimates of these two doses we constructed a dose response curve 
of the relationship between worm survival and concentration of Ivermectin. Dose 
response curves are generally sigmoidal and can be defined by four parameters: 
the first two parameters are the upper and lower asymptote, where changes in 
concentration have no effect on survival (Ritz 2010). The third parameter is the 
slope of the curve, which defines the potency of the drug where efficacy 
increases from zero to its maximum, the more potent a drug is the steeper the 
curve will be. The fourth parameter is the inflection point, where the curve 
changes from concave to convex and is located at or near the LD50 (dose causing 
50% mortality) for the drug. We fitted a range of dose-response models (log-
logistic, Weibull-1 and Weibull-2) with the lower asymptote fixed at 0% survival 
and used maximum likelihood to select the most appropriate model of survival 
data. Ivermectin concentration and batch were fitted as fixed effects in our full 
model. To assess whether the relationship between survivorship and Ivermectin 
concentration remained the same between batches performed at different times 
(i.e. repeatability), batch was removed from the model and tested against the 
full model. Estimates of the required doses, with 95% CIs, were then derived 
from model predictions. 
 
Our three remaining questions involved potential changes in survival of evolved 
lines used in the selection experiment, which could result in differential survival 
between treatments. We addressed these questions with a common general 
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approach described below. We conducted the analyses on discrete data sets 
from the resistance bioassays, which specifically addressed our research 
questions. In order to simplify our analyses, survival of high mortality (HD and 
HR) and low mortality treatments (LD and LR) were contrasted with control Z 
lines in separate tests, unless explicitly stated otherwise. The analysis compared 
survival of lines from the original selection experiment treatment groups (drug-
treated, random mortality and zero dose) using generalised linear mixed models 
with the glmer function in the lme4 package and assuming a binomial error 
distribution with a logit link function (Bates et al 2014). Treatment and 
generation, as well as the interaction between them, were fitted as fixed 
effects. The evolutionary replicate (line) was fitted as a random effect. An 
observation-level random effect was fitted to account for any overdispersion 
between replicate lines in the selection experiment and repeated sampling of 
populations in the drug resistance bioassay (Browne et al. 2005). We refer to this 
model for the fixed effects as the full model. Treatment effects in the selection 
experiment were tested using likelihood ratio tests. The null hypothesis of no 
difference in survival between the three treatments (H0: Drug treatment = 
Random mortality = Zero dose) was tested by comparing the full model with a 
null model with no fixed effect of treatment or treatment x generation 
interaction. Generation was kept in the null model to account for any drift in 
survivorship. This first step of the analysis tested for significance of fixed effects 
and interactions between them. A further three post-hoc measures were then 
used to assess the effects of individual treatments; differences in survival in the 
drug treatment relative to the zero dose treatment were tested by comparing 
the full model to a null model where survival in drug and zero dose treatments 
were constrained to be equal (H0: Drug = Zero). Differential survival in response 
to the random mortality treatment (H0: Random = Zero) and density-dependence 
in response to selection (H0: Drug treatment = Random treatment) were tested 
in the same way. This general approach was used throughout the analyses to 
answer our research questions by establishing any evidence of differential 
survival between treatments challenged with different drug doses and at 
different life-history stages.  
 
Firstly we asked: ‗Is there an increase in survivorship across generations of 
populations selected in drug-treated environments, and does this vary with 
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dosage?‘ The formal assessment of whether heritable increases in survivorship 
occurred in drug-selected lines was tested by challenging drug-selected and zero 
dose lines to the same high and low doses of Ivermectin used during selection. 
Survival data of HD lines exposed to a high dose of Ivermectin was assessed by 
the null hypothesis of no difference in survival between the three treatments 
(H0: HD = HR = Z) using the general approach discussed. After establishing a 
significant effect of treatment on survival a post-hoc test was performed with 
the null hypothesis of no difference in survivorship between HD and Z lines (H0: 
HD = Z). Any evolved increase in the survivorship of LD lines relative to Z lines 
was assessed under the null hypothesis (H0: LD = LR = Z) and if treatment was 
significant, a post-hoc test was applied to assess differential survival between 
drug-treated and control lines (H0: LD = Z).  
 
Secondly we asked ‗Does density-dependent selection affect the apparent 
evolution of resistance in selected lines?‘ We challenged random mortality (HR 
and LR) treated lines to both high and low doses of Ivermectin and again used 
our general approach to assess differential survival between selection 
experiment treatments. Differences in survivorship between high mortality 
treatments where the null model (H0: HD = HR = Z) was rejected were tested 
with two post-hoc tests. The first tested for a difference in survival between HR 
and Z lines, and the second, differential survival between HD and Z lines. 
Assessment of low mortality lines was conducted using exactly the same 
approach but with the null model (H0: LD = LR = Z). 
 
Thirdly we asked ‗Is there a cost of adaptation to drug-treated environments in 
terms of survival in drug-free environments?‘ We answered this question by 
exposing evolved lines to a drug-free environment and used our general 
approach to assess differences in survival between treatments, with the 
assumption that if there were a cost to adaptation then drug-treated lines would 
show lower survival than control (Z) lines. 
 
Finally, we asked ‗Does survival of different life-history stages (juvenile and 
adult) respond to drug-selection in the same way? To answer this question we 
conducted the analyses used in questions two to four separately on survival data 
collected at 52 and 75 hours and informally compared differences of model 
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predictions from the two time points. In addition, we pooled our whole datasets 
from the resistance bioassays using survival data from all drug-treated 
environments at both 52 hours (juvenile survival) and 75 hours (adult survival) 
and asked whether there were any interactions between selection experiment 
treatment, bioassay dosage and life-history stage. This was done for generations 
5 and 10 independently to account for any changes in survival over generations. 
If there was no evidence of a three-way interaction we explored two-way 
interactions.  We assumed that any evidence of interactions of life-history stage 
with treatment, dosage or both suggests that survival responded differently in 
juveniles and adults. We used a full model with fixed effects of treatment, 
bioassay dosage and life-history stage, as well as all possible two-way 
interactions between them. Random effects were: selection line, bioassay 
replicate and an observation-level random intercept. The full model was 
compared with a null model without the interaction of interest using a likelihood 
ratio test to assess the significance of interactions. 
 
 
Drift and loss of genetic diversity 
 
 
The evolutionary potential of small populations may be affected by drift due to 
the loss of genetic variation (Allendorf 1986). During the course of the selection 
experiment, population sizes varied both between lines within a treatment, and 
between treatments, due to bottlenecks imposed by drug application or random 
mortality. These bottlenecks could have resulted in a reduction in genetic 
diversity. Although we have no data on levels of genetic diversity it is worth 
considering the risk and extent of the loss of genetic variation in the selected 
lines used in this study. Allendorf (1986) outlines three useful measures of 
genetic variation and its loss: 1) changes in heterozygosity; 2) loss of multiple 
equally frequent alleles and 3) loss of rare alleles. Using census data from the 
selection experiment each measure of genetic variation was estimated for the 
HR and zero dose treatments at each generation (Table B2). Predicted changes 
in heterozygosity were calculated using equation (1) where N is population size. 
The expected proportion of the original heterozygosity remaining after each 
generation is:  
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                                                                      ( ) 
 
This expectation is only valid if there are no selective differences between 
alleles; all other genetic diversity calculations in this paper also make this 
assumption of allelic neutrality. Predicted changes in the loss of multiple equally 
frequent alleles were calculated using equation (2). 
 (  )      ∑(     
 
   
)                                                       ( ) 
 
Where n equals the number of alleles in the population, and p the frequency of 
an allele. We calculated the predicted number of alleles present at each 
generation of the selection experiment assuming the initial number of alleles for 
a given locus was 10. This potentially overestimates genetic diversity within our 
study species but C. remanei have been shown to be a particularly genetically 
diverse species (Cutter, Baird, and Charlesworth 2006; A. Dey et al. 2013). The 
greater the numbers of alleles are at a given locus, the more likely it is an allele 
will be lost where alleles are considered to have equal frequency. Therefore, 
our high estimate of initial allele numbers may exaggerate the risk of allele loss; 
lower estimates of initial allele numbers would result in allele loss being less 
likely. Rare alleles (P < 0.01) are especially susceptible to loss during a 
bottleneck. The probability of losing a rare allele with frequency p = 0.01 is 
given by equation (3). 
 
(     )
                                                                  ( ) 
 
An assumption was made that rare alleles were present at a frequency of 0.01, 
as this should provide some measure of the potential for rare allele loss in both 
HR and Z lines during the course of the selection experiment. 
 
In HR lines, predicted heterozygosity decreased by 10% and 15% at generations 5 
and 10, respectively (Table B2) whereas estimated heterozygosity of Z lines 
decreased by 5% and 10% (Table B2). The estimated number of alleles present in 
HR lines fell from 10 to 9.35 and 9.24 at generations 5 and 10, respectively, 
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whereas in Z lines there was no decrease over 10 generations (Table B2). The 
high cumulative risk of loss of rare alleles by generation 5 (Table B2), suggests 
that any rare alleles would be unlikely to persist within both HR and Z lines. 
Heterozygosity and the number of alleles remaining after a bottleneck are 
expected to be important in terms of a population‘s ability to respond to 
selection. Populations subjected to bottlenecks such as the HD and HR 
treatments in this study could be subject to considerable drift as a result of 
bottlenecking events. The increase in survivorship of High-dose and random-
mortality lines could be a result of loss of genetic variation due to drift, and 
would require that all populations drifted in the same direction. However, our 
theoretical predictions of the loss of genetic diversity in HR and Z lines suggest 
that both treatments went through similar losses of genetic diversity. Predicted 
heterozygosity and the total number of alleles did decrease more rapidly in HR 
lines relative to Z lines but the difference between the two treatments was 
small. In the case of rare alleles, it is likely that any rare allele would have been 
lost from populations in both HR and Z lines. Thus, it seems reasonable that any 
evolved increase in survivorship of random-mortality and potentially drug-
treated lines, was due to ecological processes occurring as a consequence of 
density-dependent selection and not loss of genetic variation due to drift. 
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Table B2 Predicted theoretical loss of genetic diversity based on a simple 
population genetic model during the course of selection (generation) in HR (High 
random) and Z (Zero dose) lines. Predictions of heterozygosity, the number of 
equally frequent alleles and risk of loss of rare alleles were made using mean 
population sizes for each treatment at each generation, using methods described 
by Allendorf (1986). Bold values show predicted diversity at generations 5 and 
10, which correspond to when resistance bioassays were performed.  
Treatment Generation Population 
size 
Heterozygosity* Number 
of Alleles 
Risk of 
loss of 
rare 
alleles 
(%) 
HR 1 15 0.97 9.58 74 
HR 2 18 0.94 9.4 33 
HR 3 28 0.92 9.38 18 
HR 4 33 0.91 9.37 13 
HR 5 33 0.9 9.35 13 
HR 6 29 0.89 9.31 17 
HR 7 35 0.88 9.29 12 
HR 8 38 0.87 9.28 10 
HR 9 31 0.86 9.25 15 
HR 10 39 0.85 9.24 9 
Z 1 47 0.99 10 39 
Z 2 48 0.98 10 38 
Z 3 49 0.97 10 37 
Z 4 47 0.96 10 39 
Z 5 46 0.95 10 40 
Z 6 47 0.94 10 39 
Z 7 47 0.93 10 39 
Z 8 47 0.92 10 39 
Z 9 47 0.91 10 39 
Z 10 47 0.9 10 39 
Number of alleles: an assumption of 10 alleles for a given locus was made; loss 
of rare alleles: rare alleles were assumed to at an initial frequency of 0.01. * 
Heterozygosity is the proportion of original heterozygosity remaining in the 
populations in each generation. 
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Fig B1 Relationship between survival and dose of Ivermectin for the SP8 strain of 
C. remanei. Panel A shows the relationship between survival and dose for two 
repeated assays (batches) accounting for differences in survival between dose-
response assays performed on different dates. Points are individual replicates for 
each batch (triangles and circles). Panel B shows the doses used in the selection 
experiment (black broken lines) estimated to cause 40% and 80% mortality after 
taking into account any background mortality not due to the drug (LD40 and 
LD80). Grey broken lines show 95% confidence intervals around the estimated 
doses. 
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Fig B2 Larval density over the course of the original selection experiment. Lines 
represent mean number of juveniles for each treatment; points are the number 
of juveniles on day two of each generation for each replicate line within a 
treatment. Panel A shows density of high mortality lines: HD and HR with Z lines. 
Panel B shows density of low mortality lines: LD and LR with Z lines; circles, 
solid line = zero dose; triangles, dashed line = drug treatment; diamonds, dotted 
line  = random mortality. Error bars; standard error for the mean number of 
juveniles. 
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Fig B3 Seventy-five hour survival of High dose, High random and Zero dose lines 
when exposed to the high dose of Ivermectin used during selection. Red, blue 
and grey lines show survival of replicate populations for each treatment during 
selection. 
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Fig B4 Fifty-two hour survival when exposed to the three drug doses used during 
selection (A and B = high; C and D = low: E and F = zero) of samples taken from 
generations 0, 5 and 10 during selection. Panels A, C and E show survivorship of 
high mortality lines: HD and HR. Panels B, D and F show survivorship of low 
mortality lines: LD and LR. Points are raw survival data from resistance 
bioassays, lines represent predictions of maximal models (generation + 
treatment + generation*treatment) for each treatment: circles, solid line = zero 
dose; triangles, dashed line = drug treatment; diamonds, dotted line  = random 
mortality.  Error bars; 95% confidence intervals for mean survival. 
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